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Abstract 
Context: It is controversial whether the treatment of subclinical hypothyroidism 
(SCH) with L-thyroxine improves cardiovascular (CV) risk factors and quality 
of life (QoL). 
Objective: To determine whether CV risk factors, endothelial function and 
patient-reported outcomes improve in people with SCH with L-thyroxine 
treatment. 
Design: Randomised double blind, cross-over study. 
Setting: Patients from primary care practices identified from laboratory 
database. 
Patients: One hundred patients (81 females) with mild SCH, and no existing 
thyroid or vascular disease, mean (SD) age 53.8 (12) years, thyrotropin (TSH) of 
6.6 (1.3) mIU/L. One patient withdrew due to perceived side-effects. 
Intervention: Oral 100 meg of L-thyroxine or matching placebo daily for 
twelve weeks each. 
Main outcome measures: Powered to detect significant improvements in two 
primary parameters: total cholesterol (TQ levels and endothelial function 
(brachial artery flow mediated dilatation-FMD), the earliest marker of 
atherosclerosis. 
Results: L-thyroxine treatment reduced (mean difference, 95% Q TSH (5.64 
mIU/L, 4.11 to 7.17), increased FT4 and FT3 levels (6.98 pmol/L, 5.97 to 7.98 
and 0.6 pmol/L, 0.37 to 0.82, respectively), FMD improved (1.65%, 1.2 to 2.1) 
and TC levels reduced (435 mmol/L, -0.52 to -0.16). Increase in FT4 levels 
was the only significant determinant of the improvement in TC and FMD. Sex- 
life and overall QoL were less negatively impacted by SCH during L-thyroxine 
treatment. Symptom bother scores did not benefit by L-thyroxine but there was a 
significant improvement in the frequency of tiredness - from 89% to 78%, 
p<0.05. Health status and treatment satisfaction did not show any significant 
change. 
Conclusion: SCH treated by L-thyroxine leads to a significant improvement in 
CV risk factors and some patient-reported outcomes. The benefit of CV risk 
reduction is related to the increased level of achieved FT-4 concentration. 
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QoL - Quality of life. 
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TSH - Thyrotropin, Thyroid stimulating hormone. 
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T4 - Thyroxine. 
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FMD - Brachial artery flow mediated dilatation. 
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CRP -C reactive protein. 
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PAI I- Plasminogen activator inhibitor 1. 
tPA - Tissue plasminogen activator. 
OR - Odds ratio. 
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CARDIOVASCULAR DISEASE AND ITS 
RISK FACTORS IN SCH 
II 
INTRODUCTION (A) 
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Background. 
Thyroid dysfunction is the second commonest endocrine abnormality after 
diabetes mellitus. Typical clinical features, a raised serum thyrotropin (TSH) 
and reduced serum thyroid hormone levels characterize hypothyroidism. 
Prevalence and incidence of hypothyroidism: 
The Whickham survey, conducted in the north of England, revealed a prevalence 
of hypothyroidism of at least 7.5% in females and 2.8% in males in the UK 
(Tunbridge, et al 1977b). A pooled prevalence from different studies is shown in 
figure I across various age groups for each gender. A 20-year follow-up study of 
the population of Whickham reported a mean incidence of 4.1 /1000 per year for 
hypothyroidism in women, the incidence in men being 0.6/1000 per year 
respectively (Vanderpump, et al 1995). 
Figure 1. 
Pooled prevalence of overt hypothyroidism per 1000 patients (Closed circles 
represent population-based studies; open ovals represent office-based studies) 
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Overt hypothyroidism could lead to typical symptoms and signs as well as 
cardiovascular effects, all of which can impact on morbidity and mortality. 
Cardiovascular disease: 
Overt hypothyroidism is associated with an increased risk of cardiovascular 
(CV) disease, although the evidence for a true association is confined to older 
literature investigating relatively fewer numbers of patients (Klein and Ojamaa 
2000, Steinberg 1968, Vanhaelst, et al 1967). An association between the two is 
likely given that diastolic hypertension, higher serum cholesterol levels and low 
cardiac output is common (Klein 1990). The diastolic hypertension and 
increased vascular resistance contribute to increased cardiac afterload and 
cardiac work (Bengel, et al 2000). However, not all patients have hypertension 
or abnormal lipid profile (Streeten, et al 1988), suggesting that there are other 
mechanisms at work in the development of atherosclerosis. These may be 
collagen induced platelet aggregation, impaired vascular smooth muscle 
relaxation, or impaired fibrinolytic activity or thrombosis (Erem, et al 2003, 
Ishikawa, et al 1989, Mamiya, et al 1989). Plasma homocysteine levels are also 
elevated in this condition (Nedrebo, et al 1998) and this is now known to be an 
independent risk factor for cardiovascular disease (Boushey, et al 1995, Clarke, 
et al 1991). It has also been suggested that hypothyroid patients are at an 
increased risk for atherosclerosis based on animal studies that showed that 
development of atherosclerosis in cholesterol fed animals is enhanced by the 
presence of hypothyroidism and reduced when thyroxine is administered 
(Steinberg 1968). The other possible mechanism of development of 
atherosclerosis in people with hypothyroidism may be due to endothelial 
dysfunction (Lekakis, et al 1997). Hypothyroidism is associated with blunted 
endothelium-dependent vasorelaxation (Delp, et al 1995, Moreno, et al 2003, 
Vargas, et al 1995) and reduced aortic nitric oxide (NO) synthase activity in rats 
(Quesada, et al 2002). Hypothyroidism, even in the subclinical stage, is 
associated with changes in arterial stiffness which may have detrimental effects 
on left ventricular function and coronary perfusion in hypothyroid subjects 
(Dagre, et al 2005). Hypothyroid patients have increased peripheral arterial 
resistance (Graettinger, et al 1958) (Klein 1989). Elevated diastolic blood 
pressure is commonly found in hypothyroid patients that is reversible with L- 
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thyroxine replacement therapy (Fuller, et al 1966). Twenty percent of patients 
with hypothyroidism have diastolic hypertension and systemic arterial 
hypertension increases by up to 30% (Klein and Ojamaa 2001). 
Thyroxine therapy reverses all the CV and endothelial changes associated with 
hypothyroidism (Klein 1990, Wieshammer, et al 1989) (Crowley, et al 1977) 
(Papaioannou, et al 2004) (Fuller, et al 1966). In a large study of patients with 
hypothyroidism who were evaluated for clinical evidence of ischernic heart 
disease after the initiation of thyroid hormone therapy, new or worsening angina 
or acute myocardial infarction was rare, and more patients had improvement in 
anginal symptoms (Keating, et al 196 1). These findings reinforce the important 
and potentially beneficial effects of thyroid hormone in improving the efficiency 
of myocardial oxygen consumption (Bengel, et al 2000) and simultaneously 
lowering systemic vascular resistance (Ojamaa, et al 1996) 
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Subdinical hypothyroidism (SCH) 
Definition: The terms subclinical hypothyroidism and mild thyroid failure refer 
to patients who have an elevated TSH level and a free T4 level within the 
laboratory reference range (Ross 2001). In these patients, the serum thyroxine 
level is reduced from the physiologically nonnal level for that patient but does 
not fall below the lower limit of the laboratory's reference range for the 
thyroxine assay. Symptoms of hypothyroidism are not necessary for this 
condition to be diagnosed since, it has been argued, most patients on close 
questioning disclose mild, non-specific symptoms (Ayala, et al 2000). 
Since serum TSH levels tend to have a skewed distribution with a "tail" towards 
higher concentrations in a healthy population (that is, not normally distributed), 
it is likely that some people with subclinical disease are included in the upper 
limit of the reference range (Surks, et al 2004). The NHANES III survey in the 
United States measured TSH levels in a subset (n=13344) aged 12 years or more 
and without any confounding factors (pregnancy, medications known to affect 
thyroid hormone metabolism or positive anti-TPO antibodies). In this 
population, the reference range of TSH concentration (5'h -95 th percentile) was 
0.4 to 4.0 mIU/L, with a geometric mean value of 1.4 mIU/L (Hollowell, et al 
2002). 
There has been a debate whether upper limit of the reference range for serum 
TSH should be reduced. Over the last two decades, the upper reference limit for 
TSH has steadily declined from about 10 mIU/L to approximately 4.0 - 4.5 
mIU/L. This decrease reflects a number of factors including the improved 
sensitivity and specificity of current monoclonal antibody based immunometric 
assays, the recognition that normal TSH values are log-distributed and 
importantly, improvements in the sensitivity and specificity of the thyroid 
antibody tests that are used to pre-screen subjects. The follow-up study of the 
Whickham cohort has found that individuals with a serum TSH >2.0 mIU/L at 
their primary evaluation had an increased odds ratio of developing 
hypothyroidism over the next 20 years, especially if thyroid antibodies were 
elevated (Vanderpump, et al 1995). An increased odds-ratio for hypothyroidism 
was even seen in antibody-negative subjects. It is likely that such subjects 11ad 
low levels of thyroid antibodies that could not be detected by the insensitive 
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microsomal antibody agglutination tests used In the Initial study (Tunbridge, et 
al 1977b). Even the current sensitive anti -thyroperoxi dase antibody (anti TPO) 
immunoassays may not identify all individuals with occult thyroid insufficiency. 
In the future, it is possible that the upper limit of the serum TSH euthyroid 
reference range may be reduced to 2.5 mIU/L because >95% of rigorously 
screened normal euthyroid volunteers have serum TSH values between 0.4 and 
2.5 mlU/L (Baloch, et al 2003). There is data indicating that African-Americans 
with very low incidence of Hashimoto thyroiditis have a mean TSH level of 1.18 
mIU/L, which strongly suggests that this value is the true normal mean for a 
normal population (Wartofsky and Dickey 2005). On the other hand, it has been 
argued that there is no evidence for associated adverse outcomes in people with 
TSH values between 2.5 - 4.0 mIU/L and that some of these TSH levels may be 
due to technical reasons with the TSH assay (abnormal isomers and heterophile 
antibodies) (Surks, et al 2004). 
Current diagnostic methods are capable of measuring TSH at the lower end and 
now cite lower normal limits between 0.2 and 0.4 mIU/L (Spencer, et al 1996). 
As the sensitivity of the methods has improved, there has been an increased 
interest in defining the true lower limit of normal to better determine the 
presence of mild (subelinical) hyperthyroidism. Current studies suggest that 
TSH values in the 0.1 to 0.4 mlU/L range may represent thyroid hon-none excess 
and in elderly patients might be associated with an increased risk of atrial 
fibrillation, and cardiovascular mortality (Sawin, et al 1991) (Sawin, et al 1994) 
(Parle, et al 200 1). 
Prevalence and incidence: 
Subclinical hypothyroidism is quite common. Biochemical assessment of 
thyroid function in a large cohort of 25,863 subjects attending a State-wide 
health fair in Colorado revealed a prevalence of elevated TSH of 9.5%, with 
most subjects being diagnosed due to the blood test (Canaris, et al 2000). In 
agreement with previous studies, the prevalence of subclinical hypothyroidism 
was found to be greater in women and increased with age, reaching nearly 21% 
in women aged 74 years and 16% in men of similar age. A survey of 12 10 
patients, aged 60 or more from one general practice, indicated rates of 
subclinical hypothyroldism of 11.6% in females and 2.9% in males (Parle, et al 
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1991). In an analysis of the Third National Health and Nutrition Examination 
Survey (NHANES 111), a population-based survey of 17,353 people at least 12 
years of age representing the U. S. population, the prevalence of subclinical 
hypothyroidism was 5.8% among white, non-Hispanic women; 1.2% among 
black, non-Hispanic women; and 5.3% among Mexican-American women. The 
prevalence of subclinical hypothyroidism was 3.4% among white men, 1.8% 
among black men, and 2.4% among Mexican-American men (Hollowell, et al 
2002). In the Whickham survey, a large, population-based cohort study, 
prevalence was 4% to 5% among women age 18 to 44 years, 8% to 10% among 
women age 45 to 74 years, and 17.4% among women older than age 75 years. 
The prevalence was 1% to 3% among men age 18 to 65 years and 6.2% among 
men older than age 65 years. Goitre is twice as prevalent among patients with 
this condition as in the general population. Up to 75% of patients with SCH 
have only mildly elevated serum TSH values (5-10 mIU/L), and 50-80% of 
patients have positive thyroid autoantibody tests, depending on the age, sex, and 
serum TSH levels (Tunbridge, et al 1977b). However, the prevalence of SCH 
has been found to be lower in more older women; being 6.2% in those over 80 
(Parle, et al 1991). It is not clear whether this reduced prevalence is due to a 
self-selection bias, in that more people with SCH may have died before they 
reach 80 years. 
These data indicate that the prevalence of SCH is much greater than overt 
untreated and unrecognised hypothyroidism and that the prevalence seems to 
increase when other autoimmune conditions are present (Gray, et al 1980) 
(Kahaly, et al 1995). 
Causes and differential diagnoses: 
Patients with treated hyperthyroidism, a history of neck irradiation, postpartum 
thyroiditis, and certain autoimmune diseases, especially type I diabetes mellitus, 
are at increased risk for SCH. It may also develop in patients who are being 
treated with the iodine containing antiarrythmic agent arniodarone, lithium, or 
immune response modulators, such as interferon alpha, but most patients have 
no obvious risk factors. The differential diagnoses of elevated serum TSH and 
normal levels of serum free thyroxine include inten-nittent non-compliance with 
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L-thyroxine therapy, recovery from non-thyroidal illness, chronic renal failure, 
primary adrenal failure, artifactual high TSH due to circulating heterophilic 
antibodies against TSH, and mutations causing inactivation of the TSH receptor. 
SCH is usually detected when patients with a history of thyroid disease are 
followed up or as a result of biochemical screening for non-specific symptoms 
(Surks, et al 1990). 
Due to the minor alterations in thyroid hon-none levels and the wide levels at 
which homeostatic mechanisms may occur, it is predictable that metabolic and 
organ function indexes will deviate only slightly from the normal. Nevertheless, 
such modifications may be clinically relevant, because they affect organ 
function over the course of many years. SCH is also likely to progress to overt 
hypothyroidism in a large number of patients, especially if it is caused by an 
autoimmune process (Parle, et al 1991). 
Screening: 
Since the majority of patients with this condition are asymptornatic or have very 
few or mild symptoms, some authors recommend routine screening (Danese, et 
al 1996). Using a decision and cost effectiveness model, it was calculated that 
screening women older than 35 years old every five years would cost about 
$9200 per quality adjusted year of life. Half of this benefit would accrue due to 
prevention of progress to overt hypothyroidism with its attendant morbidity, 
30% from improved symptoms and a smaller benefit from a decrease in heart 
disease due to a reduction in serum cholesterol levels. The costs of screening 
were mostly due to the TSH assay whereas the potential savings were due to 
decrease in costs of evaluating and treating non specific symptoms, as well as 
possible savings on lipid lowering therapy. In interpreting these conclusions, it 
is important to note that Danese and colleagues assumed that early treatment 
improved health outcomes and then proceeded to examine the likely 
consequences and costs of a screening program. Other researchers (Wiersinga 
1995) (1990) (Glenn 1996) (Franklyn 1995) have questioned these assumptions, 
citing flaws in the literature on which they are based. The Royal College of 
Physicians states that screening the healthy adult population is not justified since 
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the benefits of subsequent therapy are not proven by large prospective clinical 
trials (Vanderpump, et al 1996a). 
Implications of SCH 
The potential complications of subclinical hypothyroidism are progression to 
overt hypothyroidism, presence of symptoms and hyperlipidernia and CV 
disease. The potential of SCH to lead to overt hypothyroidism is discussed next 
whereas the implications of SCH on CV disease and its risk factors as Nvell as 
symptoms and quality of life are discussed in subsequent chapters. 
Progression to overt hypothyroidism: 
Over time, asymptomatic patients with subclinical hypothyroidism may progress 
to overt hypothyroidism at a rate of 2-5% per year. Progression is diagnosed 
when a patient with subclinical hypothyroidism develops a low free thyroxine 
level. The presence of thyroid autoantibodies in serum is a strong risk factor for 
progression. Older age and a higher TSH level also increase the chance that a 
patient with subclinical hypothyroidism will progress. The Whickham survey 
provides the best data on the chance that a person with subelinical 
hypothyroidism found by screening will develop overt hypothyroidism. The 
Whickham investigators defined a TSH level of 6 mlU/L or more as elevated. 
Two thirds of women with an elevated TSH level had antithyroid antibodies in 
serum. During 20 years of follow-up, 55% of women with a TSH level of 6 
mlU/L or more and a positive antibody test result developed overt 
hypothyroidism. About 25% of these women had an initial TSH level of 10 
mIU/L or more; for these women, the risk for overt hypothyroldism over 20 
years was close to 90%, or about 0.11 per year. Younger women and women 
with a mildly elevated TSH level (6 to 9 m1U/L) had a lower risk for progression 
(Vanderpump, et al 1995). A logistic regression equation developed by the 
Whickham investigators can be used to estimate risk in these groups. For a 50- 
year-old woman with a positive test result for thyroid antibodies, the 20-year risk 
for developing overt hypothyroidism was 0.57 (57%) if the TSH level was 6 
mlU/L and 0.72 (72%) if the TSH level was 9 mlU/L. For a 35-year-old woman 
with a positivc antibody test result, the 20-year risk for developing overt 
hypothyroidism was 0.47 (47%) if the TSH level was 6 mlU 1. and 0.67 (67%) if 
the TSH level was 9 mlU L The risk for progression was not evenly distributed 
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throughout the follow-up period. By 5 years, 8% of patients Nx. 'ith an elevated 
TSH level developed overt hypothyroidism and 92% remained well. Almost all 
patients who progressed within 5 years had a TSH level of 10 mIU/L and high 
titres of circulating antibodies. Of 57 women who had an initial TSH level 
between 6 and 10 mIU/L, none progressed within 2 years and 3 (5.2%) 
progressed within 5 years. In patients with a mildly elevated TSH level, the risk 
for progression after 5 years was not distinguishable from that of euthyroid 
patients. 
In individuals with SCH, not on L-thyroxine replacement therapy, serum TSH 
levels return to within the normal reference range after I year of follo%v-up in 
approximately 5% (Parle, et al 1991), whilst the rest remained in SCH state. 
Another prospective study of 82 women with SCH, with a mean follow-up 
period of 9.2 years, showed that 28% progressed to overt disease, 68% remained 
subclinically hypothyroid, whilst the remaining 4% returned to norinal (Huber, 
et al 2002). When patients in this study were stratified according to their initial 
TSH levels, it was found that none of the patients with mild SCH (TSH <6 
mIU/L) progressed to overt hypothyroidism, whereas the corresponding figures 
for moderate (TSH >6 and < 12 mIU/L) and severe (> 12 mIU/L) SCH were 43 
and 77% respectively. The results of this study cannot be applied to the primary 
SCH patients since 61% of these patients had SCH as a result of treatment 
(radioiodine or thyroid surgery) for hyperthyroidism in the past. 
Prevention of progression to overt hypothyroidism: 
As stated before, the 20-year follow-up of the Whickham survey cohort has 
provided the best estimates of risk of developing overt hypothyroidism in 
women with positive thyroid autoantibodies or SCH- 4.3% / year or 38 times 
that of people without antibodies or norinal TSH (Vanderpump, et al 1995). The 
number of patients needed to treat (NNT) to prevent one case of overt 
hypothyroidism ranges from 4.3 to 14.3, depending on age and TSH level at 
baseline (Helfand and Reffern 1998). This is in a similar range as that of other 
commonly practiced strategies, for example, statin treatment for 
hypercholesterolemia (Kumana, et al 1999). 
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Cardiovascular disease and its risk factors. 
The CV system (myocytes and vascular smooth muscle) has receptors for 
thyroid hormones and is a sensitive marker of peripheral thyroid hormone action 
(Klein and Ojamaa 2001). Type 115' monodeiodinase (which converts thyroxine 
to triiodothyronine) is found on non-muscle heart cells and vascular smooth 
muscle cells of the aorta and coronary arteries (Mizurna, et al 2001). This 
suggests that the CV system may respond to fluctuations in serum thyroid 
hormone levels (Biondi and Klein 2004). Effects of hypothyroidism on 
exchange of plasma proteins between the intravascular and interstitial fluid 
spaces, and on lipid metabolism and atherogenesis add further dimensions to the 
CV implication of SCH. 
The long-term effects of deficiency of thyroid hormones on the CV system can 
be assessed by CV events (by means of cross-sectional and longitudinal case- 
control and cohort studies) as well as by its influence on established CV risk 
factors. 
The concept of risk assessment was first introduced by the Framingham Heart 
Study, and has been expanded upon in the decades since (Kannel, et al 1976). 
Traditional risk factors routinely used in risk profiles or algorithms include age, 
blood pressure, serum cholesterol (high-density lipoprotein and low-density 
lipoprotein), diabetes, and cigarette smoking. About 300 such CV risk factors 
have been reported in the literature. Those described below are a combination of 
traditional and emerging risk factors that address the diverse pathogenic 
mechanisms. These biomarkers may better predict clinical events either alone or 
in combination with other CV risk factors. However, the independent relation of 
the new risk factors with atherosclerotic disease has not yet been conclusively 
proven. 
Blood pressure 
Hypertension is a strong independent risk factor for heart disease and stroke and 
a predictor of premature death and disability from CV complications 
(Chobanian, et al 2003). The association between blood pressure (13P) and major 
CV events including stroke, myocardial infarction, organ damage, and mortality 
are well documented in both non-notensive and hypertensive individuals, and 
22 
this association is greatly influenced by age. Numerous observational 
epidemiological studies and clinical trials, including the Framingham Heart 
Study, have shown a strong positive and continuous association between 
brachial artery systolic and pulse pressures and adverse CV events, especially in 
people older than 50 years of age (Domanski, et al 200 1). The long-term 
beneficial effects of lowering arterial BP on CV events (e. g., myocardial 
infarction, stroke, and mortality) have been well documented in large clinical 
trials in both hypertensive and nonnotensive patients (Davis, et al 2002) 
(Dahlof, et al 2002). 
Lipids 
Results of observational studies in different populations indicate a continuous 
positive relationship between CV disease risk and blood cholesterol 
concentrations that extends well below the range seen in many developed 
populations, without any definite threshold below which a lower cholesterol 
concentration is not associated with lower risk (Stamler, et al 1993). Several 
large studies of interventions designed to reduce cholesterol levels have shown a 
reduction in CV mortality and morbidity (The 4S Study 1994) (Shepherd, et al 
1995). 
Body weight and distribution 
The importance of obesity as a risk factor for several diseases including type 2 
diabetes, CV disease, hypertension, gallstone disease, and certain cancers, is 
well documented (Eckel 2003). Abdominal obesity is the body fat parameter 
that is closely associated with the metabolic syndrome (and hence CV disease). 
Any effective weight reduction reduces the CV risk (Eckel, et al 2005). 
Inflammatory markers 
Inflammation may be both important in the pathogenesis of athero-thrombosis 
and a distal marker of an advancing disease process. Increases in the serum C- 
reactive protein (CRP) prospectively predict coronary events (Ridker, et al 1997) 
(Thompson, et al 1995) (Liuzzo, et al 1994). Howe,,,, er, the results of a recent 
report from the Reykjavik prospective study indicated that elevated CRP levels 
23 
were only a moderate predictor of risk compared with established risk factors 
such as total cholesterol levels and cigarette smoking (Danesh, et al 2004). 
Endothelial function 
The endotheliurn regulates vascular homeostasis by secreting a variety of 
autocrine and paracrine substances that act locally in the vessel and lumen 
(Gokse, et al 1998). It is of primary importance due to its strategic location 
between the blood and underlying smooth muscle. Under normal circumstances, 
the secreted endothelial factors maintain normal vascular tone, blood fluidity, 
and limit vascular inflammation and smooth muscle proliferation (see figure 1). 
One of these factors is endothelium-derived nitric oxide (NO), which modulates 
the tone of the underlying vascular smooth muscle and also inhibits pro- 
atherogenic processes, including monocyte and platelet adhesion, oxidation of 
low density lipoproteins, synthesis of inflammatory cytokines, smooth muscle 
proliferation and migration, and platelet aggregation. However, in the presence 
of coronary risk factors, the endothelium adopts a state that facilitates 
inflammation, thrombosis, vasoconstriction, and atherosclerotic plaque 
formation (Levine, et al 1995). In humans, endothelium dysfunction manifests 
prior to the development of frank atherosclerosis and is associated with 
traditional risk factors like hypercholesterolemia, hypertension, and diabetes 
mellitus and with newer risk factors like hyperhomocystinaernia, obesity, and 
systemic inflammation (Gokse, et al 1998). Endothelial dysfunction is an early 
physiological event in atherogenesis (Healy 1990). In vitro studies have shown 
that this dysfunction is present in the earliest stages, before plaques exist and 
well before clinical manifestation of the disease (Ross 1986). Thus assessment 
of endothelial function by several different methods has emerged as a tool for 
detection of evidence of pre-clinical CV disease (Anderson 1999). Additionally, 
there is also evidence that endothelial dysfunction also contributes to the later 
stages of the disease when patients develop clinical symptoms. Cross-sectional 
studies have demonstrated the most severe endothelial dysfunction in arteries 
containing a culprit lesion that precipitates unstable angina or myocardial 
infarction (Okumura, et al 1992) (Bogaty, et al 1994). The pathophysiological 
role of endothelial dysfunction is evident by interý'entional studies, which shov, ' 
an improvement in endothelial function by diverse interventions proveii to 
reduce cardiovascular risk (Vita and Keaney 2000). For example, lipid lowering 
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therapy, ACE-inhibitors, smoking cessation, and physical exercise have been to 
shown to reduce cardiovascular risk and to improve endothelial dependent 
vasodilation in the coronary and peripheral circulations (Gokse, et al 1998). 
Loss of vascular integrity can expose sub-endotheliurn and cause the efflux of 
fluids from the intravascular space. Upregulation of leucocyte adhesion 
molecules such as E-selectin, ICAM- 1, and VCAM- I allows leucocytes to 
adhere to endothelium and then move into the tissues (Adams and Shaw 1994). 
The pro-thrombotic effects of endothelial cell activation include loss of the 
surface anticoagulant molecules thrombomodulin and heparan sulphate; reduced 
fibrinolytic potential due to enhanced plasminogen activator inhibitor type 
I release; loss of the platelet anti-aggregatory effects of ecto-ADPases and 
prostacyclin; and production of platelet activating factor, nitric oxide, and 
expression of tissue factor. 
There is also evidence from outcome studies linking endotbelial dysfunction 
with future events. Suwaidi et al examined 157 patients with mild coronary 
disease and demonstrated a greater incidence of CV events during 2.3 year 
follow-up in patients with impaired endotbelium dependent vasodilatation of 
coronary resistance and conduit arteries (Suwaidi, et al 2000). This study is 
limited by the relatively small number of clinical events and the inclusion of 
coronary revascularisation procedures as events but, it provides the first 
evidence that endothelial dysfunction has prognostic value. Halcox et al studied 
308 patients undergoing cardiac catheterisation and examined coronary blood 
flow and epicardial coronary diameter responses to endothelium dependent and 
independent vasodilators (Halcox, et al 2002). All patients had an average 46- 
month follow-up and they observed a total of 35 ischernic events, including 
sudden cardiac death, acute myocardial infarction, unstable angina, and stroke. 
These events were independently associated with impaired endothelium 
dependent dilatation, even after controlling for other clinical variables. In 
contrast vasodilator responses to endothelium independent vasodilators did not 
predict events, proving specific relationship with endothelial dysfunction. 
Patients with impaired endothelium dependent vasodilatation predicted CV 
events even in patients with angiouraphically non-nal coronary arteries. 
Several studies have reported that the risk of ischernic CV events is increased in 
patients with impaired fibrinolytic function (Pahor, et al 1999) (Salomaa, et al 
1995b) (Thompson, et al 1995). Fibrinolytic activity is primarily detennined by 
the balance between the levels of tissue plasminogen activator (tPA) and 
plasminogen activator inhibitor I (PAI-1). The endothelial cells are responsible 
for the production and blood release of tPA and of PAI- I to some extent. 
Multiple factors, such as lipoproteins, cytokines, and inflammatory markers, 
modulate endothelial cells to produce tPA and PAI- I (Pearson 1993). There are 
several arguments to suggest that hypofibrinolysis could be considered to be a 
surrogate marker of endothelial cell dysfunction (Tomiyama, et al 1998) 
(Poredos 2002). In prospective studies PAI- I and tPA independently predicted 
CV events or mortality (Held, et al 1997) (Ridker, et al 1994) (Ridker, et al 
1993). While some studies (Ridker, et al 1994) (Ridker, et al 1993) found that 
the significant associations of tPA with CV disease were independent of other 
risk factors, others (Juhan-Vague, et al 1996) (van der Bom, et al 1997) have 
found that fibrinolytic markers were correlated with obesity, and serum lipids 
such as total cholesterol and Lp(a), suggesting that the prothrombotic effect of 
altered lipids and insulin resistance are mediated by an impairment of 
fibrinolysis. 
Increased levels of biochemical markers of endothelial function and cell 
adhesion-P-selectin, E-selectin, soluble intercellular adhesion molecule I 
(sICAM 1), vascular cell adhesion molecule I (VCAM 1), and 
thrombomodulin-have been found in patients with atherosclerosis and 
dyslipidaemia (Belch, et al 1997) (Blann, et al 1997b) (Blann, et al 1997a) 
(Morisaki, et al 1997). In the Atherosclerosis Risk in Communities Study, 
increased plasma levels of sICAM I and E-selectin prospectively predicted 
coronary events (Hwang, et al 1997). In the Physician's Health Study, sICAM 1 
was significantly and independently associated with incident myocardial 
infarction (Ridker, et al 1998). 
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Assessment of endothelial function 
Endothelial function has been assessed with a variety of invasive and 
noninvasive surrogate assays (see table 1). Elevation of serum markers (e. g., 
adhesion molecules, selectins, C-reactive protein) has been associated with 
endothelial dysfunction and its risk factors, but distinguishing between 
endothelial stimulation and endothelial damage is difficult (Raitakari and 
Celennajer 2000). In addition, assays measuring NO activity in plasma and 
urine exist, but are heavily affected by dietary habits (Wang, et al 1997). As a 
result, a direct measure of endothelial function, with a variety of techniques, is 
frequently used. Although direct visualization of the coronary artery dilator 
response to acetylcholine challenge with angiography and endothelial function 
in the forearm circulation using plethysmography after brachial artery infusion 
of a variety of dilatory triggers have been studied and validated, their 
widespread clinical use is limited because of their invasive nature. 
Recently, non-invasive measures of endothelial function have become available. 
Reduced coronary flow reserve, as measured with positron emission tomography 
(PET) before and after provocation with adenosine or dipyridamole, has been 
shown to occur in patients with risk factors for vascular disease and improve 
with statin therapy (Huggins, et al 1998). However, this technique is expensive 
and involves radiation exposure. Forearm plethysmography and brachial artery 
ultrasound scanning may be used to assess increased flow in response to NO 
stimuli, and both are well tolerated and reproducible. However, data suggest that 
forearm hyperaerma is less dependent on NO release than is flow in larger 
circulatory beds (Honing, et al 2000). Moreover, there is concern that forearm 
plethysmographic measurements exhibit considerable day-to-day variability, 
potentially limiting their use in long-ten-n studies (Anderson 1999). 
Accordingly, the most widely used technique for assessing endothelial function 
is brachial artery ultrasound scanning for flow-mediated dilatation (FMD). 
Brachial artery flow mediated dilatation (FMD): 
Coronary endothelial dysfunction has been shown in response to various 
pharmacological and physiological stimuli, in patients with symptoms of 
established coronary atherosclerosis (Ludmer, et al 1986). The technique of 
assessing coronary endothelial function is useful for coronary artery events, but 
this method is limited by the risk of and expense of coronary angiography and 
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selective intra-coronary agonist infusion. Therefore, there has been considerable 
interest in the study of endothelial vasomotor function in more accessible 
vascular beds, such as the brachial circulation. Venous occlusion 
plethysmography has been used to examine vasomotor responses of forearm 
resistance vessels during brachial artery infusion of endothelium dependent 
vasodilators like acetylcholine (Creager, et al 1990). This approach has several 
advantages including the ability to examine dose-response relations and use 
specific agonists and antagonists. However, these studies are limited by the 
requirement for arterial catheterisation that renders them less well suited for 
large scale and intervention studies. An alternative approach uses vascular 
ultrasound to examine endothelium dependent flow mediated dilatation of the 
brachial artery (Corretti, et al 2002). This was first developed by Celen-najer et 
al, who followed changes in vessel diameter, in response to increased flow and 
to glyceryl trinitrate (GTN) (Celermajer, et al 1992). In arteries lined by healthy 
endothelium, increased flow causes vessel dilatation, via release of NO. This 
mechanism fails in endothelial dysfunction. In contrast, GTN causes 
vasodilatation by direct action on the smooth muscle; its effect is therefore 
independent of the endothelium. Since then, this non-invasive technique has 
gained popularity as an assessment of endothelial function that can safely be 
applied to large and varied group of patients that may involve repeated 
measurement of vascular function over time. As with the coronary circulation, 
endothelial function in the brachial artery is impaired in individuals with risk 
factors and responds to interventions known to reduce CV disease risk (Gokse, 
et al 1998). 
The systemic nature of many risk factors makes it reasonable to assume that 
they affect central and peripheral arteries in a parallel manner. In fact, there have 
been studies to suggest that endothelial dysfunction detected non-invasively in 
the an-n correlates well with coronary artery endothelial dysfunction (Anderson, 
et al 1995). Some more recent studies have shown that impaired ultrasound 
detected flow mediated dilatation predicts future CV events. Neunteufl and 
colleagues observed a relation between endothelial dysfunction and need for 
revascularisation procedure, although their study had a relatively small group of 
subjects and the relation between endothelial dysfunction and events was lost 
after controlling for extent of coronary artery disease (Neunteufl, et al 2000). 
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Another prospective study by Gokce et al showed that impaired brachial artery 
flow mediated dilatation is an independent predictor of short-terrn events in 
high-risk patients undergoing surgery for vascular disease (Gokce, et al 2002). 
Thus, endothelial function represents a very good and accessible tool to measure 
underlying vascular health. 
Blood flow through the brachial artery is increased in response to transient 
hyperaernia, which is provoked by inducing post-ischemic dilation of distal 
vascular beds. Ischemia is induced by the inflation of an arterial occlusion cuff, 
positioned on the proximal or mid-forearm. After cuff deflation, brachial artery 
flow increases because of downstream vessel dilation, and this augmented flow 
increases brachial artery shear stress, resulting in vasodilatation. The precise 
mechanism of FMD is not completely understood, but it is generally believed to 
be mediated by NO produced by the endothelial cells, perhaps via shear-stress- 
induced phosphorylation of endothelial nitric oxide synthase (eNOS) 
(Dimmeler, et al 1999). NO is of particular interest to researchers as it is an anti- 
atherogenic molecule, and a reduction in its bioavailability may play a role in 
the pathogenesis of vascular disease (Cooke and Dzau 1997). 
Biochemical endothelial markers: 
These are either secreted by the endothelium or shed from its surface in disease 
states, can be used to measure endotbelial activity. Some of these markers are 
von Willebrand factor, thrombomodulin, E-selectin, P-selectin, sICAM 1, 
VCAM I and vascular endothelial growth factor. Adhesion molecules (slCAM I 
and E-selectin, etc) are shed into the circulation. These can be measured and 
provide a biochemical means for assessing endothelial function (Abdu, et al 
2001). The clotting cascade is activated by the endothelial products tissue 
plasminogen activator (WA), thrombomodulin and plasminogen activator 
inhibitor- I (PAI- 1), which contribute to thrombosis formation on atheromatous 
plaques. Von Willebrand factor (vWF) generated by endothelial cells also 
favours thrombosis. 
sICAM 1: This is one of the cell adhesion molecules (CAMs) expressed in 
response to vascular endothelial activation via the stimulus of cytokines, tumour 
necrosis factor alpha and interleukin-1. sICAM I is a marker of white blood cell 
(WBC) interaction with the vascular endothellum, and it facilitates the trans- 
endothelial migration of NNBCs into the sub-endothelial space (Smith, et al 
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1989). 
VCAM-1: Supports the adhesion of lymphocytes, monocytes, natural killer 
cells, eosinophils and basophils to the endothelium. It is not constitutiN'ely 
expressed on endothelium, but can be upregulated invitro in response to several 
cytokines (Blann and Lip 1998). 
E-selectin: is one of the CAMs shed from the endothelium into the plasma and 
shown to be a specific marker of endothelial dysfunction as it is exclusively 
expressed by the activated vascular endothelium (Bevilacqua, et al 1989). It 
mediates the initial interaction of leukocytes and platelets with endothelial cells. 
Table 1. Surrogate indices of endothelial function 
Serum markers 
Endothelin-I (ET-1) 
Von Willebrand factor (vWF) 
Tissue-type plasminogen activator (t-PA) 
Plasminogen activator inhibitor- I (PAI- 1) 
Intercellular adhesion molecules (ICAMs) 
Vascular cell adhesion molecules (VCAMs) 
E-selectin, P-selectin 
Asymmetric dimethylarginine (ADMA) 
Nitric oxide production assays 
Urine nitrate (NO 
3-) 
Urine cyclic GMP functional tests 
Invasive provocative testing 
I. With forearm plethysmography 
2. With coronary angiography 
Positron emission tomography 
Flow mediated dilation 
I. With forearm plethysmography 
2. With brachial artery ultrasonography 
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Detection of subclinical atherosclerosis with carotid intima-media 
thickness: 
Measurement of arterial wall intima-media thickness (IMT) made with high- 
resolution B-mode ultrasound imaging was first presented as a means of 
assessing atherosclerotic changes in the aorta in 1986, when studies of excised 
aorta showed close correlation between ultrasonically measured IMT and the 
same thickness measured by light microscopy (Pignoll, et al 1986). Because of 
its ease of study, the carotid artery quickly became the vessel of choice for 
ultrasonic examination of IMT. Multiple studies have shown that the carotid 
artery IMT, as measured non-invasively by ultrasonography, is directly 
associated with an increased risk of CV disease (O'Leary, et al 1996) (Kuller, et 
al 1995) (Bots, et al 1997) (O'Leary, et al 1999). Because it has been shown to 
be an independent predictor of CV disease after adjustment for traditional risk 
factors, it is the only non-invasive imaging test currently recommended by the 
American Heart Association for inclusion in the evaluation of risk (Smith, et al 
2000). However, it remains unclear how much additional information beyond 
that afforded by traditional risk factors is gained by inclusion of IMT in risk 
profiles (del Sol, et al 2001). Change in IMT is increasingly being used as the 
end point in interventional trials. Meaningful differences in progression rates 
have been shown in progression rates in trials of either lipid-lowering drugs or 
beta-blockers involving several hundred subjects over a period of several years 
(Furberg, et al 1994) (Smilde, et al 200 1). Acceptance of a standardized 
protocol for measuring IMT change would facilitate comparison of results from 
the many trials using this technique. However, uncertainty about which measure 
of IMT offers the best end point has inhibited methodological standardisation. 
Arterial stiffness as a marker of atherosclerosis: 
Results from several studies have suggested that subjects with CV disease haN'e 
increased arterial stiffness compared with subjects without (Hirai, et al 1989) 
(Dart, ci al 1991). Arterial stiffness may be an important, independent predictor 
of CV risk. The association between arterial stiffness and CV disease may be 
explained by an increase in pulse pressure following increased arterial stiffness 
or through an association between arterial stiffness and atherosclerosis. Studies 
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examining the association between arterial stiffness and atherosclerosis have 
reported conflicting results (Maarek, et al 1987) (Wada, et al 1994) (Riley, et al 
1997) (Megnien, et al 1998). Traditionally, structural components within the 
arterial wall, together with mean arterial pressure, were thought to be the major 
determinants of vessel stiffness. However, arterial stiffness is a dynamic 
parameter, which can be modulated by changes in smooth muscle tone, and it is 
now recognized that the vascular endothelium plays an important role in the 
functional regulation of arterial stiffness. Importantly, direct phan-nacological 
manipulation of arterial stiffness is possible and therapeutic strategies that 
specifically target the large arteries to reduce stiffness may be helpful, 
particularly in those individuals with increased or premature arterial stiffening. 
Nitric oxide donor drugs are one such strategy and may be particularly useful in 
this regard. However, therapies that target changes arterial structure provide an 
interesting alternative. Further studies are required to determine the most 
effective therapies with which to reduce large artery stiffness and, thus, 
potentially, CV risk. 
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Cardiovascular disease in SCH 
The association of SCH with CV disease has been quite controversial. One of 
the earliest case-control studies showed a strong association between SCH (as 
defined by exaggerated response to thyrotropin releasing hormone) and 
angiographically demonstrated coronary artery disease (Dean and Fowler 1985). 
Since then, there have been several community-based cross-sectional (Hak, et al 
2000) (Tunbridge, et al 1977a) (Imaizumi, et al 2004) (Lindeman, et al 2003) 
(Rodondi, et al 2005) (Walsh, et al 2005) (Cappola, et al 2006) as well as 
longitudinal studies (Haký et al 2000) (Imaizumi, et al 2004) (Vanderpump, et al 
1996b) (Parle, et al 2001) (Gussekloo, et al 2004) (Rodondi, et al 2005) (Walsh, 
et al 2005) (Cappola, et al 2006) that have assessed this relationship. There has 
been no large scale randomised controlled trial of treatment of SCH in assessing 
CV disease. 
The cross-sectional component of the Rotterdam study concluded that SCH was 
a risk factor for aortic atherosclerosis and myocardial infarction in women aged 
55 years or more with a risk comparable to that associated with diabetes 
mellitus, smoking and hypercholesterolernia (Hak, et al 2000). However, the 
longitudinal component of this study (4.6 year follow-up period), did not 
demonstrate this association, but total CV events were quite low. 
The cross-sectional Whickham study showed a weak association between minor 
ECG changes and SCH in women, independent of other variables. The authors 
stated that this finding was of questionable importance since detection of ECG 
changes was observer dependent (Tunbridge, et al 1977a). A 20-year follow-up 
study of the cohort did not reveal an association between autoimmune thyroid 
disease and CV disease (Vanderpump, et al 1996b). But many patients with 
SCH in the original survey received L-thyroxine replacement therapy and the 
analysis did not differentiate between treated and not treated patients. The study 
also did not differentiate between SCH and euthyroid people with positiN, C 
antibodies. 
A Japanese study showed that SCH was associated with CV disease independent 
of all other variables in men but not in women in the cross-sectional analysis. 
There was no association xvith cerebroN, ascular disease. The longitudinal arm of 
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the same study (10-year follow-up period) showed increased all-cause mortality 
in men with SCH (the exact nature of death was not investigated) (Imaizumi, et 
al 2004). 
A longitudinal case-control study, in Birmingham, UK, of 1191 people aged 
more than 60 years followed-up for 10-years, showed no increased risk of CV 
disease in the group with SCH, although it did not differentiate between treated 
and untreated patients (Parle, et al 200 1). 
Similarly, the prevalence of CV disease was not increased in SCH patients in a 
cross-sectional survey of 3410 elderly people in Maryland, USA (Cappola, et al 
2006). 
However, a cross-sectional study in New Mexico, USA, of a randomly selected 
sample of 112 people aged 65 years or more, found that there was an increased 
prevalence of CV disease in participants whose TSH >I OmIU/L (Lindeman, et 
al 2003). 
A recent study with both cross-sectional and longitudinal arms of people aged 
between 70-79 years reported no association between SCH and CV disease at 
baseline but there was an increased incidence of congestive heart failure after 4 
years of follow-up only in the moderate and severe SCH groups (TSH 7-9.9 and 
>I 0 mIU/L, respectively) but not the mild SCH group (Rodondi, et al 2005). 
Another recent study that had cross-sectional and longitudinal arms (follow-up 
of 20-years) found a significant association of CV disease at baseline as well at 
follow-up (Walsh, et al 2005). 
On the other hand, the Leiden study of people aged 85 years or more showed 
that an elevated TSH was associated with a decreased risk of death from CV 
disease during 4 years of follow-up (Gussekloo, et al 2004). However, 62% of 
the participants with SCH had reverted to being euthyroid at the time of follow- 
up, suggesting that a high proportion of people with SCH at the outset may have 
had non-thyroidal illness or their SCH was not stable. 
Details of these studies ate given in Tables 4 and 5. As can be seen from these 
tables, there have been a number of cross-sectional as well as longitudinal 
studies that have assessed the risk of ischernic heart disease (IHD) in people 
Nvith SCH, with varying results. The differences in results are quite likely to be 
due to the different population samples studied (inclusion or exclusion of 
subjects with history of thyroid disease, previous CV event, current L-thyroxine 
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therapy) as well as variations in definitions of IHD, length of follow-up and 
varying limits of TSH cut off values that defined SCH. Therefore, a systematic 
review and meta-analysis of these studies that have assessed lHD and its risk 
factors was performed. The methods of the meta-analysis are outlined below. 
Methods: 
Inclusion criteria: 
Cross-sectional and longitudinal studies assessing IHD risk, mortality, and 
cross-sectional studies assessing lipids and body mass index (BMI): 
1. Population-based cross-sectional or longitudinal study of unselected 
community living adults. 
2. Should have reported validated IHD events (myocardial infarctions, angina, 
coronary artery interventions like angioplasty or surgery), mortality, lipids and 
BMI in both SCH and euthyroid groups, and stated variance, if applicable. 
3. Should have measured thyroid hormone (thyroxine) as well as TSH levels as a 
prerequisite to diagnose SCH. 
4. Should have included patients with TSH levels < 10 mIU/L in the study. 
Literature search criteria: 
A comprehensive search of PubMed, Embase and the Cochrane database of 
systematic reviews was conducted between February 2004 and June 2006, for all 
relevant articles published between 1976, when a reliable TSH assay became 
available, and 2006, using the Mesh terms "thyroid", "cardiovascular", 
"ischemic heart disease", "lipids" and "cholesterol". The references of these 
articles were then studied to compile any missed articles. Authors of studies 
where data was incomplete were contacted for additional information. 
Data abstraction: 
1HD events or mortality were abstracted from included studies along with 
number of participants in each arm. Where data was presented for lHD events, 
strokes and peripheral vascular disease, then only IHD data was included. If data 
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was reported as CV disease events, then all data was included for both groups. 
For those studies that reported results that were stratified according to baseline 
TSH levels, data was abstracted for TSH levels < 10 mIU/L. When studies 
reported data for different subgroups (for example by age or by gender), the 
average across all subgroups was calculated for both euthyroid and SCH groups. 
For those studies where variance of difference of means was not available, 
variance was calculated (for trials that reported difference from baseline) or 
imputed (for trials that reported final values). All analyses were by intention to 
treat. 
Statistical analyses 
The results are calculated using both fixed and random effect models. IHD 
events (both prevalence and incidence) and mortality was expressed as odds 
ratio (OR). Continuous data is expressed as weighted mean difference. 
Heterogeneity was tested by the y, 2 test and 12 test, p<0.1 and a value greater 
than 50% is indicative of substantial heterogeneity, respectively. Odds ratio and 
the mean difference is expressed in a fixed manner for analyses that are 
statistically homogenous and in a random manner for those that are 
heterogeneous. The statistical package Revrnan 4.2 was used for analyses and 
for generating figures. 
Results 
The studies that assessed IHD prevalence, incidence and mortality are shown in 
tables 2-3, and meta-analysis of the data shown in figures 2-4. 
Prevalence of IHD in SCH (table 2 and figure 2): It is significantly increased 
with an odds ratio (OR) of 1.27 (95% Cl 1.03 - 1.58), p=0.03. Tests for 
heterogeneity reveal that the studies are significantly different (Chi 
2 18.36, df 
=9, p=0.03), hence the random effects model was used. Subgroup analysis 
shows that the prevalent IHD association with SCH is due to trials that have 
studied individuals less than 65 years of age, OR 1.55 (1.10 - 2.19), p=0.01. 
Studies of populations aged more than 65 years failed to show this association, 
OR 1.04 (0.88 - 1.22), p=0.64. 
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Table 2. 
Cross-sectional studies of cardiovascular disease in SCH 
Study No. of 
participant 
Eu SCH 
Recruitment CVD in 
Eu n 
CVD in 
SCH n 
(%) 
Signific 
ance 
Whickham 2460 132 Population 145 (5.9) 11(8.3) NS 
Rotterdam 867 116 Population 61 (7) 17(14.6) S 
CV Health 2639 496 > 65 years 489(18.5) 98 (19.7) Ns 
Japanese 2293 257 Atomic bomb 
survivors 
29(l. 3) 9(3.5) S 
New 
Mexico 
643 112 >65 years 181 (28.1) 32(28.6) Ns 
Australian 1906 119 Population 154(8.1) 18 (15.1) S 
Tennessee 2392 338 70-79 years 710(29.7) 101 (29.9) Ns 
Denmark 963 249 1 PHC 189(19.6) 50(20.1) S (men) 
German 1745 29 Population 96(5.5) 2(6.9) NS 
NHANES 1551 57 Population 218 (12) 7 (13) NS 
Eu - Euthyroid, SCH - Subclinical hypothyroidism, CVD - Cardiovascular 
disease, Ns - Not significant, S- Significant, PHC - Primary Health Centre. 
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Figure 2. 
Forrest plot of CV disease in cross-sectional studies of SCH 
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Incidence of IHD in SCH (table 3 and figure 3): Incidence of IHD is not 
increased in the total cohort of SCH patients, random OR 1.25 (0.70 - 2.24), 
p=0.45. In subgroup analysis by age, trials that studied subjects with SCH below 
65 years showed a significant association with incident IHD, OR 3.04 (1.97 - 
4.69), p<0.00001. In contrast, trials with subjects aged 65 years or more failed to 
show any association, OR 0.87 (0.68 - 1.12), p=0.28. 
Table 3. 
Longitudinal studies of CVD in SCH. 
Study No. of F/U in Age CVD in EU CVD in Sig Remarks 
participants years 
N SCH N 
Eu SCH (%) 
Whickh 126 126 20 20+ 21 (16.7) 32 (25.4) NS SCH - +ve 
am antibodies 
& normal 
TSH 
Birmin 1026 76 8.2 20+ 180 (17.5) 11 (14.5) NS 30 pts in 
gham SCH on 
LT4 
Australi 1752 101 20 58 229(13.1) 33 (32.7) S Excluded 
an patients on 
LT4 
Tenness 2392 338 4 70 - 79 298 (12.4) 36 (10.6) NS 51 pts in 
ee SCH on 
LT4 
Leiden 472 30 4 > 85 185 (39.2) 7(23.3) NS 62% were 
years eu at Vu 
v 1838 347 12.5 > 65 462(25.1) 85 (24.5) NS 142 pts in 
Health years SCH on 
Study LT4 
Eu - Euthyrold, SCH - Subdinical hypothyroid, (-'VL) - (Ardiovascuiar cusease, 
Ns - Not significant, S- Significant, ATD - autoinimune thyroid 
disease. 
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Figure 3. 
Forrest plot of CV disease in longitudinal studies of SCH 
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Mortality (due to IHD) (figure 4): Mortality due to IHD is not increased, 
random OR 1.31 (0.93 - 1.85), p=O. 12. In subgroup analyses by age, studies of 
people with SCH aged less than 65 years showed a significant association, OR 
1.57 (1.03 - 2.39), p=0.03. People with SCH aged 65 years or more did not show 
this association with mortality, OR 1.01 (0.73 - 1.40), p=0.95. 
Figure 4. 
Forrest plot of CV mortality in SCH. 
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It is not clear why SCH may have a protective CV influence in older people (> 
65 years). Many negative longitudinal studies of CV endpoints have included 
patients on L-thyroxine therapy, which could have a normalising influence on 
important parameters like endothelial function and lipids (table 3). 
The impact of SCH on the CV system has been evaluated by investigating 
cardiac function and anatomy, as well as vascular resistance and endothelial 
function. Diastolic and systolic function, both on effort as well at rest have been 
shown to be impaired in patients with SCH (Monzani, et cil 2001) (Vitale, et a/ 
2002) (Biondi, et al 1999) (Bell, et al 1985) (Forfar, et al 1985). Another study 
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has shown impaired cardiopulmonary exercise testing (Kahaly 2000). Another 
study, using ultrasonic myocardial textural analysis has found an altered 
myocardial composition which may represent early structural changes (Di Bello, 
et al 2000). Studies have shown that systemic vascular resistance has a 
significant inverse correlation with FT3 and a direct relationship with TSH in 
people with SCH (Faber, et al 2002). There have been 2 studies that have shown 
impaired endothelial function in people with SCH, suggesting that nitric oxide 
availability is reduced in this condition (Lekakis, et al 1997) (Taddei, et al 
2003). 
Thyroid autoimmunity and CV disease: The association between thyroid 
autoirnmunity and cardiovascular risk is also similarly controversial. Autopsy 
studies (Gaspar 1968) and hospital inpatient studies (Bastenie, et al 1967) 
(Bastenie, et al 197 1) (Tieche, et al 198 1) suggested a link between 
asymptomatic autoimmune thyroiditis and coronary artery disease. But these 
findings were not confirmed by other studies (Heinonen, et al 1972) (Tunbridge, 
et al 1977a) (Miura, et al 1996) (Wells and Hueston 2005). The Rotterdam study 
found a significantly higher association of a history of myocardial infarction and 
atherosclerosis in women who were positive to thyroid peroxidase antibodies 
(Hak, et al 2000). 
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CV risk factors in SCH 
The relationship between SCH and serum lipids is unclear (Tanis, et al 1996) 
(Helfand and Reffern 1998) (Toft 1994). This is partly because of the range of 
populations studied and different designs addressing the issue. The list of 
different population based cross-sectional studies is given below (table 4). All 
the twenty studies are cohort studies apart from the one reported by Parle and 
colleagues, which is a case-control study where patients with SCH were 
identified from one primary health care centre in Binningham and matched to 
euthyrold controls. Figure 5 shows the difference in meta-analysis between SCH 
and euthyroid individuals in terms of total cholesterol levels. 
Total cholesterol (flgure 5): Total cholesterol is higher in patients with SCH as 
compared to euthyroid individuals, weighted mean difference (95% Cl) of 0.2 
mmol/L (0.1 - 0.3), p<0.0001. The studies were sufficiently heterogeneous 
(Chi2 = 157.5, df=19, p<0.00001), therefore a random effects model was used 
for analysis. 
Other lipid parameters: LDL cholesterol is higher in individuals with SCH 
than euthyroid people by random weighted difference of 0.20 mmol/L (0.08 - 
0.33), p<0.002. The studies were positive for heterogeneity (Chi 2= 161, 
df=l l, p<0.00001). HDL cholesterol showed no difference at all in SCH versus 
euthyroid individuals, random weighted difference of 0.0 mmol/L (-0.07 - 0.06), 
p=0.90. Test for heterogeneity was positive (Chi2 = 135.6, df=I 1, p<0.00001). 
Triglyceride levels are higher in SCH patients as compared to euthyroid 
counterparts by 0.28 mmol/L (0.12 - 0.44), p<0.0008. The tests for 
heterogeneity were positive, necessitating the use of a random effects model 
(Chi 2 =76, df=10, p<0.00001). 
BMI: There is no difference in the BMI of people with SCH as compared to 
euthyroid individuals, weighted mean difference of 0.16 kg/m 
2 (-0.1 - 0.43), 
p=0.22. The studies were significantly heterogeneous to warrant analysis by the 
random effects model, Chi2 = 15.2 7, df=9, p=O. 0 8. 
Blood pressure: There was no difference in systolic blood pressure in either 
group (SCH versus euthyroid), random weighted mean difference of'I . 00 (- 1 . 30 
- 3.3 1), p=0.39. Diastolic blood pressure tended to 
be higher in SCII group but 
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failed to reach statistical significance, fixed weighted mean difference of 0.57 (- 
0.26 - 1.40), p=O. 18. 
Table 4. 
Cross-sectional population based unselected studies of lipids in SCH 
patients versus euthyroid controls. 
Study Patients 
SCH Eu 
TC 
SCH Eu 
Triglycerides 
S CH Eu 
LDL c 
SCH Eu 
HDL c 
SCH Eu 
Australian 119 1906 6.3 5.8 1.7 1.4 4.1 3.5 1.5 1.5 
NHANES 111 215 8013 5.8 5.6 2 1.8 3.6 3.5 1.3 1.3 
Danish 249 963 5.2 5.3 1.4 1.3 2.8 2.9 1.5 1.5 
Slovakian 169 1797 5.7 5.4 2.2 1.8 - - 
Korean 375 65017 5.2 5.0 - 3.2 3.1 
Kanaya(Ame 
rica) 
62 1858 5.9 5.3 - - 
New Mexico 112 643 5.4 5.3 - 3.5 3.3 1.3 1.2 
Birmingham 57 ? 57 6.6 6.3 - 4.4 4.2 1.4 1.4 
SOF study 19 250 6.7 6.2 2.1 1.9 4.4 4.0 1.2 1.4 
Whickharn 
1977 
132 2460 6.2 6.0 1.4 1.3 - 
CV Health 
Study 
496 2639 5.5 5.5 
Colarado 233622842 5.7 5.5 - - - 
German 
study 
29 1745 6.5 6.1 - 4.1 3.9 1.6 1.4 
Tennessee 338 2392 5.4 5.2 - - - 
Rotterdam 116 867 6.7 7.0 - - 1.4 1.5 
Japanese 257 2293 5.0 5.0 - - - 
CUI study 31 1167 7.2 7.4 - - 
Leiden 30 472 6.4 5.7 1.9 1.5 - - 
Pirich 2 1885 5.9 5.6 2.8 1.4 3.8 3.7 1.2 1.3 
frornso 127 4894 ý. 6 6.2 1.6 1.5 4 4.0 1.6 1.5 
SCH - subclinical hypothyroidism, Eu - euthyroid, 
TC - Total cholesterol, LDL 
c- Low density lipoprotein cholesterol, HDL c- High density lipoprotein 
cholesterol. Cholesterol and triglyceride levels are in mi-nol/L. 
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Figure 5. 
Forrest plot of difference in total cholesterol levels in SCH versus euthyroid 
people in population-based unselected studies. 
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There have also been other cross-sectional studies of people with 
hypercholesterolernia that have reported increased prevalence of SCH compared 
to normocholesterolearn ic control groups (Oettgen, et al 1994) (Ball, et al 199 1 
(Pallas, et al 1991) (Series, et al 1988). Since SCH may be present for many 
years before overt hypothyroidism develops, it may be worthwhile to know 
whether there is any potential to improve lipid profiles in this group. 
Conclusion: The meta-analysis shows that SCH is associated with increased 
prevalence and incidence of IHD as well as increased CV mortality in people 
less than 65 years of a0c. There is an also increased total cholesterol level of 
0.20 mmol/L in people Nvith SCH as compared to euthyroid individuals. It is I 
Unclear why there seems to be a difference in outcomes in people ý\ ith SCH 
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according to age. It may be that there is a self-selection bias in these trials in that 
some people with SCH may not reach an age greater than 65 and beyond, and 
those that do have an inherently strong and healthy constitution that overrides 
the negative impact of SCH. The other possibility is SCH has a protective 
influence in elderly people, by some unknown mechanism. There is also a slight 
but significant increase in BMI in people with SCH although blood pressure is 
not significantly different. One of the explanations, which is not accounted for 
by the meta-analysis is that there might be other differences in people with SCH 
that could explain some of these differences, compared to euthyroid individuals. 
It is well known that SCH is more prevalent in older individuals and a difference 
in age could explain all of these differences, especially in differences in lipids 
and BMI. The mean ages of people with SCH in all the different studies in tables 
4-7 were no different compared to the euthyroid group, random v', eighted mean 
difference 0.98 years (453 - 2.50), p=0.20. 
It therefore seems quite likely that SCH is associated with a significantly worse 
CV risk factor profile in people with SCH compared to euthyroid individuals. 
The next chapter examines whether treatment of SCH with L-thyroxine has 
shown any significant improvement in these risk factors in the published 
literature. 
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Effect of L-thyroxine treatment on cardiovascular risk 
factors. 
The potential benefits and risks of treating SCH have been debated for a fev", 
decades. The possible advantages are prevention of progression to overt 
hypothyroidism, reversal of symptoms of hypothyroidism and improvement of 
QoL, and potentially decrease CV events and mortality. 
There has been no randomised controlled trial (RCT) that has investigated the 
effect of L-thyroxine on CV disease incidence. There have been a number of 
studies that have looked at various CV risk factors. RCTs of L-thyroxine in SCH 
are shown below (table 5). 
Table 5. 
RCTs assessing effect of L-thyroxine therapy on lipid profile in SCH. 
Study TC 
Before Change Sig 
LDLc 
Before Change Sig 
HDLc 
Before Change Sig 
Triglycerides 
Before Change Sig 
Cooper 6.5 -0.33 NS 1.4 -0.12 NS 
Nystrom 6.8 -0.2 NS 
Jaeschke 5.7 0.3 NS 3.6 0.18 NS 1.4 0.04 NS 1.5 0.07 NS 
Meier 6.3 -0.1 S 4.1 -0.2 S 1.7 0 NS 1.3 0 NS 
Caracclo 5.5 -0.5 S 3.6 -0.6 S 1.5 -0.1 NS 1.3 0 NS 
Monzani 5.5 -0.8 S 3.5 -0.6 S 1.5 0 NS 1.0 -0.15 NS 
Kong 5.5 0.2 NS 3.3 0.1 NS 1.0 0.02 NS 1.8 -0.1 NS 
lqbal 5.9 -0.2 NS 3.7 -0.1 NS 1.5 0 NS 1.5 0 NS 
SCH - subdinical hypothyroidism, TC - total cholesterol, LDL c- Low density lipoprotcIn 
cholesterol, HDL c- High density lipoprotein cholesterol. 
These studies show that the effect of L-thyroxine on serum lipids is variable. 
The variability arises due to the differing nature and number of patients 
recruited, study design and dose of L-thyroxine therapy. Previous meta-analysis 
has shown that reduction in total cholesterol ranges from 0.2 to 0.4 rnrnol/L and 
LDL cholesterol by 0.26 mmol/L (Tanis, et al 1996) (Danese, et al 2000). There 
has been no reported beneficial effect on HDL cholesterol or triglycerides. 
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There has also been studies investigating the effect of L-thyroxine on cardiac 
function that have shown a beneficial effect (Ridgway, et al 198 1) (Cooper, et al 
1984) (Nystrom, et a/ 1988) (Bell, et al 1985) (Forfar, et al 1985) (Foldes, et al 
1987) (Kahaly 2000) (Arern, et al 1996) (Monzani, et al 2001) (Biondi, et cil 
1999) (Yazici, el al 2004). One study that looked at endothelial dysfunction by 
intra-arterial infusion of acetyl-choleine found that L-thyroxine had a beneficial 
effect (Taddei, et al 2003). 
Results of meta-analysis on CV risk factors in SCH 
Effect of L-thyroxine on total cholesterol levels: The meta-analysis done here 
reveals that the mean reduction in total cholesterol is 0.25 rnmol/L (0.03' - 0.46), 
p=0.02, as seen in figure 6. Tests for heterogeneity show that there was 
significant diversity in all the trials included, and therefore a randorn effect 
model was chosen (Ch i2 15.75, df=7, p=0.03). 
Figure 6. 
Forrest plot of effect of L-thyroxine treatment on total cholesterol levels in 
randomised controlled trials of SCH. 
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This is very similar to the results of the previous meta-analyses, although the 
previous studies had included many before-after studies and only three RCTs 
and therefore had potential for bias. Furthermore, there have been five more 
RCTs that have published their results since the last meta-analysis. 
Effect of L-thyroxine on other lipid parameters: L-thyroxine reduces LDLc 
by 0.24 mmol/L (0.02 - 0.46), p=0.04. This was analysed by a fixed effect 
model since test for heterogeneity was negative (Chi2 =6.76, df=:: 5, p==0.24). 
There was no significant effect of L-thyroxine on HDLc or serum triglyceride 
levels noted in the meta-analysis of the RCTs that have assessed them. Serum 
apolipoprotein B was measured in only two trials and showed a significant 
reduction in both, whereas there was no effect on apolipoprotein Al. 
Effect of L-thyroxine on BMI: L-thyroxine reduces BMI by 0.38 kg/m 2 (0.15- 
0.60), p=0.001. Tests for heterogeneity were negative (Chi2 =8.34, df=6, 
p=0.21), therefore a fixed effects model was used. This has not been shown in 
any of the individual trials that have assessed this parameter, and confirms that 
none of them were designed to detect body weight response to L-thyroxine 
therapy. 
Effect of L-thyroxine on blood pressure: There have been eight RCTs 
assessing the effects of L-thyroxine on various parameters but only one has 
reported changes in blood pressure, and that showed no significant difference as 
compared to placebo (Monzani, et al 200 1). 
Conclusion 
It can be seen that the CV risk factor profile in SCH is an unclear area. This 
absence of clarity is even more present in people with milder forms of SCH 
(TSH levels between 4- 10 mIU/L). The reason for this uncertainty is lack of 
well-designed RCTs that have sample sizes calculated to detect a significant 
difference. Furthermore, there is no RCT that has assessed endothelial function 
and its response to treatment with L-thyroxine in patients with SCH. T11crefore a 
RCT was conducted to assess CV risk factors, endothelial function and patient- 
reported outcomes in a large group of patients with SCH. 
49 
Aims of the study 
It can be seen that the area of SCH has remained controversial and unclear 
despite much research having been conducted. Although there Is some evidence, 
by no means unchallenged, that there is increased risk of CV disease in people 
with SCH, it is unclear whether traditional CV risk factors account for this 
increased risk or whether it could be attributed to by other "newer" risk factors 
like endothelial dysfunction and vascular inflammation. There has been no RCT 
measuring endothelial function, which is the earliest marker of atherosclerosis in 
SCH patients. One of the major reasons for this lack of clarity has been the 
absence of proper design in terms of power calculations in all the previous 
studies. 
The area of QoL has remained untested in people with hypothyroidism and there 
has been no systematically designed and validated instrument to measure this 
important aspect of patient reported outcome. Also, other instrument to measure 
satisfaction with treatment and symptom bother scores have also not been 
designed or validated in this area. 
This study was therefore designed with the following aims in mind: 
1. To perform a double-blind placebo-controlled trial of L-thyroxine treatment in 
patients with SCH. The aim was to recruit a large sample, reinforced by power 
calculations, to be able to detect very subtle improvement as well as side-effects, 
due to the mild area of the disease spectrum being studied. 
2. To recruit at least 75% of patients with TSH levels between 4.0 - 10.0 mIU/L, 
since this is the degree of SCH with the greatest degree of confusion. 
3. To set up and validate the technique of non-invasively measuring endothelial 
function via the technique of FMD and to assess it in people with SCH, before 
and after treatment with L-thyroxine in a double-blind controlled manner. 
4. To design and validate instruments to measure disease-specific QoL, treatment 
satisfaction and frequency of symptoms and their bother-scores and to utilise 
these instruments in assessing these parameters in people with SCH. 
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METHODS (A) 
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Hypothesis and endpoints 
Hypothesis: Treatment of SCH with L-thyroxine improves CV risk factors and 
patient-reported outcomes. 
Primary endpoints: 
1. Improvement in brachial artery flow mediated dilatation (FMD) as a marker 
of vascular endothelial function 
2. Reduction in total cholesterol (TC) levels, after 12 weeks of L-thyroxine 
treatment. 
The 2 primary endpoints were chosen because: 
Reduction in total cholesterol, especially LDL cholesterol is probably the most 
widely used and recognised CV risk factor ((Expert Panel on Detection 200 1). 
There is"some controversy whether L-thyroxine therapy reduces TC levels and if 
so, by how much ((Cooper 1998). 
Endothelial function is a novel and increasingly recognised method of assessing 
CV risk status and an excellent barometer of vascular health ((Vita and Keaney 
2002); and FMD is the most reproducible way of measuring this. It also has the 
advantage of being most influenced by nitric oxide activity. There has been no 
RCT assessing the effect of L-thyroxine on endothelial function. 
Secondary endpoints: Changes in: 
Weight and its distribution (assessed by weight, waist-hip ratio and waist 
circumference). 
Triglyceride (TG). 
HDL cholesterol (HDLc). 
LDL cholesterol (LDLc). 
Apolipoprotein Al (apoAl). 
Apolipoprotein B (apoB). 
Patient-reported outcomes, (assessed by questionnaire): 
Perceived health status. 
Hypothyroidism-specific quality of life (QoL). 
Hypothyroid symptoms. 
Hypothyroid-specific satisfaction with treatment. 
Vascular studies: validation and measurement 
Technique of FMD. 
The capacity of blood vessels to respond to physical and chemical stimuli in the 
lumen confers the ability to self-regulate tone and to adjust blood flow and 
distribution in response to changes in the local environment. The phenomenon 
of blood vessels dilating in response to an increase in flow (shear stress) is 
called flow-mediated dilatation or FMD. A principal mediator of FMD is 
endothelium derived Nitric Oxide (NO). 
Numerous factors affect flow-mediated vascular reactivity, including 
temperature, food, drugs and sympathetic stimuli, among others (Corretti, et al 
2002). Therefore subjects were prepared as follows: 
1. Fast for at least 12 hours before. 
2. Studied in a quiet, temperature controlled room. 
3. All vasoactive medications withheld for at least 4 half-lives, if possible. 
4. No exercise, caffeine, high fat foods, vitamin C or tobacco for at least 4-6 
hours before. 
5. The phase of the subject's menstrual cycle should be taken into account. All 
pre-menopausal women were scanned in follicular phase. 
Brachial arteries were imaged with a standard HDI 5000 ultrasound system 
(ATL, Bothell, Washington, USA) with a 5-12 MHz linear transducer (figure 
7A). The ultrasound system was connected to a personal computer equipped 
with a frame grabber and artificial neural network wall detection software 
[vessel image analysis (VIA)]. The VIA software automatically detects and 
tracks the anterior and posterior walls within a user defined region of interest 
(figure 713). The vessel diameter is detennined by averaging a large number of 
local vessel diameters. The software can also accommodate angulation of the 
artery (up to 20') relative to the perpendicular. The B mode images are 
processed at 25 frames/s and the vessel diameter, including diameter changes 
over the cardiac cycle, is displayed in real time (figure 8). This allov"'s 
ultrasound-imaging parameters to be optimised at the start of the scan and the 
transducer position to be adjusted immediately for optimum tracking 
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performance during the entire test. The brachial artery was scanned 
longitudinally 2-10 cm above the elbow until the clearest possible image of the 
anterior and posterior wall media was obtained. Depth and gain settings were 
kept constant during the rest of the study. A stereotactic clamp was used to hold 
the transducer and a screw gauge was used to make small compensatory 
movements of the transducer to accommodate subject movement during the test. 
The distance of the transducer from the antecubital fossa was noted and a two 
dimensional image of the brachial artery was saved on the computer's hard drive 
for reference in repeat studies. 
Brachial artery FMD was determined according to a conventional protocol 
(Corretti, et al 2002). The right brachial artery was scanned continually 
throughout the test. Pulsed Doppler was used to assess arterial flow at rest and 
immediately after tourniquet deflation. Firstly, a baseline scan was perforined 
for 2 minutes. Then a tourniquet located at the right proximal forearin was 
inflated to a pressure of 250 mm Hg for 5 minutes. Brachial artery dilatation 
following reactive hyperaernia was recorded for 5 minutes after tourniquet 
release. After at least ten minutes, to allow for baseline conditions to be re- 
established, sublingual glyceryl trinitrate (400 ýtg) was then administered and 
imaging perforined for another 5 minutes to determine endothelium independent 
vasodilatation. At the end of the study a graph of diameter against time was 
immediately displayed. The FMD (defined by the percentage increase in mean 
diameter over a 10 second period, 55 seconds after tourniquet deflation) was 
automatically calculated by VIA from diastolic vessel diameters (figure 9). The 
endothelium independent dilatation was calculated similarly to the percentage 
increase in mean diameter 5 minutes after glyceryl trinitrate administration. 
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Figure 7. 
(A) The brachial artery is imaged such that the media-lumen interface is 
clearly seen. 
(B) The arterial media-lumen interface is automatically located and 
tracked within the region of interest. 
Figure 8. 
The mean vessel diameter within the region of interest displayed in real 
time at 25 frames/s. This allows the operator to optimise image quality 
continually. 
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Figure 9. 
Graph of brachial artery diameter versus time in a normal subject. FloNN, 
mediated dilatation for this subject was 7.3% when comparing mean 
diastolic diameter before cuff inflation and between the "peak start" and 
"peak end" cursors. 
2.8 
-. ' 
el 
2 2.6 
0 22.4 
2.3 
09-42: 30 09: 44: 10 09: 45A 0 9: 4 17: 30 09: 49: 10 09.51: 09 09: 41: 41.09: 43: -10 09: 45: 00 09: 46: 40 09A8: 20 09: 5 0: 00 
VIA Software: 
Each conventional FMD study (with manual diameter calculation) typically lasts 
for 10 to 15 minutes and images are usually updated at diastole and recorded. 
Artery diameter is calculated by detecting the vessel walls within a user-defined 
image region, using an automated computer algorithm. However, retrospective 
analysis can give rise to several problems. At commencement of the study, 
adjusting the scanner controls to suit the visual preferences of the operator 
optlinises the images. This may adversely influence perfon-nance of the wall 
detection algorithm, but the effect will not be apparent until the study is 
completed. Additional operator effort and time is required for analysis. VCR 
recording involves some loss of image quality during record and playback, and L- I 
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computer storage may require a low acquisition rate or short acquisition period 
to avoid unwieldy archives. For example, storing a reduced image section of 256 
x 256 pixels at 25 images s-l requires almost I Gbyte of disk space for a 10- 
min study. It is not possible to recover the artery diameter changes as a function 
of the cardiac cycle if the image acquisition rate is low. Recovery of these 
changes allows diastole to be established without the need for image 
synchronisation and is potentially useful in elasticity studies. These problems 
can be resolved if the data are analysed online. 
Several groups have reported retrospective methods of automatically identifying 
vessel walls. However, the reported techniques do not lend themselves easily to 
online analysis. For example, dynamic programming (Wendelhag, et al 1997) 
requires the images to be intensity-normalised, based on the average intensity 
over all images, and smoothed horizontally to remove vessel wall dropouts. 
Smoothing may compromise accuracy due to blurring on all but straight 
horizontal vessel walls, and some rotational normalisation is, therefore, 
desirable. To recover diameter changes over the cardiac cycle, it is necessary to 
measure vessel diameter at twice the Nyquist frequency of the cardiac cycle to 
avoid aliasing. Output from most scanners is limited to 25 images s-1, giving 40 
ms per image for all processing. The graph-search dynamic programming 
method of Liang and colleagues (Liang, et al 2000) is computationally intensive, 
requiring Is per image for processing. Some current retrospective systems also 
require significant manual intervention in setting up and/or in monitoring 
performance. 
Therefore a PC-based system that automatically locates the correct vessel walls 
in a user-defined region-of-interest (ROI) and measures vessel diameter online 
throughout a FMD study was used (Newey and Nassiri 2002). The system was 
designed to minimise operator workload; the only user input normally required 
is to drag an orthogonal ROI over the required vessel section and to press a start 
button. This technique has several advantages over established practice. FMD 
results are available immediately. Data for the complete study are available, 
rather than just a feý, v salient events, and changes in vessel diameter over the 
cardiac cycle are recovered. Vessel wall tracking quality can be optimised by 
adjustment of the scanner controls before the study proper. This largely 
normalises the intensity range of the images to the range presented to the neural 
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networks in the training regimen, thereby optimising the images to suit the 
networks. With retrospective analysis, however, images are subjectively 
optimised for visual, rather than wall detection properties and the detection 
algorithm must, therefore, handle a wider range of image quality. Online 
analysis provides continuous graphical presentations of vessel diameter, 
detected walls and wall probability levels as tracking quality indicators. These 
features, some of which are only available retrospectively with off-line 
techniques, make minor changes in image and tracking quality and vessel 
alignment readily apparent at a time when they can be rectified. The method also 
avoids the image quality loss associated with VCR recording, and no processing 
of the image is necessary. Retrospective systems, however, often require 
processing steps, such as intensity or rotational normalisation or smoothing 
which, although improving the tracking qualities may cause some spatial 
degradation of the image. There is no unwieldy image archive; file size for a 
complete study is typically approximately 0.3 Mb and the study is completed 
much faster than retrospective methods, contributing to lower study costs. 
Although conferring more robust tracking, these points correspond to the media 
interface. The intima interface was ignored and the technique, therefore, 
overestimates vessel diameter because the intima-media distance represents the 
wall thickness. However, these error sources should not be significant in FMD 
studies, where relative rather than absolute change in diameter is of importance. 
As with all FMD studies, good image quality is mandatory for both accurate 
measurements and optimum wall tracking. The technique can also be used to 
detect non-horizontal vessel interfaces by searching the ROI sequentially with 
network input line sections at more than one orientation (i. e., vertical and 
horizontal) and combining the outputs to obtain the probability matrix. 
The simulated cardiac sequence required 7 to 8 min of data to recover diameter 
changes over the cardiac cycle with reasonable quality. In clinical practice, 
however, the cardiac cycle is generally recovered with good quality from I to 3 
min of data. Recovery of diameter changes over the cardiac cycle may be useful 
in other studies, such as investigation of the elastic properties of the %ýessel wall, 
where wall displacement combined with blood pressure can be used to calculate 
elasticity indices. 
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Validation of FMD technique 
The ultrasonographic assessment of brachial artery FMD is technically 
challenging and has a significant learning curve. FMD guidelines suggest that 
initial training is most efficiently gained by visiting experienced laboratories and 
hands-on training by an experienced individual (Corretti, et al 2002). Both these 
criteria were met by obtaining the initial training from Coronary Artery Disease 
Research Unit, St George's Hospital Medical School, London with Professor 
Juan Kaski (learning and orientation on 6 healthy volunteers) and by further 
training with Dr Crispian Oates, Head of Vascular Ultrasound, Newcastle 
General Hospital, Newcastle upon Tyne (further practice and training on 24 
healthy volunteers at least on 100 occasions). After 6 months of learning and 
practicing, normal healthy volunteers were scanned on 2 separate days under 
similar conditions to assess intra-observer variability. 
The baseline demographic, clinical examination and biochemical parameters are 
outlined in table 6. The characteristics of the vascular ultrasound results are 
shown in table 7. 
Table 6. 
Clinical examination and biochemical characteristics of healthy volunteers 
for FMD studies (n=29). 
Characteristics Results Mean (SD) 
Age (years) 34.9(7.2) 
Male/Female 13/16 
Systolic/diastolic blood pressure (mm Hg) 123 (6.4) 75 (5.7) 
BMI (kg/m2) 23.1 (2.3) 
Waist circumference (cm) 79.2(8.9) 
Waist hip ratio 0.8(0.1) 
Total cholesterol (mmol/L) 4.7(0.7) 
HDL cholesterol (mmol/L) 1.5 (0.5) 
LDL cholesterol (mmol/L) 2.6(0.5) 
Triglycerides (mmol/L) 1.1 (0.4) 
Glucose (mmol/L) 4.9(0.4) 
TSH (mlU/L) 1.8(0.9) 
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Table 7. 
Brachial artery FMD characteristics on healthy volunteers on 2 separate 
occasions (n=29). 
Characteristic Value (95%CI) Pearson's 
correlation 
coefficient 
Baseline diameter (mm) 
I" measurement 3.7 (3.4 - 3.9) 0.98 (P<0.001) 
2d measurement 3.6 (3.3 - 3.9) 
FMD (%) 
I" measurement 6.4 (5.1 - 7.6) 0.71 (p<0.01) 
2 nd measurement 6.4 (5.2 - 7.6) 
Absolute change in diameter (mm) 
Is'measurement 0.2 (0.2 - 0.3) 0.73 (p<0.01) 
2 nd measurement 0.2 (0.2 - 0.3) 
The mean of the differences (SID) in FMD for the healthy volunteers on 2 
occasions was 0.1% (2.1), suggesting that the mean difference in result for the 
group as a whole was minimal but there was a higher intra-individual variation 
(Sidhu, et al 2002). 
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Carotid intima-media thickness 
Common carotid artery (CCA) imaging was performed with an ATL HDI 5000 
ultrasound system by use of a 5- to 12-MHz linear transducer. All examinations 
were perforined on images frozen on the ultrasound screen. Settings for depth- 
gain compensation, pre-processing, persistence, and post-processing were held 
constant. Images were analyzed with the researcher and patient in a state of 
being blinded to the treatment group. Mean CCA intima-media thickness (IMT) 
was measured in the far wall over the distal 2-cm segment of the right common 
carotid artery, defined by the carotid bulb. Far wall measurements were chosen 
in accordance with methodological recommendations because the far wall is 
more easily and consistently visualized than the near wall ((Kanters, et al 1997). 
Mean IMT was measured from the lumen-intima interface to the media- 
adventitia interface, taking care to avoid areas of arterial plaque formation. 
Single IMT values were obtained from measurements on neighbouring lines 
perpendicular to the vertical line and then averaged and expressed as the mean 
IMT for that patient. The outcome measure was the difference in mean CCA 
IMT at the end of the study as compared to baseline. 
Reproducibility: Eight subjects had scans performed by the same researcher 
separated by I to 2 weeks. The mean of the absolute difference (SD) between the 
paired mean CCA IMT measurements was 0.05 (0.03) mm, and Pearson's 
correlation coefficient was 0.81, which compares satisfactorily with that reported 
in previous studies. 
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Carotid distensibility and stiffness. 
Distensibility is the ability of the artery to expand as a response to pulse 
pressure, that is, the change in arterial diameter during the cardiac cycle. 
Distensibility is the inverse phenomenon of stiffness, that is, if distensibility is 
decreased then that reflects increased arterial stiffness. Distensibility decreases 
with age. Cross-sectional studies showed associations between decreased 
distensibility and cardiovascular risk factors, i. e., hypertension, diabetes 
mellitus, hypercholesterolemia, and myocardial infarction ((Arnett, et al 1994) 
(Safar, et al 1987) (Salomaa, et al 1995a) (Riley, et al 1986). 
All measurements were performed with patient lying supine on the right 
common carotid artery, 2 cm proximal to the carotid bulb. The ultrasound 
scanner was connected to a vessel wall tracking system for elasticity 
measurements (Newey and Nassiri 2002). The same researcher who was blinded 
to the patients treatment group perforined all scans. Blood pressure was recorded 
at baseline prior to each study using an automated blood pressure recorder. 
Arterial distensibility is calculated by the fon-nula: (dA/Ad)/dP 
Where dA = systolic - diastolic arterial cross-sectional area change. 
Ad = diastolic arterial cross-sectional area. 
dP = systolic - diastolic pressure change. 
The CCA was scanned continuously for at least two minutes and measurements 
noted. 
Reproducibility: Scans were performed on 8 healthy volunteers I-2 weeks 
apart, showed that the mean of the paired differences (SID) of distensibility was 
0.5 (0.9) mmHg-' x 10-3. 
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Biochemical investigations 
Blood samples were drawn in the morning after at least 12 hours of fasting and 
immediately centrifuged. Samples were then stored at -40'C until analysis. 
Samples belonging to the same participants were analysed as one batch, in 
duplicate. Serum free thyroxine (FT4) free tri-iodothyronine (FT3) and TSH 
concentrations were measured by an electro-chemiluminescence immunoassay 
(Roche Diagnostics, UK). Thyroid autoirnmunity was assessed by the 
quantitative measurement of anti-thyroid peroxidase autoantibodies (anti-TPO) 
by ELISA (Orgentec Diagnostika GmbH, Mainz, Germany). Serum TC, HDLc 
and TG were assayed using automated enzymatic methods (Roche Diagnostics, 
UK). LDLc was calculated as per Friedewald's formula. Serum apoA I, apoB 
and hsCRP were determined by immunoturbidimetric methods (Roche 
Diagnostics, UK). Serum sICAM-1, e-selectin (R&D Systems, UK), and PAI- 
I and tPA (Diagnostica Stago, France) were measured by sandwich 
immunoassay technique. Normal ranges in our laboratory are as follows: FT4 
9- 25 pmol/L, FT3 =5-8.5 pmol/L, TSH = 0.4 -4 mIU/L, and anti-TPO 
antibody less than 50 IU/mL. Co-efficients of variation were below 5% for all 
tests except FT3, which was 5.5%. 
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Study design 
Randomised controlled trials are generally and rightfully regarded as the best 
fori-ris of evidence to evaluate the effectiveness of any intervention. Since 
clinicians, decision makers, scientists and increasingly patients turn to medical 
literature, it is imperative that all trials are conducted and reported in a rigorous 
and transparent manner (Moher, et al 200 1 a) (Moher, et al 200 1 b). 
Design 
Crossover trial: In an AB/BA crossover trial, patients are randomly assigned to 
receive either treatment A in the first period followed by treatment B in the 
second period or treatment B in the first period followed by treatment A in the 
second period. The crossover trial allows for a within-patient comparison 
between treatments and comparison between treatments, and can provide 
unbiased estimates for the differences between treatments in the two periods. 
The advantages of using a crossover design are: 
1. Removes inter-patient variability since each patient act as their own control. 
2. Smaller sample sizes are required to achieve a specific power. 
3. More statistical power due to paired comparisons. 
4. Sometimes, patients might agree to take part if they are assured that they 
would get to experience one of the drugs at least once. 
The disadvantages and pitfalls that can occur and need to be kept in mind are: 
1. Period effect: Differences in the effectiveness of interventions that occurred 
between the treatment periods due to the passage of time are called period 
effects. This can occur when a patients' condition changes between the two 
observations. Example: drug tolerance or resistance. Period effects increase 
within-patient variability and therefore reduce the overall power of the study. 
Period effects that affect both treatment conditions equally have a neutral effect 
on results. 
2. Sequence effect: Difference in effectiveness that results due to the order in 
which the drugs were administered. 
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I Carryover effect: This is the effect of the first treatment period that persists 
into the second period. Unlike sequence effects, carryover effects only affect the 
response in the second period. The effects of carryover can be reduced by a 
washout period in-between the two treatment periods. 
4. Double the time: Since each patient takes part in both interventions, the time 
period required to be available for the study is twice as long. This may lead to 
higher dropout rates. 
Sample size calculation 
Sample size calculation: The sample size needed to show an intended treatment 
benefit was based on the primary outcomes (FMD and TC), (x =0.05 and P=0.20. 
For FMD: to detect a minimal improvement of I%, standard deviation of 2.1, 
the required sample size was 8 1. The obtained sample size of 100 would give 
the study a power of 0.99 to detect the above difference. For TC: to detect a 
difference of 0.2 mmol/L, standard deviation of 0.5, sample size was calculated 
as 101 patients. 
Patient recruitment 
Patient recruitment to a clinical trial is recognised as a very difficult task 
(Lovato, et al 1997). Patients (n= 864), from General Practices in Gateshead, 
were identified from the laboratory database after they had a raised index TSH 
in the presence of normal FT4 level, in the period starting January 2003 and up 
to March 2003. General Practitioners had been informed via a letter, outlining 
the aims, objectives and details of the study, and their consent obtained to recruit 
their patients for this study. Inclusion and exclusion criteria were applied (those 
that could be determined from laboratory data like age, L-thyroxine treatment, 
diabetes mellitus, ischeamic heart disease, previous treatment for thyroid 
disease, concomitant medications, renal impairment, psychiatric disease and 
current pregnancy) and potential participants short-listed (n=322). In this group, 
thyroid function tests (TFTs) had been undertaken due to symptoms that could 
be attributed to hypothyroidism (n= 179), coincidental finding (n= 103), or due 
to family history of thyroid disease (n= 24). No reason for undertaking TFTs 
could be ascertained in 16 people. Those people who fitted the criteria, or the 
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criteria were not clear or who had had only one blood test for thyroid function 
tests (TFTs) at least 3 months prior were invited to come to the Hospital 
Diabetes Research Centre for a screening visit in a fasting state. This was done 
either via telephone or by sending a letter in the post. Of the 322 people so 
identified, 196 people were excluded after telephonic contact: 
1. Already on L-thyroxine (n=75). 
2. Previous thyroid disease or its treatment (n=59). 
3. Refused (n=36). 
4. Could not be contacted (n=26). 
Of the 126 people who attended for a screening visit, the following were 
excluded (n=26): 
1. Normal TFTs (n=23). 
2. Abnormal electrocardiogram (n=I). 
3. Raised fasting plasma glucose (n=2) 
Inclusion criteria: 
1. Persons aged between 18-80 years. 
2. Stable SCH (TSH >4 mIU/L and FT4 levels in the normal reference range, 
on at least two occasions, at least three months apart) 
Exclusion criteria: 
1. Previous thyroid disease and its treatment. 
2. Medications that could cause thyroid hormone dysfunction (interferon, 
lithium, amiodarone, corticosteroids and dopamine. 
3. Diabetes mellitus (by history and a fasting plasma glucose test). 
4. Renal impairment (serum creatinine > 120 umol/L). 
5. Vascular disease (history and ECG) for ischearnic heart disease, strokes and 
peripheral vascular disease. 
6. Psychiatric conditions or their treatment (by history). 
7. Current or previous pregnancy in the last 2 years. 
Therefore, the sample size of 100 participants was obtained. In all participants, 
TFTs N-,,, ere perforined at least 3 months apart (median 5 months, range 3 to 41 
months). 
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Ethical approval and registration 
The local (Gateshead) research ethics committee and the Gateshead NHS Trust 
Research validation committee approved the study. In keeping with recent 
guidelines from the International Committee of Medical Journal Editors (De 
Angelis, et al 2005), this trial was registered on a database, the ISRCTN with 
number ISRCTN35570362. 
Intervention 
One hundred meg of L-thyroxine or matching placebo capsules (Royal 
Hallamshire Hospital Pharmacy, Sheffield, UK) were obtained. Approval from 
the Medicinal and Healthcare Regulatory Authority (MHRA) was obtained prior 
to manufacture of the capsules. The participants were asked to swallow the 
treatment capsules whole with water early in the morning, half an hour before 
food. Compliance was assessed at the next visit by counting the number of 
capsules left over in the container, and was judged to be good (median 94%, 
range 83-100%). 
Previously it has been suggested that the dose of L-thyroxine required to treat 
SCH is between 50 - 75 mcg per day(Cooper 2001). This is based on three 
studies that used mean doses ranging from 68 to 150 mcg per day and the treated 
group's TSH values ranged from 1.9 to 4.6 mIU/L(Cooper, et al 1984, Jaeschke, 
et al 1996, Nystrom, et al 1988). However, another study that used 100 meg per 
day in biochemically-euthyroid patients with hypothyroid symptoms found that 
mean TSH levels did not drop below the reference range(Pollock, et al 2001). 
Thus, the dose of 100 mcg per day was deemed adequate to treat patients in our 
study. Also, the aim was to increase the free thyroid hormone levels 
significantly and a treatment dose of 1.6 mcg/kg/day would be required - for 
persons weighing between 60 and 70 kg, a dose of 96 to 112 mcg/day would be 
sufficient. Therefore, 100 mcg capsules were deemed adequate for the trial. It 
was expected that there would be certain patients in whom the dose would be 
excessive or inadequate, but the large study numbers would compensate for this 
eventuality. 
The treatment period of twelve weeks duration was deemed adequate for the 
present study since it takes about 4-6 weeks of full replacement therapy with L- 
thyroxine to correct the dyslipidaemia of overt hypothyroidism(Kuusi, et al 
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1988). However, it may be insufficient time for some benefits (such as 
perceptible reduction in some symptoms and psychological factors) to become 
apparent to patients. 
Randomisation 
Sequence generation: Independent external pharmacists (Royal Hallamshire 
Hospital Phan-nacy, Sheffield, UK) drew up a computer generated 
randomisation list and the treatment was then distributed in sequentially 
numbered identical containers. The investigators having no knowledge of 
treatment allocated the next available number on entry to the trial. 
Allocation concealment: A generated allocation schedule should ideally be 
implemented by using allocation concealment, a process that prevents 
foreknowledge of treatment assignment and prevents enrollers of study 
participants from being influenced by this knowledge. This is not to be confused 
with blinding, a process that tries to prevent performance and ascertainment 
bias. Since a third party assignment is desirable, the pharmacy department of 
Royal Hallamshire Hospital, Sheffield, UK, the producers of the interventional 
capsules generated, assigned and distributed the sequenced containers. 
Implementation: Failure to separate the creation of allocation sequence from 
study group assignment can introduce bias in a clinical trial. Therefore, these 
processes were independent of each other and the two did not have any 
knowledge of the other. 
Blinding 
Blinding refers to keeping participants, study investigators and also those who 
collect and analyse data unaware of the assigned intervention since this may be a 
major source of bias at several stages in a trial. In this trial, all study 
investigators and participants remained blinded to the treatment assignment for 
the duration of the study and the analysis. Even the analysis was done as 
treatment "A" versus "B" rather than L-thyroxine and placebo, respectively. The 
study code was only broken after all analysis had been completed. The blinded 
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nature of participants was assessed at the end of the two treatment periods by 
asking them to identify the L-thyroxine phase. 44% of patients correctly 
identified the active treatment period, 32% did not while 24% were unsure 
(p=O. 12). 
Statistics 
Data analyses were perfonned by one investigator (SR) and then confirmed by 
another (JUW). All analyses were performed as per pre-established plan and 
with an intention to treat. The data were analysed in accordance with previous 
guidance on the analyses of crossover trials (Hills and Armitage 1979). This 
method (difference of differences) takes into account period and subject effects 
and also checks for any carry-over effect. Suppose participants allocated to L- 
thyroxine first and then placebo are termed Group A and those to placebo and 
then L-thyroxine as Group B; and the results of variables assessed in each period 
are terined yI and y2, then: 
Group A 
Study No. Period on L-thvroxine Period on nlacebo Difference WA) Sum (sA 
I YI(l) y2(l) y2(l)-yl(l) y2(1)+yl(l) 
3 yl(3) y2(3) y2(3)-yl(3) y2(3)+yl(3) 
and so on .... 
Group B 
Study No. Period on placebo Period on L-th yroxine Difference (dB) Sum (sB) 
2 y1 (2) y2(2) y2(2)-yl(2) y2(2)+yl(2) 
4 yl(4) y2(4) y2(4)-yl(4) y2(4)+yl(4) 
and so on ............. 
Comparing half of the mean of the differences between dA and dB by unpaired 
Student's t-test can assess whether variable "y" is significantly different between 
L-thyroxine and placebo. The treatment effect is measured by subtracting dB 
from dA. This method takes into account period and sequence effect. 
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If instead of difference, the variable y in period 1 and 2 are added up separately 
for the two groups (sA and sB), and are compared by unpaired Student's t-test, 
then this assesses for carry-over effect. 
To test for proportions, it is possible that there may be a time trend in response 
and it is sensible to carry out a test that takes order of treatment into account. 
Group A Group B 
Prefers period I nA(l) nB(l) 
Prefers period 2 nA(2) nB(2) 
Total nA(l +2) nB(1+2) 
To test whether the difference between nA(I)/nA(1+2) and nB(I)/nB(1+2) is 
significant, Chi-squared test on I degree of freedom was used. This can be done 
since the sample size was relatively large. 
Since intention to treat analyses does not always reflect clinical practice, we also 
analysed the data after excluding patients with discordant TFT results (TSH and 
FT4 levels outside the expected values during the course of the study). 
Norinally distributed data were analysed using student's t-test and Pearson's r 
correlation coefficient. Non-normally distributed data were analysed using 
Wilcoxon's rank sum test and Spearman's rho correlation coefficient. Treatment 
effects are reported as the mean difference between the two treatment periods, 
with both 95% confidence intervals and p value. Since the order of 
administration of L-thyroxine or placebo did not alter the results, the results for 
each were combined. Two-sided significance tests were used throughout. 
Multivariate analyses were conducted by general linear model with backward 
selection, after assessment for collinearity and interactions. The two primary 
outcomes (TC and FMD) were the dependent variables and correlated factors as 
independent variables. ne binomial sign test was used to estimate if there were 
significant differences between the m, o treatment periods in a consistent 
direction within a questionnaire, even if the magnitude of the difference were 
small. The statistical software SPSS 11.0 for Windows Nvas used to perform 
analyses (SPSS, Chic, 111). 
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Adjustments for multiple comparisons: In a clinical trial, if a large number of 
variables are tested, then there is a possibility that one or more of these ", III be 
found to be significantly different (Bland and Altman 1995). In general, if we 
have a number (kappa) of independent significance tests at the significance level 
alpha (usually 0.05), all of whose null hypothesis are true, then the probability of 
getting no significant difference is (1-0.05) kappa . Even 
if the tests are dependent 
on each other, the problem remains the same. For example, if a clinical trial 
analyses and reports 20 different variables, then the required p value to detect a 
true significance will be 0.05/20=0.0025. Since many variables will not be 
independent of each other, the required correction by the Bonferrom method is 
too stringent. Some others have called for other corrective tests to be used 
(Bender and Lange 1999). In fact, other statisticians have questioned the need to 
correct raw p values (Rothman 1990) (Perneger 1998) (Perneger 1999). They 
have argued that Bonferroni correction leads to type 2 error (finding no 
significant difference where one exists), which leads to truly important 
significant differences being discarded as non-significant. They cite the analogy 
with real-life clinical situation where results of tests are interpreted in their 
clinical context rather than being based on what other tests have been asked for. 
They advocate that simply describing what tests of significance have been used, 
and why, are all that is necessary. In this study, therefore, we report the raw p 
values and also state what results would remain significant if the Bonferroni 
correction is applied. 
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RESULTS(A) 
73 
Baseline results 
The study protocol is outlined in figure 10. Participants attended for 
randomisation (baseline visit), 12 weeks for cross over, and at 24 weeks. 
Outcome measures were obtained at each visit. Ninety-nine participants 
completed the study. One person dropped out of the study, after reporting side 
effects following 12 days of placebo treatment; therefore baseline results were 
carried forward in the final data analyses. There was no significant carry-over 
effect in any of the outcomes reported, endorsing the decision to not have a 
washout period between the two treatment periods. 
Figure 10. 
Flow of patients through each stage of the study. 
0 
SCH patients assessed for eligibility 
(n=322) 
Random ised (n= 100) 
C 
0 
C 
V 
(f) 
L-Thyroxine, 
1 00i-ncg/d 
(n=5 0) 
12 weeks 
L-Thyroxine, 
I 00mcg/d 
(n=49) 
12 weeks 
Excluded (n=222) 
Exclusion criteria (n= 137) 
On L-thyroxine therapy (n=75) 
Previous thyroid disease (n=59) 
Diabetes mellitus (n=2) 
Abnormal ECG (n=l) 
Refused/couldn't be contacted (n=62) 
Thyroid function normal (n=23) 
Discontinued 
V (n=l) due to 
Placebo perceived side 
(n=50) effects and 
personal problems 
Placebo 
(n=50) 
End of study 
Analysed (n=99) 
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The baseline clinical and biochemical characteristics are outlined in table 8. 
Table 8. 
Baseline clinical and biochemical parameters of entire group (n=100). 
Mean (SD) or median (range) 
Age in years 53.8(12.6) 
Male (n) 18 
Weight in kg 76.5(16.4) 
Smokers (n) 25 
Medications (n) 
Antihypertensive 
Statins 
18 
6 
Systolic blood pressure in mm 
Hg 
132.5 (21.5) 
Diastolic blood pressure in 
mm Hg 
79.9(9.2) 
Waist hip ratio 0.83(0.1) 
TSH in mIU/L 5.3 (3.7 - 15.8) 
FT4 in pmol/L 13.6(2) 
FT3 in pmol/L 4.7(0.6) 
Total Cholesterol in mmol/L 6.0(1.2) 
LDLc in mmol/L 3.6(l) 
HDLc in mmol/L 1.7(0.5) 
Triglycerides in mmol/L 1.2 (0.5 - 3.7) 
Apolipoprotein B in mg/dl 104.4 (33.8) 
Apolipoprotein AI in mg/dl 152(30) 
Apolipoprotein 
B/Apolipoprotein AI 
0.7(0.3) 
FMD (%) 4.8(3.2) 
The randomisation of the participants was effective as seen by table 9, where the 
two groups were not different in any aspect. This is not a very important aspect 
in a crossover trial where each patient acts as their own control, but highlights 
the fact that randomisation was efficient and successful. 
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Table 9. 
Various clinical and biochemical parameters of the two groups at 
randomisation (baseline). 
Mean (SD) or 
Median (range) 
Randornised to L- 
thyroxine (n=50) 
Randomised to 
placebo (n=50) 
Age in years 53.5 (13.3) 54.2(12.1) 
Males (n) 10 8 
Weight in kg 75.9(15.9) 77(16.9) 
Smokers (n) 14 11 
Medications (n) 
Antihypertensives 
Statins 
10 
3 
8 
3 
Systolic blood pressure in mm Hg 135.7 (22.6) 129.4 (20.1) 
Diastolic blood pressure in mm Hg 80.8(8.3) 79.1 (10) 
Waist hip ratio 0.84(0.1) 0.83 (0.1) 
TSH in mlU/L 5.4 (3.8 - 15.8) 5.3 (3.7-13.9) 
Free T4 in pmol/L 13.5 (2.1) 13.7(2) 
Free T3 in pmol/L 4.7(0.7) 4.7(0.6) 
Total Cholesterol in mmol/L 6.1 (0.9) 6.0(1.4) 
LDL Cholesterol in mmol/L 3.6(0.8) 3.6(l. 2) 
HDL Cholesterol in mmol/L 1.7(0.5) 1.6(0.4) 
Triglyceride in mmol/L 1.2 (0.7 - 3.7) 1.2 (0.5 - 3.1) 
Apolipoprotein B in mg/dl 104.7(34) 104.1 (33.6) 
Apolipoprotein Al in mg/dl 157.2 (31.3) 147(28) 
Apolipoprotein B/A 1 0.7(0.3) 0.7(0.3) 
FMD in % 5.1 (3.3) 4.6(3) 
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Other baseline anthropornetric and biochemical parameters are outlined next. 
Table 10 shows the body composition of participants at baseline as measured by 
bio-impedance method. 
Table 10. 
Baseline body composition parameters (n=100). 
Mean (SD) 
Fat 37.2(8.3) 
Fat mass (kg) 28.8(10.5) 
Lean mass (kg) 47.7(10.6) 
Water (%) 48.1 (6.4) 
Basal metabolic rate (kcal/kg) 1499.8 (249.5) 
Table II outlines the biochemical markers of endothelial function (pro and anti- 
thrombotic) as well as a marker of vascular inflammation at baseline. 
Table 11. 
Baseline biochemical parameters of thrombosis and inflammation (n=100). 
Mean (SD) or median (range) 
PAI- 1 338.7 (487.7) 
sICAM 1 257.4 (60.6) 
e-selectin 42.3 (21.4) 
tPA 51.0(30.4) 
hsCRP 2(0-40) 
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The effect of thyroid autoantibodies on various baseline 
parameters 
Thyroid auto-antibodies were measured to elucidate the nature of the SCH. 
Forty nine patients had positive anti-TPO antibody levels (titre >50) whereas 
the rest were negative. There have been concerns in the past as well as more 
recently that people with positive thyroid antibodies are at an increased risk of 
vascular disease (Bastenie 1967; Bastenie 1971; Hak et al 2000). This 
association between thyroid autoirnmunity and CV disease has not been shown 
in some other studies (Tunbridge et al 1977) (Hueston et al). 
The results were therefore compared in all 100 patients at baseline with regards 
to positive versus negative antibody status (table 12). This shows that anti-TPO 
antibody positive individuals were younger, had a higher proportion of men, 
have a higher serum TSH level and lower serum free T3 level. The rest of the 
CV risk factor profile was similar in both groups. This suggests that auto- 
immune SCH is more likely to affect people at a younger age, likely to involve 
a higher proportion of men, and have a more advanced disease in terms of 
higher serum TSH and lower free T3 levels. 
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Table 12. 
Various clinical and biochemical parameters at baseline in positive versus 
negative anti-TPO antibody individuals. 
Mean (SD) or Anti-TPO positive Anti-TPO P value 
median (n=49) negative 
(range) (n=51) 
Age (years) 51.0(12.2) 56.6(12.6) 0.02 
Gender (n) 11/38 7/44 0.01 
(Male/Female) 
Body mass index 27.7(4.5) 29.3 (5.7) 0.13 
(k g/M2) 
Waist circumference 89.2(14.2) 92.3(15.1) 0.30 
(cm) 
FMD (%) 5.3 (3.4) 5.3 (3.4) 0.95 
TSH (mlU/L) 5.8 (2.9 - 15.4) 5.0(2.7- 0.02 
15.8) 
Free T4 13.3 (1.8) 13.9(2.1) 0.13 
(pmol/L) 
Free T3 4.8(0.6) 4.6(0.6) 0.04 
(pmol/L) 
Total Cholesterol 5.8(1.2) 6.2(l. 2) 0.17 
(mmol/L) 
LDL cholesterol 3.5 (1.1) 3.8 (1) 0.10 
(mmol/L) 
HDL cholesterol 1.7(0.5) 1.6(0.5) 0.30 
(mmol/L) 
Triglycerides 1.2 (0.5 - 3.7) 1.3 (0.5 - 3.7) 0.24 
(mmol/L) 
Apolipoprotein B 99.2(31.2) 109.3 (35.5) 0.14 
(mg/dl) 
Apolipoprotein Al 153.3 (29.8) 150.8 (30.5) 0.68 
(mg/dl) 
hs CRP (mg/dl) 2(0- 13) 2(0-40) 0.65 
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Effect of TSH levels on baseline parameters. 
It is possible that SCH may have a graded effect depending on the degree of 
thyroid failure. The best way to gauge whether patients with lesser degree of 
SCH have different levels of various parameters was to evaluate results at 
baseline based on serum TSH levels. Therefore, baseline results were 
compared between two groups of SCH patients, based on their mean TSH 
level (6.1 mIU/L). These results are shown in table 13. These do not show 
any significant differences between the two groups for any parameter. 
Table 13. 
Various clinical and biochemical baseline results based on serum TSH 
levels at baseline. 
Mean (SD) or median 
(range) 
TSH 
-< 
6.1 mIU/L 
(n=61) 
TSH > 6.1 mIU/L 
(n=39) 
P value 
Age (years) 54(13.6) 53.6(11.2) 0.89 
Gender (n) (Male/Female) 10151 8/31 0.31 
Body mass index (kg/m2) 29.3 (5.3) 27.2(4.9) 0.06 
Waist circumference (cm) 92.5 (15) 88.1(13.8) 0.14 
FMD (%) 5.0(3.2) 4.6(3.2) 0.54 
TSH (mlU/L) 4.7 (3.7 - 5.9) 7.9 (6 - 15.9) <0.001 
Free T4 (pmol/L) 13.9(2) 13.3 (2) 0.14 
Free T3 (pmol/L) 4.8(0.7) 4.6(0.6) 0.28 
Total Cholesterol (mmol/L) 6.0(1.2) 5.9(l. 1) 0.67 
LDL cholesterol (mmol/L) 3.7(l. 1) 3.6(l) 0.67 
HDL cholesterol (mmol/L) 1.7(0.5) 1.7(0.4) 0.70 
Triglycerides (mmol/L) 1.2 (0.5 - 3.7) 1.3 (0.5 - 3.1) 0.46 
Apolipoprotein B (mg/dl) 105.6 (33.2) 102.5 (34.7) 0.66 
Apolipoprotein AI (mg/dl) 148.9 (30.1) 156.9 (29.6) 0.19 
Hs CRP (mg/dl) 2(0-27) 2(0-40) 0.91 
Body fat (%) 38.2(8.1) 35.7(8.4) 0.15 
Body fat (kg) 30.3 (10.7) 26.6(9.9) 0.08 
Lean mass (kg) 48.1 (10.4) 47.0(10.9) 0.63 
Basal metabolic rate (kcal/kg) 1509.9 (245.8) 1483.9 (257.7) 0.61 
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Baseline correlations 
Variables that were not normally distributed were transformed and then 
correlations calculated. High sensitive CRP could not be transformed into 
non-nality, therefore non-parametric tests were utilised for analysis. Figure 
11, and tables 14 and 15 show the correlations between serum TSH and free 
T4 and various clinical and biochemical parameters, respectively. 
Table 14. 
Correlations between inverse serum tan TSH levels and various clinical 
and biochemical parameters at baseline (n=100). 
Parameters Pearson's correlation co- 
efficient (r) or Spearman's rho 
P value 
Age in years -0.13 0.21 
Systolic blood pressure (mm Hg) 0.03 0.76 
Diastolic blood pressure (mm Hg) -0.05 0.64 
Weight (kg) -0.17 0.09 
Waist (cm) -0.18 0.07 
Waist hip ratio -0.13 0.20 
Square root FMD -0.03 0.74 
Fat mass (kg) -0.16 0.12 
Total cholesterol (mmol/L) -0.18 0.06 
Log Triglycerides (mmol/L) -0.10 0.32 
Log HDL cholesterol (mmol/L) 0.10 0.38 
Log free T4 (pmol/L) -0.18 0.08 
hs CRP (mg/dl) -0.07 (rho) 0.31 
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Figure 11. 
Correlation between baseline serum TSH levels and baseline total 
cholesterol levels. 
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Table 15. 
Correlations between log serum free T4 levels and various clinical and 
biochemical parameters at baseline (n=100). 
Parameters Pearson's correlation co-efficient 
(r) or Spearman's rho 
P value 
Age in years 0.09 0.37 
Systolic blood pressure in mm Hg 0.14 0.17 
Diastolic blood pressure in 
mm Hg 
0.16 0.10 
Weight in kg 0.08 0.45 
Waist in cm 0.12 0.25 
Waist hip ratio 0.16 0.11 
Square root FMD -0.05 0.64 
Fat mass in kg 0.05 0.60 
Total cholesterol in mmol/L 0.02 0.87 
Log Triglycerides in mmol/L 0.11 0.28 
Log HDL cholesterol in mmol/L -0.01 0.92 
hs CRP -0.02 (rho) 0.87 
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Effects of intervention with L-thyroxine versus 
placebo in people with SCH 
After baseline visit, all one hundred patients were randomised in a double 
blind fashion to either 100 meg of L-thyroxine capsules or matching 
placebo, for a period of twelve weeks each. Fifty patients were allocated to 
the L-thyroxine an-n whereas the remaining fifty were allocated to the 
placebo an-n. 
Discordant results 
The design of the study was such that patients were randomised to a fixed 
dose of L-thyroxine, in order to increase efficiency as well as minimise 
patient visits and blood tests. Also, people with SCH can revert back to 
euthyroidism at a rate of about 5% at the end of a year (Parle, et al 1991). 
Intermittent compliance or even missing some capsules for a few days and 
then taking them all together may also account for some of these results. 
During the course of the study, there were four groups of patients whose 
TFTs were outside the expected range. This was seen at the end of the study 
at the time of analyses of data. The details of discordant groups have never 
been previously described in detail by the authors of other RCTs in SCH. 
These groups were: 
1. Normal TSH at baseline (n=8): Despite having had abnormal TSH levels 
with non-nal free T4 concentrations on at least three occasions, each at least 
three months apart, eight patients had reverted back to normal TSH levels at 
randomisation. This is difficult to explain and the normal result may 
represent an anomaly; for example, this may be a manifestation of non- 
thyroidal illness at randomisation. 
2. TSH levels below 0.4 mIU/L on L-thyroxine therapy (=I 0): The fixed 
dose of 100 mcg/day was slightly excessive for some patients. Of these, 2 
people had suppressed TSH levels whereas 8 had levels between 0.0 1 and 
0.4 mIU/L. The two patients with undetectable TSH levels also had mildly 
elevated free T4 levels (26 and 27 pmol/L) whereas none had free T3 levels 
outside the reference range. 
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3. TSH levels above 4.0 mIU/L on L-thyroxine therapy (n=2): This may be 
due to either non-compliance or inadequate dose of L-thyroxine therapy. 
4. Normal TSH on placebo therapy (n=14): Three patients had normalised 
their TSH levels during placebo therapy when they were randomised to it 
during the first period treatment, and II patients had normal TSH levels 
during placebo phase of treatment after they had completed the L-thyroxine 
phase. This may be due to non thyroidal illness, spontaneous normalisation 
or a carryover effect of L-thyroxine. 
5. TSH levels above 15 mIU/L on placebo therapy (n=2): This could 
represent progression of hypothyroidism. 
Altogether there were 36 instances of discordant results but 7 patients had 
these on more than one occasion, therefore 29 patients' endpoint data were 
excluded and results analysed separately to see if there was any difference in 
results for each parameter. 
Effect of L-thyroxine on thyroid function tests (TFTs) 
The aim of utilising a 100 mcg of L-thyroxine replacement therapy was to 
non-nallse serum TSH concentration and to increase serum free T4 and free 
T3 levels. The result of intervention with L-thyroxine on TFTs can be seen 
in tables 16 and 17. 
Table 16. 
Effect of L-thyroxine on serum thyroid function tests (n=100). 
Mean (SD) L-thyroxine Placebo Adjusted difference P value 
or median (95% CI)' 
(range) 
TSH (mlU/L) 0.53 (0.01 - 5.25(0.9- -5.64(-7.17to-4.11) <0.001 
12.1) 63.4) 
Free T4(pmol/L) 20.5 (4.8) 13.5 (2.3) 6.98 (5.97 to 7.98) <0.001 
Free T3 (pmol/L) 5.3 (1) 4.7(0.7) 0.6 (0.37 to 0.82) <0.001 
ject aiiu [)(: I IOU T ACIJUSICCI lor suo 
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Table 17. 
Effect of L-thyroxine on serum thyroid function tests with discordant 
TFTs excluded (n=71). 
Mean L-thyroxine Placebo Adjusted P 
(SD) or difference value 
median (95% CI) 
(range) 
TSH (rnIU/L) 0.8 (0.4 - 3.9) 5.2 (4.1 - 12.1) -4.7 (-5.1 to -4.3) <0.001 
Free T4 20.2(4.2) 13.8(2.2) 6.4 (5.7 to 7.1) <0.001 
(pmol/L) 
Free T3 5.2(0.8) 4.7(0.6) 0.4 (0.3 to 0.5) <0.001 
(pmol/L) 
I PLUJUSLCU IOF SUUJCCL UTIU PCIIOU 
These results show that the intervention with L-thyroxine was effective in 
normalising serum TSH levels and also increasing free T4 and free T3 levels 
significantly. Table 16 shows that the dose of 100 mcg daily of L-thyroxine 
suppressed TSH levels in some individuals and also increased free T4 levels 
but serum free T3 levels were never outside the reference range at any point 
during the study. This table also shows that in some individuals, serum TSH 
remained above the desired reference range whilst on L-thyroxine (this may 
represent non-compliance), and in certain others serum TSH normalised on 
the placebo. There has been a recent trial that utilised a dose-titration 
approach to the dose of L-thyroxine in SCH that found that some individuals 
still do not achieve the desired TFT levels (Iqbal, et al 2006). It is seen in 
table 17, after exclusion of individuals of discordant results, that 71 
participants achieved the desired TFT criteria. All results were therefore 
analysed for all 100 participants and also for these 71 individuals, to see if 
there was any significant difference for all parameters. 
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Effect of L-thyroxine on vascular function. 
Flow mediated dilation: 
L-thyroxine had a positive influence on endothelial function as measured by 
FMD. This was not associated with any change in baseline diameter or 
baseline blood flow or peak flow after reactive hyperaemia. This 
improvement was independent of smooth muscle function since there was 
no change in response to GTN (table 18). 
Table 18. 
Effect of L-thyroxine on brachial artery measurements (n=100). 
Mean (SD) L-thyroxine Placebo Adj usted P 
difference value 
(95% CI) I 
Baseline 3.44(0.6) 3.47(0.6) 0.02 (-0.005 to 0.11 
diameter (mm) 
0.05) 
Baseline flow 58.5 (43.8) 55.1(42.4) 3.4 (-4.9 to 11.7) 0.42 
(ml/minute) 
Peak flow 147.3 (59.2) 142.7 (56.5) 4.6 (-8.1 to 17.3) 0.48 
(ml/minute) 
Absolute 0.2(0.09) 0.14(0.1) 0.06 (0.02 to 0.08) <0.00 
changein I 
diameter (mm) 
FMD 5.9(3.1) 4.2(3.0) 1.65(l. 19to2.1) <0.00 
1 
GTN 21.3 (6.3) 20.6(7.1) 0.7 (-0.26 to 1.65) 0.15 
T ACIJUSIed Ior suojeci ano periou ei iu(: ts 
FMD measurement enables us to potentially identify patients at risk for 
atherosclerotic complications. Hypothyroidism can also lead to smooth 
muscle dysfunction (Ojamaa, et al 1996). The lack of change in GTN 
mediated dilatation along with the improvement in FMD confirrns that this 
is due to increased NO availability rather than due to changes in blood flow, 
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vessel diameter or smooth muscle function. The increase in absolute terins 
confin-ris that the change in diameter is not due to change in baseline 
diameter since any increase in percentage terms is higher if baseline 
diameter is smaller (Corretti, et al 2002) 
Table 19. 
Effect of L-thyroxine on brachial artery measurements with discordant 
patients excluded (n=71). 
Mean (SD) L-Thyroxine Placebo Adj usted P value 
difference (95% 
CI), 
Baseline 3.5 (0.6) 3.5(0.6) -0.0 (-0.0 to 0.1) 0.06 
diameter (mm) 
Baseline flow 60.5(46.4) 59.3 (45.2) 1.9 (-6 to 9.7) 0.69 
(ml/minute) 
Peak flow 147.2 (56.1) 150.3 (61.4) -2.4 (-13.9 to 9.1) 0.76 
(ml/minute) 
FNID (%) 5.8(3.1) 4.2(3.2) 1.6 (1.2 to 2.0) <0.001 
Absolute 0.2(0.1) 0.15(0.1) 0.06 (0.04 to 0.07) <0.001 
changein 
diameter (mm) 
GTN (%) 21.1 (6.1) 20.2(6.6) 0.7 (-0.2 to 1.5) 0.23 
T lk(]-IUStC(I 101 SUUJ"t UIIU pCI iuu uiiutuý. 
Tables 18 and 19 show that there was no significant difference in any of the 
parameters when comparing all 100 patients to the ones without discordant 
TFTs. This confinns that people with TSH levels in the desired range of 0.4 
to 4.0 mlU/L after treatment, still have a similar improvement in FMD 
response without any significant changes to baseline diameter, blood flow or 
response to GTN. 
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Carotid intima-media thickness (CIMT) and distensibility: 
This was measured in some individuals (n=39). The reason that this was not 
measured in all was because this was an add-on to the study protocol after 
the initiation of the study. Furthermore, some individuals declined to take 
part in this part of the study due to the greater time commitment required. A 
preliminary study of healthy volunteers (n=8), examined on 2 separate 
occasions, showed that the mean difference (SD) in CIMT was 0.01 mm 
(0.03). The characteristics of these 39 individuals were no different to those 
of the larger group. The results of the effects of L-thyroxine compared to 
placebo on CIMT and carotid artery elastic properties are outlined in table 
20. 
Table 20. 
Effect of L-thyroxine on carotid artery measurements (n=39) 
Mean (SD) L-thyroxine Placebo Adjusted P value 
Mean (SD) Mean (SD) difference (95% 
CI) I 
CIMT (mm) 0.1 (0.0) 0.1 (0.0) 0 (-0.0 to 0.0) 0.50 
Carotid elasticity 12.3 (5.5) 11.0(4.4) 1.2 (-0.2 to 0.11 
2.6) 
Carotid 12.0(5.0) 10.5 (3.8) 1.2 (-0.0 to 0.07 
stiffness 2.4) 
Carotid 2.3 x 10-3 2.2 x 10-3 0 (-0.0 to 0.64 
distensibility (0.0) (0.0) 0.0) 
T ACIJ US ICCI i or suojecL anu pt: i iou %-, I IVI I-k., CLIV LIU I I[ IIII la-I I IUUICI LI I It, r, I IC33, IýIa3LI%. It) -uII Lk"3-"u)/ "U 
x 100], Stiffness= Ln (Ps/Pd)/[(Ds-Dd)/Dd], Distensibility-- (dA/Ad)/dP. dA=systolic-diastol ic artery cross- 
sectional area change; Ad=diastolic artery cross-sectional area; dP--systolic-diastolic pressure change; 
Ln=logarithm base n; Ps=systolic blood pressure; Pd=diastolic blood pressure; Ds=artery diameter at systole and 
Dd=artery diameter at diastole. 
There was no significant change observed in any carotid artery parameter in 
people with SCH after treatment with L-thyroxine when compared to 
placebo. This could be because the treatment period of 12 weeks may not be 
sufficient to observe any significant changes. One RCT in the past has 
shown the beneficial effect of L-thyroxine in improving carotid INIT but the 
treatment period was much longer at six months (Monzani, et al 2004). 
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Effect of L-thyroxine on anthropornetric and clinical 
parameters. 
Blood pressure: 
There is a tendency to increased diastolic hypertension in patients with SCH, 
which extends even into the euthyroid range (Biondi and Klein 2004) 
(Gumieniak, et al 2004). There was no effect of L-thyroxine on either 
systolic or diastolic blood pressure as seen in tables 21 and 22. 
Weight and waist/hip measurements: 
There is some evidence that body weight may be influenced by thyroid 
function status, although it is not consistent (Manji, et al 2006) (Nymes, et 
al 2006). 
Table 21. 
Effect of L-thyroxine on blood pressure, weight and waist/hip 
measurements(n=100) 
Mean (SD) L-thyroxine Placebo Adjusted difference P 
(95% CI)' value 
Systolic blood 132.8 (22.8) 134.6 (22.9) - 1.8 (-4.6 to 1.0) 0.21 
pressure (mmHg) 
Diastolic blood 78.8(10.3) 79.9(9.6) - 1.1 (-2.8 to 0.5) 0.16 
pressure (mm Hg) 
Pulse rate per 68.4(10.9) 67.9(11.4) 0.47 (47 to 1.6) 0.57 
minute 
Weight (kg) 75.8(16.5) 76.5(16.7) - 0.6 (- 1.1 to -0.1) 0.02 
BMI (k g/M2) 28.3 (5.2) 28.5 (5.3) - 0.2 (-0.37 to - <0.02 
0.03) 
Waist circumference 89.1 (14.1) 90.3 (14.2) - 1.13 (-2 to -0.23) 0.01 
(cm) 
Waist hip ratio 0.81 (0.1) 0.83 (0.1) - 0.0 1 (-0.02 to - 0.001 
0.01) 
T Ad ILI SWCI I OF SLID I VýJ UIIU [)C II OU (-A I UL 1-') 
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There was no significant reduction in either systolic or diastolic blood 
pressure. This could be because the study was not powered to detect a 
significant change in mild hypothyroidism. There was a significant 
reduction in weight and waist circumference as well as waist hip ratio by L- 
thyroxine. This is a novel result that has not been shown before in any RCT. 
This may be because: 
1. A relatively higher dose of L-thyroxine was used than most other studies. 
2. A higher number of patients were studied as compared to any other RCT. 
The concern that the reduction in weight could be due to significant over- 
treatment (low TSH levels with or without high free T4 levels) was 
addressed by analysing the data with patients with discordant TFTs excluded 
(table 22). 
Table 22. 
Effect of L-thyroxine on blood pressure, weight and waist/hip 
measurements with discordant patients excluded (n=71). 
Mean (SD) L- Placebo Adjusted P value 
thyroxine difference (95% 
CI) I 
Systolic blood 134.5 (22.7) 136.2 (22.8) -1.9 (-4.4 to 0.6) 0.28 
pressure (mmHg) 
Diastolic blood 79.4(10.4) 80.6(9.9) -1.4 (-2.9 to 0.04) 0.16 
pressure (mm Hg) 
Pulse rate per minute 66.7(11.4) 67.2(10.9) -0.61 (-2.0 to 0.8) 0.52 
Weight (kg) 77.9(17.5) 78.4(17.9) -0.5 (-0.8 5 to -0.15 0.04 
BMI (kgIM2) 28.6(5.3) 28.8(5.5) -0.17 (-0.3 to -0.05) 0.04 
Waist circumference 90.2(14.1) 91.1 (14.5) -0.87 (-1.5 to -0.3) 0.05 
(cm) 
Waist hip ratio 0.82(0.1) 0.83 (0.1) -0.0 1 (-0.0 1 to - 0.009 
0.004) 
T Ad-justecl tor suo. jeci ano periou eiiccLs 
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Body composition: 
The effect of L-thyroxine on body composition in patients with SCH Nvas 
assessed by electrical bio-impedance. The results are outlined in tables 23 
and 24. 
This method has been shown to be a valid tool to measure body fluid 
distributions in SCH (De Lorenzo, et al 2000) (Seppel, et al 1997) and has been 
used in assessing response to thyroid function changes (Hsieh, et al 2002) 
(Pinkney, et al 2000). 
Table 23. 
Effect of L-thyroxine on body composition measurements (n=100). 
Mean (SD) L-thyroxine Placebo Adjusted P value 
difference (95% 
CI) I 
Fat 36.9(7.8) 37.4(7.7) -0.44 (-1.26 to 0.14 
0.38) 
Fat (kg) 28.3 (10.0) 28.9(10.2) -0.57 (-0.93 to - 0.03 
0.21) 
Lean mass (kg) 47.5(10.8) 47.6(10.9) -0.1 (-0.64 to 0.79 
0.52) 
Water (%) 48.6(5.8) 48.2(5.7) -0.35 (-1.10 to 0.21 
0.40) 
Basal metabolic 1495.9 (254.8) 1493.9 (259.1) 2.19 (-9.8 to 0.65 
rate (kcal/kg) 14.2) 
t AUJUSLCU 101 SUUJCL: L UIIU Pt: l IUU Cl ICI-LY 
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Table 24. 
Effect of L-thyroxine on body composition measurements with discordant 
TFTs excluded (n=71). 
Mean (SD) L-thyroxine Placebo Adj usted P value 
difference (95% 
CI) I 
Fat 37.0(8.1) 37.1 (8.4) -0.2 (-1.3 to 0.92 
1.5) 
Fat (kg) 29.1 (10.5) 29.4(11.2) -0.4 (-0.9 to 0.33 
0.1) 
Lean mass (kg) 48.8(11.7) 49.0 (11.9) 0.1 (-0.4 to 0.5) 0.47 
Water (%) 48.3 (5.8) 48.3 (6.0) 0.1 (- 1.2 to 1.4) 0.96 
Basal metabolic 1524.9 1524.6 0.1 (-8.7 to 8.9) 0.96 
rate (kcal/kg) (278.5) (284.8) 
1 mujusteu ior suo. leut anu periou ei ieuLs. 
This is the first time that body composition has been studied in a randomised 
controlled fashion and shows that body fat in terms of kilograms is reduced by 
L-thyroxine in people with SCH. The reduction is not by a large amount but 
may account for some reduction in body weight. The reduction was no longer 
significant when people with discordant results were excluded. This could be 
due to loss of power since less number of patients were analysed or could be 
because that people who had discordant results were the driving force of the 
significant results in all 100 patients. It should also be kept in mind that the 
magnitude of weight reduction may change in the longer term. This can be 
assessed in a study of a longer duration. 
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Effect of L-thyroxine on lipids in patients with SCH. 
There have been a number of studies that have looked at the effect of L- 
thyroxine in patients with SCH, but the results have been inconsistent. This 
study showed a significant reduction in total and LDL cholesterol in response to 
treatment with L-thyroxine and this result remained significant when patients 
with discordant TFTs were excluded (tables 25 and 26). 
Table 25. Effect of L-thyroxine on serum lipids and apolipoproteins in 
patients with SCH (n=100). 
Mean (SD) L-thyroxine Placebo Adj usted P value 
difference 
(95% CI) t 
Total cholesterol 5.7(l) 6.0(l) 0.35 (-0.5 to - <0.001 
(mmol/L) 
0.2) 
LDL cholesterol 3.4(0.8) 3.7(0.9) 0.2 (-0.4 to - 0.01 
(mmol/L) 
0.1) 
HDL cholesterol 1.6(0.5) 1.7(0.5) 0.06 (-O. l to - 0.02 
(mmol/L) 0.01) 
Triglycerides 1.3 (0.5 - 4.1) 1.3(0.4- 0.06 (-0.2 to 0.26 
(mmol/L) 5.1) 0.1) 
Apolipoprotein B 101.6(34) 108.8(38) 7.2 (-12.7 to - 0.01 
(mg/dL) 1.7) 
Apolipoprotein Al 152.1 (30.6) 156.8 (34.4) 4.8 (-8.9 to - 0.02 
(mg/dL) 0.6) 
ApoB/ApoAI 0.69(0.2) 0.72(0.3) 0.04 (-0.1 to - 0.04 
0.01) 
T AdJUS I CLI I Or SU0.1 CC L ýi IIu 1'ý: l IýIULIIý: ý- L-ý 
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Table 26. 
Effect of L-thyroxine on serum lipids and apolipoproteins in patients with 
SCH with discordant TFTs excluded (n=71). 
Mean (SD) L- Placebo Adjusted p 
thyroxine difference (95% value 
CI), 
Total 5.7(l. 1) 6.0(l) -0.28 (-0.4 to - 0.008 
cholesterol 0.1) 
(mmol/L) 
LDL cholesterol 3.4(0.9) 3.7(0.9) -0.2 (-0.3 to -0.1) 0.02 
(mmol/L) 
HDL cholesterol 1.7(0.5) 1.7(0.5) -0.01 (-0.04 to 0.98 
(mmol/L) 0.02) 
Triglycerides 1.3 (0.5- 1.4(0.5- -0.1 (-0.2 to 0) 0.09 
(mmol/L) 4.1) 4.3) 
Apolipoprotein B 102.2 106.5 (35.7) -6.4 (-12.5 to - 0.04 
(mg/dL) (33.9) 0.3) 
Apolipoprotein 152.1 153.8 (34.3) -2.1 (-5.7 to 1.4) 0.41 
AI (mg/dL) (32.1) 
ApoB/ApoAI 0.70(0.3) 0.72(0.3) -0.04 (-0.09 to 0.05 
0.01) 
T AU. IL]SteCl ior SUD)eCl anU pt: [IUU Cll(: LLý. 
Table 25 shows that there was not only a significant reduction in serum total 
cholesterol but also LDL cholesterol. In addition, serum apolipoproteins B and 
AI reduced significantly, but the atherogenic apoB reduced more than the 
protective A I, as seen by the ratio of the two. Similarly, there was a statistically 
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significant reduction in HDL cholesterol, although the clinical relevance of a 
reduction of 0.06 mmol/L is questionable. 
Table 26 is of considerable interest since it shows that the reduction on HDL 
cholesterol as well as apolipoprotein Al was primarily due to inclusion of 
individuals who had discordant TFTs, since this was no longer significant. This 
may be due to inclusion of people with suppressed TSH levels and high free T4 
levels. It is also interesting to note that the apoB/Al ratio loses its significance 
in this group. This may be due to reduction in numbers. 
It can be estimated that the reduction in LDL cholesterol alone could amount to 
aI 0-year CV mortality reduction by 10% (Anderson, et al 199 1). There may be 
further benefits of improvement in endothelial function and central reduction in 
adiposity that cannot be quantified. 
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Effect of L-thyroxine on biochemical endothelial 
markers and inflammatory protein. 
The influence of L-thyroxine on these parameters is outlined in tables 27 and 
28. This shows that there was no effect of L-thyroxine on any biochemical 
endothelial markers, apart from tPA. 
Table 27. 
Effect of L-thyroxine on thrombotic, endothelial and inflammatory 
biochemical markers in patients with SCH (n=100). 
Median L-thyroxine Placebo Adj usted P 
(range) difference value 
(95 % CI) t 
hsCRP mg/L 2(0-17) 2(0-25) 0.4 (-0.86 to 0.29 
1.2) 
e-selectin 37.2(11.5- 37.85 (9.7- 0.4 (-1 to 1.3) 0.52 
103) 118.4) 
sICAM ng/ml 251.4 (165.8 - 247.1 (165.1 - 2.2 (4.2 to 8.6) 0.51 
602.4) 603.8) 
PAI- 1 194.7 (49.9 - 177.6 (50.1 - 10.5 (-14.5 to 0.4 
726.9) 815.9) 35.5) 
tPA 50.9(21.4- 46.1 (22.1- 1.6 (-1.2 to 4.4) 0.01* 
322) 321.4) 
T ACIJUSle(I IOF SUO_JeCl LMU PCHUU 
hsCRP=high sensitive CRP, PAI- I =plasminogen activator 1, tPA=tissue 
plasminogen activator. 
*p as calculated by Wilcoxon's rank sum test. But there was a significant carry- 
over effect of L-thyroxine into the placebo period making analyses by the 
adjusted method meaningless. 
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Since there was a significant carry over effect for tPA, this was analysed as a 
parallel group trial as well and this showed no significant difference, p 0.23. 
Table 28. 
Effect of L-thyroxine on thrombotic, endothelial and inflammatory 
biochemical markers with discordant TFTs excluded (n=71). 
Median L-thyroxine Placebo Adj usted p 
(range) difference (95% value 
CI) t 
hsCRP mg/L 2(0-17) 2(0-25) -0.5 (-1.3 to 0.2) 0.16 
e-selectin 40.1 (11.5- 39.2(9.7- 0.5 (-1.6 to 2.1) 0.58 
103) 118.4) 
sICAM ng/ml 243.8 (165.8 - 246.4 (165.1 -3.6 (-8.9 to 1.7) 0.86 
388.8) -465.4) 
PAI- 1 199.3 (49.9 - 191.5(68.8 8.4 (-10.8 to 0.56 
682.9) -748.9) 27.6) 
tPA 51.2(21.4- 47.7(22.2- 1.9 (- 0.9 to 4.7) 0.09 
122.6) 129.9) 
I AUJUSLCCI IOU SUDJCCL arIU periou t: lleCLS. 
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Association between serum TFTs and cardiovascular 
risk factors after treatment. 
There were significant improvements in the two primary outcomes of this trial, 
namely improvement in total cholesterol levels as well as improvement in 
endothelial function as measured by FMD, after L-thyroxine therapy. Further 
tests were then performed to try and observe how these improvements related to 
thyroid function tests. 
There was no correlation between baseline serum TSH levels and change in 
total cholesterol levels (figure 12). This suggests that, at least in participants in 
this study, that there was no cut off TSH level at which therapy is beneficial. 
This shows that all participants had a similar degree of benefit. 
Figure 12. 
Correlation between TSH level at baseline and change in total cholesterol 
level. 
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To investigate if there were any differences between various baseline 
parameters that affected the change in total cholesterol levels, baseline serum 
TSH levels, baseline serum free T4 levels and baseline serum total cholesterol 
levels were divided into quartiles and this was analysed in relation to change in 
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total cholesterol levels after treatment (figure 13). This shows that the people 
who derive the most benefit with L-thyroxine therapy are those whose serum 
total cholesterol levels are between 5.3 and 5.9 mmol/L, whose free T4 levels 
are between 12.4 and 14.4 pmol/L and whose serum TSH is between 4.0 and 4.6 
mIU/L. 
Figure 13. 
Relation between baseline serum TSH, free T4 and total cholesterol levels 
and change in total cholesterol after treatment with L-thyroxine. 
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p<0.05 when compared to baseline TSH level in 4 th quartile. 
p<0.05 when compared to baseline TC level in other quartiles. 
*** p<0.05 when compared to other FT4 levels in I" and 4 th quartiles. 
Each quartiles (1 -4, n=25) of baseline Total Cholesterol (TC), TSH and FT4 
levels. 
Mean, range in each 
group TC mmoILLh 
1 =4.8,3.8 - 5.2; 
2=5.6,5.3-5.9; 
3=6.3,6-6.6; 
4=7.4,6.7-8.7. 
Mean,, range in each 
w, roup TSH (mIULL). 
1=4.3,4-4.6; 
2=4.9,3 4.7-5.2; 
3=6,5.3-6.8; 
4=9.6,7-15.8. 
Mean, range in each 
group FT4(pmol/L): 
I= 11.4,9.6-12.3; 
2= 12.9,12.4-13.4; 
3=13.9,13.5-14.4; 
4=16.2,14.5-22.6. 
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The possible reasons for these results are: 
I- Highest reduction in total cholesterol in patients with baseline TSH between 
4.0 and 4.6 mIU/L: This is likely to be due to the fact that a fixed dose of 100 
mcg of L-thyroxine was used in the entire group, thus the group with the 
mildest increase in TSH levels had the greatest reduction. 
2. Highest reduction in total cholesterol in patients with baseline total 
cholesterol between 5.3 and 5.9 mmol/L: This could be due to the fact that 
individuals with total cholesterol at the lowest and highest end of the spectrum 
(3.8 to 5.2 and 6.7 to 8.7 mmol/L) are genetically programmed to have those 
levels, and therefore the least likely for SCH and L-thyroxine to have any major 
influence. 
3. Highest reduction in total cholesterol inpatients with baseline free T4 levels 
between 12.4 and 14.4 pmol/L: This result is unexpected and there is no direct 
explanation for this. This would need to be confirmed in a prospective study. 
Since there was no association between baseline total cholesterol levels and 
baseline serum TSH levels and reduction in total cholesterol levels, associations 
were sought between other parameters. There was no correlation between 
increase in free T3 levels and change in total cholesterol (r---O. 13, p=0.34). 
There was a significant negative correlation between increase in free T4 levels 
and reduction in total cholesterol levels (r= -0.43, p<0.01) (figure 14). There 
was also a significant positive correlation between change in free T4 levels and 
increase in FMD (r---0.3, p<0.0.5) (figure 15). 
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Figure 14. 
Relationship between change in total cholesterol levels with change in 
serum free T4 levels (significant outliers not excluded). 
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Increase in FT4 levels (pmol/L) 
Figure 15. 
Relationship between changes in FMD with change in serum free T4 levels 
(significant outliers not excluded). 
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There were no significant correlations between change in FT4 levels and 
reduction in weight (r-- -0.05, p=0.76), and reduction in waist-hip ratio (r-- - 
0.04, p=0.52). 
Correction for multiple comparisons: If the Bonferroni correction is applied 
(6 variables: required p value is <0.008), the primary endpoints (reduction in TC 
levels and improvement in FMD) remain significant, as well as the most 
frequent symptom of SCH (improvement in tiredness). The six variables are the 
two primary endpoints, total cholesterol and FMD, weight, and the patient 
reported outcomes of QoL, symptoms and perceived health status. 
Multivariate regression analyses: 
Multivariate forward stepwise regression analyses, for changes in TC and FMD 
(dependent variables) and gender, smoking, waist hip ratio, TSH and FT4, 
(independent variables), showed that the change in FT4 concentrations was the 
only variable which predicted these two outcomes [change in TC: adjusted 
r2 =0.28 for whole model with change in FT4 (F=9.2, df=2, p<0.005) and change 
in FMD: adjusted r 2=0 . 31 for whole model and change 
in FT4 (F= 13.8, df=3, 
p<0.001), respectively)] (tables 29 and 30). Addition of change in diastolic 
blood pressure (less likely to change with changes in arterial compliance than 
systolic blood pressure) did not change the results. 
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Table 29. 
Model of forward stepwise regression analysis for change in total 
cholesterol levels in people with SCH treated by L-thyroxine (n=100). 
Variables Adjusted R2 F change df p value 
Gender -0.02 0.18 2 0.84 
Gender + Smoking -0.01 0.70 2 0.50 
Gender + Smoking + 0.04 0.44 2 0.66 
A WHR 
Gender + Smoking + 0.06 1.12 3 0.18 
A WHR +A TSH 
Gender + Smoking + 0.28 9.2 2 <0.005 
A WHR +A TSH +A 
Free T4 
Difference between treatment and baseline levels. 
Table 30. 
Model of forward stepwise regression analysis for change in FMD in people 
with SCH treated by L-thyroxine (n=100). 
Variables Adjusted R2 F change df p value 
Gender -0.005 0.48 1 0.48 
Gender + Smoking -0.01 0.20 1 0.65 
Gender + Smoking -0.23 0.16 1 0.69 
+A WHR 
Gender + Smoking -0.16 1.64 2 0.20 
+A WHR +A TSH 
Gender + Smoking 0.31 13.8 3 <0.001 
+A WHR +A TSH 
+A Free T4 
A= Difference between treatment and baseline levels. 
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The effect of thyroid antibodies and serum TSH levels at 
baseline on various parameters after treatment 
Forty-nine patients had positive anti-TPO antibodies (titre > 50). The results 
were then compared in all 100 patients with regards to positive versus negative 
antibody status. This showed no significant changes between individuals who 
were anti-TPO positive compared to anti-TPO negative with regards to any 
parameter. 
Participants were then compared with regards to their baseline TSH levels. 
Sixty-two individuals had TSH < 6.1 mIU/L (the mean TSH of the group) and 
the remaining 38 had TSH > or = 6.1 mIU/L. There was no significant 
difference in change of any parameter measured in any individual apart from 
change in fat measured in kilograms as calculated by bio impedance. The 
change in fat mass in individuals with initial TSH < 6.1 mIU/L averaged 0.3 kg 
(I%) whereas the change averaged I kg (3.8%) in those with TSH > 6.1 mIU/L, 
p< 0.03. 
104 
DISCUSSION (A) 
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Synopsis of study findings 
This randomised controlled study shows that treatment of SCH with L-thyroxine 
provides significant improvement across a wide spectrum of cardiovascular risk 
factors. The reduction in total cholesterol was consistent with reductions seen in 
previous studies. The improvement in endothelial function is a new finding that 
had never been assessed by a RCT before. There was no improvement in other 
CV risk factors like biochemical markers of endothelial function or markers of 
vascular inflammation. There was no improvement in carotid intima-media 
thickness in this 12-week study. 
Possible mechanisms and explanations of findings 
Elevated total and LDL cholesterol levels are a well documented feature of overt 
hypothyroidism (Staub, et al 1992), and treatment with L-thyroxine is standard 
practice. The association between increased total, LDL cholesterol levels and 
SCH has been inconsistent. There is evidence that SCH is associated with 
increased CV risk (Hak, et al 2000) (Imaizumi, et al 2004) (Walsh, et al 2005), 
although it is not supported by all (Tunbridge, et al 1977a) (Parle, et al 1991) 
(Rodondi, et al 2005) (Cappola, et al 2006). This increased risk may be as a 
direct result of higher concentrations of LDL cholesterol and its constituent 
apolipoprotein B in these patients. This study, which is the largest to date, shows 
that there is a significant reduction in LDL cholesterol by 0.2 mmol/L. It can be 
estimated that the possible relative reduction in I 0-year CV mortality, due to 
reduction in LDL cholesterol alone, at about 10% (Anderson, et al 1991). The 
effect of L-thyroxine on LDL cholesterol may be due its action of reducing LDL 
cholesterol synthesis and increasing degradation (Friis and Pedersen 1987) 
(Walton, et al 1965). Data from cultured human skin fibroblast cells suggest that 
the increased LDL cholesterol degradation is mediated by triiodothyronine (T3) 
induced increase in LDL receptor number and not due to changes in the 
receptor's affinity to LDL cholesterol (Chait, et al 1979). Functional elements 
for thyroid hormones have been observed in the promoter region of the LDL 
receptor gene (Bakker, et al 1998). Previously it has been shown that doses of 
L-thyroxine that suppress TSH below the non-nal level have a more powerful 
LDL cholesterol reducing effect than doses that non-nalise TSH (Diekman, et al 
2000). The present study confirms that finding. 
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It is well known that HDL cholesterol and its constituent apolipoprotein AI are 
protective against atherosclerosis. Most studies have observed that SCH does 
not seem to have any effect on serum HDL cholesterol levels (Walsh, et al 
2005) (Hueston and Pearson 2004) (Kvetny, et al 2004) (Canaris, et al 2000), 
with the exception of a few (Althaus, et al 1988) (Caron, et al 1990). RCTs that 
have examined the effect of L-thyroxine on HDL cholesterol have not found any 
benefit (Meier, et al 2001) (Kong, et al 2002) (Iqbal, et al 2006). There was a 
trend towards reduction in two other studies although it did not reach statistical 
significance (Caraccio, et al 2002) (Monzani, et al 2004). The present study did 
show a statistical reduction in HDL cholesterol and apolipoprotein AI levels, 
although its clinical significance is questionable (0.06 mmol/L and 4.8 mg/dI, 
respectively). L-thyroxine therapy, at TSH suppressive doses, leads to a 
significant reduction in HDL cholesterol levels due to increased activation of 
hepatic lipase (Barth, et al 1987). This finding was confirmed in the present 
study when the reduction in HDL cholesterol levels became statistically non- 
significant when patients with biochemical evidence of over-replacement (TSH 
< 0.4 mIU/L) were excluded from the analyses. 
It has been argued recently that apolipoprotein B and Al are better predictors of 
CV risk than conventional cholesterol levels (Walldius, et al 200 1). It has also 
been shown that the ratio of apolipoprotein B to Al (apoB/apoAl) is linked to 
the highest risk of developing a cardiac event (Yusuf, et al 2004). The present 
study found a reduction in apoB/apoAl. 
Vascular inflammation has been shown to predict CV disease and its effect is 
seen above and beyond traditional risk factors like cholesterol and blood 
pressure (Ridker, et al 1997). There is conflicting evidence that CRP is 
increased in people with SCH. Three large population-based studies found no 
difference in CRP levels between euthyroid controls and SCH patients (Hueston, 
et al 2005) (Kvetny, et al 2004) (Cappola, et al 2006), whereas a case-control 
study has shown a higher level in the SCH group (Christ-Crain, et al 2003). The 
intervention arin of the latter study found no reduction, following L-thyroxine 
therapy, in CRP levels. This was confirmed in the present study, where no 
improvement in hsCRP levels was noticed. 
The present study has found a significant reduction in body weight, especially 
central adiposity as measured by waist circumference and Nvaist-hip ratio. This 
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has never been shown before in a RCT. Body fat analysis by bio-impedance 
showed that the reduction in weight was correlated to a reduction in body fat 
mass. The mechanism of this action is unclear. It may be related to increase in 
resting energy expenditure, although this was not tested. It is also possible that 
body weight may be modulated by thyroid hormones due to effects on 
adipokines (Yu, et al 2006), although these were not measured in this study. 
There is no evidence that people with SCH have increased body weight. Most 
population-based studies that have identified SCH by screening have reported a 
small but non-significant increase in body weight (Imaizumi, et al 2004) (Iqbal, 
et al 2006) (Gussekloo, et al 2004) (Cappola, et al 2006) (Tunbridge, et al 
1977a) (Pirich, et al 2000) (Volzke, et al 2004), whereas some have reported 
lower or no different values (Rodondi, et al 2005) (Kvetny, et al 2004) (Walsh, 
et al 2005). This study has shown a significant effect of L-thyroxine on reducing 
BMI, especially central adiposity as measured by waist circumference, which is 
an independent risk factor for CV disease (Hirsch, et al 2001). 
The positive effect of L-thyroxine on endothelial function may be due to its 
action in increasing insulin-like growth factor- I and vascular endothelial growth 
factor, both of which can improve endotbelial nitric oxide synthase activity 
(Schmid, et al 2004). An improvement in FMD response may suggest better 
nitric oxide bioavailability and an associated improvement in vasoprotection in 
clinically relevant areas of the vasculature, such as coronary and carotid 
circulation (Pyke and Tschakovsky 2005). This improvement in endothelial 
function could translate into reduction in CV morbidity and mortality (Bonetti, 
et al 2003). 
This study failed to find any reduction in carotid-intima media thickness in a 
subgroup of patients. This is dissimilar to the findings of a RCT that 
investigated this CV disease marker (Monzani, et al 2004). This could be 
because the duration of treatment with L-thyroxine was only 12 weeks in this 
study whereas the Monzani study had a treatment period of 6 months. Also 
patient numbers were low in this study. Similarly, there was no improvement in 
carotid elasticity and stifffiess markers in this study, although it has never been 
investigated in a randomised fashion before. 
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Comparison with relevant findings from other published studies 
Previous RCTs studying the effect of L-thyroxine on LDL cholesterol have 
shown conflicting results. Some RCTs (number of patients ranging from 45 to 
63) (Meier, et al 200 1) (Caraccio, et al 2002) (Monzani, et al 2004) showing an 
improvement in the atherogenic lipid profile whereas other RCTs (number of 
patients ranging from 17 to 84) (Cooper, et al 1984) (Nystrom, et al 1988) 
(Jaeschke, et al 1996) (Kong, et al 2002) (Iqbal, et al 2006) showing no 
difference. The variation in results may be due to small numbers, inappropriate 
selection of patients and study design (Ineck and Ng 2003). A systematic review 
of the effect of L-thyroxine on lipids in SCH suggested that the approximate 
mean reductions in TC is -0.24 mmol/L (95% Cl, -0.06 to -0.42) and LDLc is - 
0.3 mmol/L (95% Cl, -0.01 to -0.54) with no significant change in HDLc 
(Danese, et al 2000). The same review concluded that serum apoB decreased by 
8.5mg/dl (95% C1, -4.2 to -13) whereas apoA I did not change significantly. 
Another systematic review concluded that the reduction in total cholesterol due 
to L-thyroxine in patients with SCH was 0.4 mmol/L (Tanis, et al 1996). The 
present study confirms these findings. 
The reduction in body weight, especially central adiposity as measured by waist 
circumference has not been shown by any previous randomised controlled trial. 
This could be due to the fact that in comparison to others we studied more 
patients and used 100 meg of L-thyroxine per day. Previous studies used doses 
less than 100 mcg, with one exception (Nystrom, et al 1988). The reduction in 
BMI and waist circumference was obtained in this study even when patients 
with evidence of over-replacement (TSH < 0.4 mIU/L) were excluded. 
This study has shown that a significant increase in FT4, although within the 
normal reference range, may be a better marker for risk factors for CV disease in 
monitoring response to treatment in SCH than TSH level alone. This is in 
agreement with previous research that has shown that changes in serum 
lipoproteins, in both hypothyroid and hyperthyroid patients, are correlated with 
changes in FT4 levels (Wiseman, et al 1993). 
Brachial artery FMD is emerging as an independent predictor of future cardiac 
events (Gokce, et al 2002). FMD in brachial artery correlates very well with 
FMD in a major coronary artery (Takase, et al 1998). The present study has 
confirmed the beneficial effect of treatment with L-thyroxine on brachial artery 
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endothelial function in people with SCH, as found in a previous study (Taddei, 
et al 2003). However the latter was not a randomised controlled trial and studied 
only six patients whose TSH was below 10 mIU/L- 
Limitations of the study 
The limitations of the present study are that patients were not identified from a 
population sample, the length of treatment was only twelve weeks, and the dose 
of L-thyroxine was a fixed 100 mcg per patient. The patient sample was 
obtained primarily from people presenting to general practice and excluded 
those with other chronic (and high CV risk) diseases, the results cannot therefore 
be extrapolated to these patient groups. The patient sample was primarily 
selected to reflect mild SCH, as this is the commonest and most controversial 
area of clinical practice (Tunbridge, et al 198 1). The treatment period of twelve 
weeks duration was deemed adequate for the present study since it takes about 
4-6 weeks of full replacement therapy with L-thyroxine to correct the 
dyslipidaemia of overt hypothyroidism (Kuusi, et al 1988). However, it may be 
insufficient time for some benefits (such as perceptible reduction in some 
symptoms and psychological factors) to become apparent to patients. The fixed 
dose of 100 mcg per day was deemed adequate, as a previous study that had 
used it in biochemically euthyroid patients with hypothyroid symptoms had 
shown that TSH did not drop below the reference range (Pollock, et al 2001). 
This may have led to a few patients (10%) being over-treated, but the subgroup 
analysis of patients who had achieved desired TSH and free T4 levels confirmed 
all of the major findings of the study (apart from the reduction in HDL 
cholesterol and apolipoprotein A I, which become non-significant and the QoL 
domain of motivation which became significant). Another recent RCT that 
titrated the dose of L-thyroxine based on patient's TSH levels utilised a mean 
dose of 97.5 mcg/day (Iqbal, et al 2006), further justifying the decision to 
employ the standard dose of 100 mcg/day. 
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Summary 
In conclusion, people with SCH can obtain significant improvement in their CV 
risk factor profile (weight loss with reduction in central adiposity, a favourable 
shift in lipoprotein pattern and improvement in endothelial function), and 
reduced perceived negative impact of hypothyroidism on QoL, after treatment 
with 100 mcg of L-thyroxine. These results suggest that serum FT4 levels 
should also be taken into account when monitoring treatment. Long-term studies 
are required to confirm whether this translates into reduction in CV mortality 
and morbidity. 
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Overt hypothyroidism 
Symptoms and Quality of life (QoL): 
Hypothyroidism often remains undetected because of the difficulty with 
ascribing symptoms to disease. The pathophysiologic changes generally require 
months or years to manifest as clinical signs and symptoms (Larsen and Ingbar 
1992). Furthermore, the onset of hypothyroidism is so insidious that even classic 
symptornatology may go unnoticed or undiagnosed (Gavin 1988). Although 
most hypothyroid patients do have some signs and symptoms indicative of 
disease (Tachman and Guthrie 1984), it may be difficult to identify a "classic" 
clinical picture because symptoms may be nonspecific and thus confused with 
other health problems (Schectman, et al 1989). 
The relation between symptoms and physiologic disease is so complex that 
clinicians turn to biochemical measures of thyroid dysfunction for diagnosis. 
However, it is unclear who should be tested. Many investigators (Bahemuka and 
Hodkinson 1975) (Sawin, et al 1979) (Eggertsen, et al 1988) (Danese, et al 
1996) (Helfand and Crapo 1990) and several organizations, such as the 
American Thyroid Association and the American Association of Clinical 
Endocrinologists recommend testing persons who have a greater likelihood of 
being hypothyroid (Singer, et al 1995) (2002). The U. S. Preventive Services 
Task Force does not recommend for or against screening in high-risk patients, 
such as older women. However, it does alert clinicians to maintain a low 
threshold for diagnostic evaluation of thyroid function when subtle or 
nonspecific symptoms of thyroid dysfunction occur in such patients (Helfand 
2004). In the UK, the Working Group of the Royal College of Physicians and 
Society for Endocrinology, in a consensus statement for good practice in thyroid 
diseases, did not focus on presenting symptoms or signs since they were detailed 
in the report by the American Thyroid Association (Vanderpump, et al 1996). 
Evidence is lacking as to which symptom or symptoms increase the likelihood 
of confin-ning biochemical hypothyroidism. However, patients who report more 
symptoms, and more recently developed symptoms, are more likely to have 
hypothyroidism. This being the case, patients who report more symptoms, 
particularly recent symptoms, should be tested with serum thyroid function tests. 
See tables 31 - 33 [from: (Canaris, et al 1997)]. These highlight the prevalence 
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of common symptoms usually attributed to hypothyroidism, subsequently 
confirmed via biochemical means, by hypothyroid patients, and compared to 
euthyroid controls and also test the likelihood of predicting the disease (table 
3 1). Table 32 shows the prevalence of recently acquired symptoms amongst 
hypothyroid and euthyroid individuals, permitting evaluation of onset of 
symptoms in portrayal of the disease. This showed that change in symptoms is 
more powerful in predicting the disease than current symptoms. Table 33 shows 
that higher number of symptoms reported (current as well as changed), the more 
the likelihood of predicting hypothyroidism. For example, an individual 
reporting 11 or more recently acquired symptoms of hypothyroidism has a 13.5 
times chance of having the disease compared to eutbyroid controls. 
Table 31. 
Current symptoms of Hypothyroidism (from Canaris et al, 1997) 
Hypothyrold with Euthymid with Likelihood Raflo p 
Symptom Symptoms, % syrpioms, % (95% Confidence Intervol) Volue 
Hoarse voice' 17 4 4,2 (1.7,10,6) . 001 
Deep voicc 16 8 9.1 (1,0.4.6) . 05 
Dty skIn' 71 54 1,3 (1,1,1 ý6) 02 
Coarsv hair 9 14 0.7 (03.1.5) . 32 
Cold sensitive 51 40 1.3 (0.9.1.7) . 12 
Tired 40 30 1.4 (0,9,2 ý 0) . 12 
hifly eyes 27 17 1.6 (1,0,2.7) . 08 
Mt&,. le crauips' 34 is 12 (1-4,3.7) . 001 
WC, A 11111sck's 21 21 1 .0 (O; o. 1.7) A 
Constipated 17 10 1.6 (0.8,3.3) . 15 
Deprcssed 16 12 1.4 (0-7,2.7) 37 
Slow thinking 18 10 1.8 (0ý9,13.5) . 08 
Poor memoq 18 16 1ý 110.6,2.0) 711, 
Math difficultv 15 11 1A (0,7,2.8) . 41, 
lurgular memses 30 29 1.0 (OA 2-0) '90 
I leaNy mensts 36 29 1.2 (01,23) . 48 
Indicates statishcal soif . ra n- 
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Table 32. 
Changed symptoms of Hypothyroidism (from Canaris et al 1997). 
-- 
Hypothyroid with 
......... ... ---- ------- -, - 
Euthyrold with Likerihood Rotio 
symptom Symptoms, % Symptom % (95% Confidence Infervol) Volue 
Hoarser voice" 21 4 5,2 f2-1,12.6) ". 0001 
Dcqxr voirel 14 2 7.1 J2,0,24.7) . 0006 
Dder skin' 48 24 2.0 (1 ý 4,2.9) . 000.13 
Coarser hair 7 2 3.2 (0-8.13-1) . 12 
Colder' 39 11 15 (2-0.6ý01 <. 000 I 
More tired' 54 26 2A (L15ý 3-0) ý 1, . 000 1 
Eyes more puffy* 36 D 4.0 (2.2.7.31 ". 0001 
sleet) 1110re 42 31 1.4(0.9,1.9) . 11 
Muscles cratrip morel 39 16 2.4 (1.5,3,8) . 0001 
kk'eaker muscles' 41 18 2.2 (1.4,14) . 0003 
Constipated more often* 20 6 3.6 (1,6. 'S. II AI 
More 38 18 2.2 f 1.4,141 . 0008 
SIffiVeTihinking" 36 14 2,5 (1,5.4.21 0002 
Poorer memory, 39 15 2.6 (1,6,4.2) <. 000 I 
Niath more difficult' 22 4 5.4 (2.2,13-1) <Mol 
Menses more irregular 44 27 1.6 (0,9.2.9) . 10 
I ft, avier rnen-ses 38 26 L5 (0A, 2.8) . 24 
" Indicnies staiistical signyie. ance. 
Table 33. 
Number of symptoms reported by hypothyroid patients and controls (from 
Canaris et al, 1997). 
Symptoms 
Reported, n 
Cases, 
n 
Controls, Likelihood Ratio 
(95% cl) 
C. Airrent" 
symptonis 
0 (of 3)* 15 (19.7) 58 (39.4) 0.5 (0-3. Oý8) 
1 35 (46.1) 72 (49.0) 0.9 (0.7.1.3) 
2* 22(28.9) 1500.2) 2.8 (1 - (;. 
5.1) 
3 4(5.31 2(1.4) 3.9 (0ý7.20.6) 
-Ch. wiged' 
syniptorns, 
0 (of 13), 115 (17.1) 51 (36.7) 0.5 (0.3.0.8) 
1 1)* - 19(25.0) 63 
(42.9) 0.6 (0.4, Oý9) 
3-4 10 (13.2) 13(8-8) 1.5 (0.7.3.2) 
5 (; 7(9,2) 11(7.5) 1.2 (0.5.3.0) 
7-80 14(18.4) 3(2-0) 9.0 (2-7.30.4) 
9-100 6(7.91 2 0. -1) 5.8 (1.2.28.1) 
--111 7 (9.2) 1 (0.7) 13-5 (1.7,108.0) 
6 fildicyltes Statistical significallef'. 
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Thus, overt hypothyroidism is a common condition that may be difficult to 
diagnose on clinical grounds alone and requires a high degree of clinical 
suspicion as well as confirmation with biochemical testing for serum TSH and 
thyroid hormone levels. Untreated, it may cause CV disease and may have the 
potential to be fatal, although this has never been tested in a controlled fashion. 
Overt hypothyroidism should be suspected in any person who complains of 
typical symptoms and the chances of diagnosing the disease are directly 
proportional to the number of symptoms. Reliance on blood testing to diagnose 
an easily treatable condition has led to a spectrum of results, one of which is the 
state of a raised TSH with free thyroid hormone levels, called subclinical 
hypothyroidism. 
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Symptoms and Quality of life in SCH. 
Most patients found by screening to have subclinical hypothyroidism have at 
least one symptom that could be related to this diagnosis (Parle, et al 199 1). 
Symptoms include muscle cramps, dry skin, intolerance to cold, constipation, 
poor energy levels, fatigue, and mental slowness. Baseline data from a study by 
Cooper et al showed an increased prevalence of hypothyroid symptoms (Cooper, 
et al 1984). The Colorado cross-sectional study of 25,862 participants reported 
increased prevalence of hypothyroid symptoms in response to a validated 
survey. The 2,336 subjects who were identified as having SCH, more often 
reported having dry skin (28%; P<0.001), poor memory (24%; P<0.001), 
slow thinking (22%; P<0.00 1), muscle weakness (22%; P<0.00 1), fatigue 
(18%; P<0.01), muscle cramps (17%; P<0.001), cold intolerance (15%; P< 
0.001), puffy eyes (12%; P<0.05), constipation (8%; P<0.05), and voice 
hoarseness (7%; P<0.05) than did euthyroid subjects (Canaris, et al 2000). It is 
important to note that, whereas euthyroid subjects experienced a mean of 12.1 % 
of all listed symptoms, overtly hypothyroid subjects had 16.6% of these 
symptoms (P < 0.05 vs. eutbyroid group), and subjects with mild thyroid failure 
reported an intermediate 13.7% of the symptoms (P < 0.05 vs. euthyroid group) 
(figure 16). This suggests a "dosage effect" between the degree of thyroid failure 
and symptoms. Consistent with these findings, a Swiss study involving 332 
women with hypothyroidism reported that 24% of the 93 subjects with mild 
thyroid failure exhibited typical symptoms of hypothyroidism (Zulewski, et al 
1997). 
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Figure 16. 
The Colorado Thyroid Disease Prevalence Study-symptom frequency 
stratified according to thyroid status (from McDennott & RIdgway, JCEM 
2001) 
18 
16 
14 
12 
lo 
6 
4 
0 Percent 
Positive 
Symptoms 
Other cross-sectional studies have demonstrated evidence of specific 
neurobehavioral and neuromuscular dysfunction in SCH patients. Depression 
(Monzani, el al 1993) (Tappy, et al 1987) (Joffe and Levitt 1992) (Haggerty, et 
al 1993) (Manciet, et al 1995), memory loss (Canaris, et al 2000) (Monzani, et 
al 1993) (Baldini, et al 1997), cognitive impairment (Ganguli, et al 1996), and a 
range of neuromuscular complaints (Monzani, et al 1997) have been reported to 
occur more frequently in patients with this condition. Objective peripheral nerve 
dysfunction, manifested by decreased conduction amplitude in peripheral nerves 
(Misiunas, et al 1995), and an abnormal stapedial reflex (Goulls, et al 1998) 
have been demonstrated in these patients. Skeletal muscle abnormalities, 
Including elevated serum creatinine phosphokinase levels (Beyer, et al 1998), 
increased circulating lactate levels during exercise (Monzani, et al 1997), and 
repetitive discharges on surface electromyography (Monzani, et al 1999) have 
also been reported. Finally, there is compelling evidence that mild thyroid 
failure in pregnant women may result in reduced intellectual development of 
their euthyroid offspring (Haddow, et al 1999). 
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Failure 
Reacting to some of this, some experts have argued that the Colorado study was 
not a population-based study and it also included people with under-treated 
hypothyroidism (Surks, et al 2004). The only cross-sectional study that stratified 
individuals by TSH levels noted significantly altered ankle reflex times and 
myoglobin levels only in those patients with TSH higher than 12 mIU/L (Staub, 
et al 1992). The biological significance of the impairment of the stapedial reflex 
in patients with SCH has also been questioned (Chu and Crapo 200 1). The 
association of SCH with psychiatric disorders has also not been consistent. 
Many such reports are hindered by not controlling for the effects of age, gender, 
inpatient hospitalisation, and use of lithium on the prevalence of elevated TSH 
levels (Griffin 1990). Additionally, the mere association between SCH and 
psychiatric disorders should not lead to the conclusion that SCH brings about 
these associated disorders (Haggerty, et al 1993). The four large epidemiological 
studies that examined cognitive and affective scores in SCH subjects found few 
(Lindeman, et al 1999) (Manciet, et al 1995) or no (Luboshitzky, et al 1996) 
(Jorde, et al 2006) significant differences overall, and none in those with TSH 
between 5 and 10 mIU/L. 
There has been no large-scale population-based study to investigate QoL in 
people with SCH. Sonino and Fava have pointed out the need for 
multidimensional assessments of the effects of treatment in thyroid disorders. 
These should also include psychosocial aspects, as there is "a new interest for a 
global approach to the endocrine patient" (Sonino and Fava 1998). The 
symptoms of hypothyroidism, if present, are likely to have a considerable 
impact on QoL, yet there is no known measure of QoL in hypothyroidism in 
use, nor any measure of satisfaction with thyroid hormone treatment. Searches 
of websites including QOLID (Quality of Life Instruments Database) and 
ISOQoL (International Society for Quality of Life) did not indicate any 
hypothyroid QoL instruments available. Searches of Web of Science, PubMed 
and PsychLit found a Canadian disease-specific health-related QoL instrument, 
the Chronic Thyroid questionnaire, with questions relating to symptoms of 
hypothyroidism (Jaeschke, et al 1994). This is not, however, a measure of QoL 
or of the impact of thyroid conditions on QoL, but rather, more specifically, a 
measure of symptoms. ne term 'health-related quality of life' is often 
misleadingly used to refer to measures of health status and symptoms when it 
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blurs the boundaries between quality of health and quality of life. Health-related 
QoL emphasises quantity of life, physical function and symptoms; whilst often 
including aspects of psychological well being there is less emphasis on the 
individual patient's perceptions of their quality of life. Even if people feel that 
their health is poor, they may or may not also feel that their QoL is impaired, 
and vice versa (Bradley 2001) (Razvi, et al 2005). 
No search found any measures of treatment satisfaction relating to 
hypothyroidism. The Chronic Thyroid questionnaire is not suitable to measure 
patients' perceptions of their QoL for reasons discussed above. The research 
required developing questionnaires to measure the impact of hypothyroidism on 
QoL or treatment satisfaction in this disorder has not been conducted before. 
Measures of individualised condition- specific QoL and of treatment satisfaction 
in hypothyroidism were not available for use in clinical trials. Therefore a 
disease specific QoL and treatment satisfaction questionnaire would be a useful 
tool in assessing patients who require treatment as well as their satisfaction with 
subsequent treatment 
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Effect of L-thyroxine therapy on patient-reported 
outcomes in SCH. 
There have been 6 randomised, prospective, placebo-controlled trials of L- 
thyroxine therapy in SCH published so far, that have assessed symptoms of 
hypothyroidism or health status (Cooper, et al 1984) (Nystrom, et al 1988) 
(Jaeschke, et al 1996) (Kong, et al 2002) (Meier, et al 2001) (Jorde, et al 2006). 
Cooper et al and Nystrom et al reported significant improvements in symptoms 
of hypothyroidism. Jaeshke and colleagues did not find any improvement in 
health status (general or disease-specific) in their patients with SCH, apart from 
some improvement in a composite psychometric memory score. This study has 
been criticised because of insufficient treatment of the SCH patients - the 
treated patients' mean TSH levels were 4.61 mIU/L. Meier and colleagues 
concluded that physiological L-thyroxine replacement therapy in people with 
SCH (the mean TSH at baseline in this group was 12.1 mIU/L at baseline) 
improves clinical symptoms of hypothyroidism (as assessed by Billewicz index 
and Zulewski's scores). On the other hand, Kong et al did not find any 
significant improvement in their patients with mild SCH, in terms of symptom 
scores as measured by modified Billewicz and Zulewski's scores. In fact, there 
was a significant worsening in anxiety scores on L-thyroxine therapy. The 
patients in this study were not recruited by population screening and did not 
have stable SCH, and had a rigid dosing regimen (50 or 100 mcg/day) leading to 
a treated TSH level of 3.4mIU/L (towards upper limit of norinal range) (Biondi, 
et al 2003). The most recent study by Jorde and colleagues did not find any 
significant improvement in symptoms or other psychological parameters after L- 
thyroxine therapy. All RCTs assessing symptoms in response to L-thyroxine are 
summarised in table 34. 
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Table 34. 
RCTs assessing effect of L-thyroxine therapy on hypothyroid symptoms in 
SCH. 
Study No. of 
patients 
Mean TSH 
levels mIU/L 
Initial Final 
Dose of 
LT4 
mcg 
Duration of 
treatment 
(months) 
Significant 
improvement? 
Cooper 33 10.8 2.6 71.2 12 Yes 
Nystrom 17 7.7 1.9 150 6 Yes (analysed 
as before-after) 
Jaeschke 31 12.1 4.6 68 6-10 No 
Meier 63 12.8 3.1 85.5 11 Yes 
Kong 35 8 3.4 77.5 6 No 
Jorde 36 5.6 1.5 110 12 No 
RCT - Randomised controlled trial, SCH - subclinical hypothyroidism, LT4 - 
levothyroxine. 
The effect of L-thyroxine on cognitive function and memory are not clear. Some 
studies have shown a beneficial effect whereas others have not (Nystrom, et al 
1988) (Jaeschke, et al 1996) (Monzani, et al 1993) (Baldini, et al 1997) (Jorde, 
et al 2006). 
One of the most important reasons for the conflicting results in all the trials 
listed above could be the small sample size. As seen above from the Colorado 
study, people with mild TSH elevations are likely to have fewer symptoms 
unlike those with higher TSH levels. This would mean a higher sample size 
would be required to show a significant improvement after intervention. In other 
words, it would be easier to detect a significant difference in a smaller sample if 
the degree of thyroid failure was higher as compared to when the failure was 
relatively mild and subtler. For example, in the trial by Meier and colleagues, 
subgroup analysis failed to show significant improvement in symptoms in 
people with TSH less than 10 mIU/L. 
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Instruments available to assess patient-reported 
outcomes in hypothyroidism 
Symptoms of hypothyroidism can be varied and are frequently found in the 
general population (Ladenson, et al 2000). This makes it impossible for 
clinicians to diagnose the condition solely on clinical grounds and they therefore 
have to rely on biochemical measurement of thyroid hormones and TSH in 
confirming the diagnosis (Spencer, et al 1996). On the other hand, the wide use 
of these biochemical measurements has led to a spectrum of abnormalities being 
detected, ranging from subclinical to overt disease (Cooper 2001). 
Patients with both overt and SCH may have symptoms, which could lead to 
impairment in health status and QoL (Jaeschke, et al 1994). There is evidence 
that not everyone is satisfied with treatment due to persisting symptoms 
(Kaplan, et al 2003) (Saravanan, et al 2002). It is therefore important to assess 
QoL and symptoms in patients with hypothyroidism to help in assessing its 
appropriate management. 
In achieving efficiency and high level of quality of care, health providers need 
to estimate as best they can the relationship between medical interventions and 
health outcomes (Guyatt, et al 1997). Measuring health status is imperative 
when the goal of treatment is to improve how people are feeling and 
physiological parameters of patients' experience are lacking. QoL is the sense of 
well-being that addresses multiple dimensions of life. It has been defined by the 
World Health Organisation as 'an individual's perception of their position in life 
in the context of the culture and value system in which they live, and in relation 
to their goals, expectations, standards and concerns'(1 995). Patients are the best 
judges of their own perceived QoL and tools should be designed keeping their 
perspective in mind (Guyatt, et al 1997). There is evidence that although it is 
feasible to measure QoL accurately in randomised trials, it is still not widely 
done (Guyatt, et al 1989). 
It is therefore very useful for clinicians to monitor the patient's perspective in 
addition to disease progress. Below is a discussion and review of various 
instruments currently available and used in adult hypothyroidism. 
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Method of acquiring evidence: All published literature was obtained from 
MEDLINE until March 2005 using the search tenns "hypothyroidism", 
cc symptoms", "quality of life" and "health status". Only articles reporting 
controlled trials or reporting the design of instruments to be used in 
hypothyroidism, and written in English, were included in the review, and were 
analysed to ascertain which instruments were used in relation to the stated 
objective (see table 35). 
Instruments to measure QoL and Health Status: Measurement of QoL is 
becoming a key component in the evaluation of controlled clinical trials and 
interventions, being an important outcome of interest in evaluating treatment 
effect (Guyatt, et al 1997). Patients are sometimes more concerned about their 
present QoL than longevity (McNeil, et al 198 1). Many studies have 
erroneously measured presence or absence of symptoms when assessing QoL. 
Health status has often been described as QoL (Smith, et al 1999) (Bradley 
200 1) due to lack of clear understanding of the ten-n. QoL and health status are 
distinct and separate entities, as people may not necessarily feel that their QoL is 
impaired if their health is poor, and vice versa, and instruments for one should 
not be used for measuring the other since the results could be misleading. 
Psychological well-being is another patient-reported outcome frequently 
described as QoL. 
Tools measuring patient-reported outcomes can be broadly divided into two 
categories; generic and disease-specific. 
Generic tools 
Generic instruments are designed to measure very broad aspects of health and 
are therefore potentially suitable for a wide range of patient groups and the 
general population. The main advantage of generic instruments is that they are 
suitable for use across an extensive range of health problems. They can be used 
for comparisons between treatments for different patient groups to assess 
comparative effectiveness. They can also be used with healthy populations to 
generate non-native data to compare different patient groups. Their broad scope 
means that they have potential to capture the influence of co-morbidity on 
health, as well as unexpected positive or negative effects of an intervention. This 
makes them useful for assessing the impact of new health care technologies 
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when the therapeutic effects are uncertain. Their disadvantage is that wide 
applicability means that some level of detail has to be sacrificed which may 
limit the relevance of generic instruments when applied to a specific patient 
population. Generic instruments are less responsive to clinically important 
changes in health. 
Two instruments in use to measure perceived health status are the Short Form- 
36 (SF-36) (Ware, et al 2000a) and the Nottingham Health Profile (NHP) (Hunt, 
et al 1985). The General Health Questionnaire (GHQ) (Goldberg and Williams 
1988) and the Hospital Anxiety and Depression Scale (HADS) (Herrmann 1997) 
measure psychological well -being/mental health, and are, therefore, more 
dimension specific. These are briefly described below and their use in 
hypothyroidism discussed. 
SF-36: The SF-36 has been used in evaluating a wide variety of medical 
interventions (Garratt, et al 1993), yet its layout and wording of some items 
have been criticised. Therefore a newer modified version has been produced 
with improved wording and instructions- the SF-36 version 2. This has better 
internal consistency reliability and reduced floor and ceiling effects than the 
earlier version - and this increases its precision (ability to differentiate between 
groups) and its sensitivity to change (Jenkinson, et al 1999). Despite this, 
suitability of the SF-36 in older people is uncertain (Hayes, et al 1995). 
The SF-36 has been used widely in studies involving thyroid diseases. Bianchi 
and colleagues assessed health status in people with various thyroid disorders 
including euthyroid goitre (Bianchi, et al 2004). Pollock et al found no 
difference in health status in treating euthyroid individuals presenting with 
hypothyroid symptoms with L-thyroxine (Pollock, et al 2001). Health status has 
also been assessed using the SF-36 in patients with thyroid cancer (Botella- 
Carretero, et al 2003) (Golger, et al 2003) (Crevenna, et al 2003) and in studies 
of L-thyroxine versus L-thyroxine/liothyronine combination therapy in 
hypothyroidism (Walsh, et al 2003) (Sawka, et al 2003) (Escobar-Morreale, et 
al 2005), and erroneously as a QoL measure in assessing subtle changes in doses 
of L-thyroxine (Walsh, et al 2006). 
NHP: This generic instrument assessing perceived health status has been widely 
used in a variety of chronic diseases (O'Brien, et al 1988) (Jenkinson, et al 
1988). It is acceptable to the general population and takes little time to complete 
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(Wiklund, et al 1988). It has been criticised for tapping the extreme end of ill- 
health and therefore being unsuitable to detect improvements in health in a 
general population, or those with less severe disease, since it produces highly 
skewed distributions (Kind and Carr-Hill 1987). The SF-36 may be better in 
picking up minor derangements in health status in the community or in general 
practice (Brazier, et al 1992) where the majority of patients with 
hypothyroidism are seen. Nevertheless, the NHP has been used in 
hypothyroidism in a few studies (Bianchi, et al 2004) (Botella-Carretero, et al 
2003) (Escobar-Morreale, et al 2005). Expectedly, in one of these studies 
(Bianchi, et al 2004), the NHP was found to be less sensitive than the SF-36 in 
people with hypothyroidism. In another study (Botella-Carretero, et al 2003), 
both the SF-36 and the NHP have been incorrectly reported as measures 
assessing QoL. 
GHQ: The GHQ is a measure of current mental health. Originally developed as 
a 60-itern instrument (Goldberg, et al 1976), a range of shortened versions of the 
questionnaire including the GHQ-30, the GHQ-28, the GHQ-20, and the GHQ- 
12 are now available. The questionnaire asks whether the respondent has 
experienced a particular symptom or behaviour recently. Each item is rated on a 
four-point scale (less than usual, no more than usual, rather more than usual, or 
much more than usual); but scores may vary depending on the selected scoring 
method, for example the GHQ-12 has a total score of either 36 or 12 (Goldberg 
and Williams 1988). The GHQ has been used in assessing psychiatric symptoms 
in different thyroid function states as well as response to treatment (Saravanan, 
et al 2002) (Walsh, et al 2003) (Kent, et al 1999) (Larisch, et al 2004) 
(Saravanan, et al 2005). It has been erroneously described as measuring health- 
related QoL in a study of treatment of SCH (Kong, et al 2002), and also as a 
measure of generic QoL in a study assessing symptoms and well-being in 
response to small L-thyroxine dose changes (Walsh, et al 2006) . 
Hospital Anxiety and Depression Scale: A questionnaire that can be used to 
establish the presence and severity of both anxiety and depression 
simultaneously, and separate scores for each can be calculated (Herrmann 
1997). This scale has been used to study the effects of combined L- 
thyroxine/liothyronine therapy (Saravanan, et al 2005) as well as the effects of 
L-thyroxine therapy in SCH (Kong, et al 2002). 
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Both the GHQ and HADS were developed with the primary measurement 
objective to screen for psychological disorders; hence before being used in 
evaluative applications, their appropriateness as an outcome measure should be 
examined carefully. 
Life Satisfaction Questionnaire: Petersen and colleagues designed and used 
this tool to measure satisfaction with different aspects of life in patients 
receiving L-thyroxine therapy and compared it to euthyroid controls (Petersen, 
et al 1990), although it is not a disease-specific measure. There are 19 randomly 
selected questions about aspects of life, such as home, family, work, leisure 
time, hearing, physical fitness, etc. This questionnaire is a life satisfaction and 
sensory function assessment since it asks respondents to indicate their perceived 
position in various aspects of life as well as health. It is not clear how the items 
were generated and whether the instrument had been validated previously. 
Disease-specific questionnaires 
These instruments measure the patient's perceptions of a specific disease or 
health problem. The targeted focus of disease-specific instruments makes them 
clinically relevant. An instrument developed to address a particular disease 
should be responsive to clinically important changes in health that result from 
interventions. Di sease- specific instruments should not contain any items or 
health dimensions that are not pertinent to the disease. Furthermore, if the 
instrument has clear applicability to patients with the presenting problem, 
acceptability is likely to be high. 
The disadvantage of these instruments is that it is not generally possible to 
administer disease-specific instruments to samples that do not have the relevant 
health problem. This means that health status scores cannot be compared with 
those for the general population, which is a common approach for assessing the 
impact of a particular disease on health status. It follows that it is not possible to 
make comparisons across treatments for different diseases, which limits the 
application of disease-specific instruments in economic evaluation. Finally, the 
restricted focus of disease-specific instruments may prevent them from detecting 
side effects or unforeseen effects of treatment. 
Most disease-specific instruments in use assess symptoms and/or signs in 
hypothyroidism. However, we first describe a disease-specific measure of 
quality of life and health status, noting that, there is no hypothyroid-specific 
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measure of QoL, although there is one available for patients with Gra""e's 
ophthalmopathy - the GO-QoL (Terwee, et al 1998). 
The Chronic Thyroid Questionnaire (CTQ): This instrument measuring 
health status in hypothyroidism was developed after a literature review, and 
discussion with specialists and hypothyroid patients (Jaeschke, et al 1994). It 
has 104 items grouped into four domains: physical complaints, energy and 
general well-being, and mood/emotions and cognitive functioning, and requires 
an interviewer's help to complete. An impact score is calculated as the product 
of the item score and the importance attributed to it by a respondent. The items 
were included after asking patients to focus on problems that improved after 
treatment with L-thyroxine. The CTQ was piloted by distribution to 220 
hypothyroid patients of whom 70 completed the questionnaire (response rate of 
31.6%). The characteristics of the non-responders are not known, as the authors 
themselves acknowledge. It is possible that patients with severe symptoms or 
those who were highly motivated (45 of the 70 responders were members of the 
Thyroid Foundation of Canada) completed the pilot questionnaire thus 
incorporating a certain amount of bias in the items. This questionnaire has been 
validated in patients with SCH (Jaeschke, et al 1996). The authors found that the 
symptoms in SCH patients were similar to those with overt hypothyroidism 
although not as frequent. A modified version of this instrument has since been 
used in a study of combined L-thyroxine and liothyronine therapy in primary 
hypothyroidism (Clyde, et al 2003). 
Questionnaires assessing symptoms and signs 
There have been a number of questionnaires developed over the years to aid in 
assessing symptoms and diagnosing hypothyroidism. Physical examination on 
its own does not always help in diagnosing hypothyroidism (Indra, et al 2004). 
Tools to quantify symptoms and signs are useful in situations where a 
biochemical diagnosis of SCH has been made incidentally or in a clinical trial to 
assess response to treatment. Some of these questionnaires are briefly discussed 
below. 
Billewicz index: Billewicz and colleagues designed this as a diagnostic index 
for hypothyroidism (Billewicz, et al 1969). Twenty-one symptoms and signs of 
hypothyroidism were evaluated in 152 patients with suspected hypothyroidism. 
The final diagnosis of hypothyroidism (in an era before ultra sensitive TSH 
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assays were available) was based upon 48-hour radioactive iodine uptake, serum 
protein bound iodine, thyroid autoantibodies, electrocardiogram, serum 
cholesterol and therapeutic response to L-thyroxine replacement therapy. A 
higher positive score indicates a greater degree of clinical hypothyroidism. The 
same results were obtained in a further I 10 patients assessed by colleagues at 
three other hospitals, although no further details have been provided. A large 
British follow-up study of 10 17 patients given radioactive iodine therapy 
confinned the usefulness of this score in the absence of ultra-sensitive TSH 
assays (Philp, et al 1968). A double blind cross-over study of twenty women 
with SCH by Nystrom and colleagues used a modification of this index in 
detecting the usefulness of L-thyroxine in treatment (Nystrom, et al 1988). 
Cooper et al used a modified version in their study of SCH, in which patients 
were also asked about any change in symptoms on subsequent visit (Cooper, et 
al 1984). 
The Billewicz index is therefore useful in detecting symptoms and signs of 
hypothyroidism but is not useful anymore in diagnosis since the advent of 
biochemical thyroid hormone measurements. 
Zulewski index: Zulewski and colleagues designed a symptom rating score 
based on the Billewicz index to evaluate symptoms and signs in the new thyroid 
function-testing era (Zulewski, et al 1997). Fourteen symptoms and signs of 
hypothyroidism, similar to the ones described by Billewicz and colleagues were 
evaluated in 332 subjects (50 with overt hypothyroidism, 93 with sub clinical 
hypothyroidism and 189 euthyroid controls based on TSH assays). Using this 
score, 62% of overtly hypothyroid patients were correctly diagnosed as 
compared to 42% with the Billewicz index. Similarly, 24% of sub clinically 
hypothyroid patients were classed as overtly hypothyroid (Billewicz index - 
6%). This score showed correlation with free thyroid hormone levels but not 
with TSH in overtly hypothyroid patients. In sub clinically hypothyroid patients, 
there was positive correlation with free thyroxine and TSH levels. This score is 
currently useful in helping to evaluate overt hypothyroidism clinically but is less 
helpful in the context of SCH. It also carries the inconvenience of a trained 
clinician asking patients about 12 symptoms and examining them for 5 signs. It 
has nevertheless been used, sometimes with the original Billewicz index, in 
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some clinical trials (Escobar-Morreale, et al 2005) (Saravanan, et al 2005) 
(Meier, et al 200 1) (Meier, et al 2003). 
The Thyroid Symptom Questionnaire (TSQ): Designed by Saravanan et al, 
the TSQ assesses persisting symptoms in people with hypothyroidism on 
treatment with L-thyroxine (Saravanan, et al 2002). The TSQ has 12 questions 
based on the same format as the General Health Questionnaire (GHQ- 12), and 
derived from the response to a British Thyroid Foundation newsletter (Roberts 
1996). This study showed that hypothyroid patients, even with adequate L- 
thyroxine replacement therapy, have significant psychological impairment and 
hypothyroid symptoms when compared to euthyroid controls. 
The 12 symptoms seem to have been rather arbitrarily chosen, as the 
questionnaire has no questions about skin, hair and depression, which are quite 
common and important for patients with hypothyroidism (Jaeschke, et al 1994). 
It had not previously been validated and is not clear whether a pilot study was 
conducted before being used in the community study. The TSQ has since been 
used thrice in studying the effects of combined L-thyroxine /liothyronine versus 
L-thyroxine alone in the treatment of hypothyroidism (Walsh, et al 2003) 
(Saravanan, et al 2005) or effect of small changes in L-thyroxine dose (Walsh, 
et al 2006). 
Colorado Health Fair Thyroid Disease Symptom Survey: This study was 
undertaken to determine the prevalence of abnormal thyroid function as well as 
to determine symptoms (Canaris, et al 2000). Participants were recruited from a 
state wide health fair (n=25,862) and their total thyroxine and TSH levels 
measured. A questionnaire for hypothyroid symptoms (14 items) was also 
administered to all participants. The items selected were based on a previous 
study in which 76 newly diagnosed patients with overt hypothyroidism were 
compared for traditional symptoms of hypothyroidism with 147-matched 
euthyroid controls (Canaris, et al 1997). The questionnaire is divided into two 
parts based on whether the symptom was present at the time of completion 
(current symptom - three items) or whether the symptom was a new occurrence 
compared to the previous year (changed symptom - 11 items). This study found 
that people with overt hypothyroidism were more likely to have symptoms than 
euthyroid participants (16.6% vs 12.1 %, p<0.05) and that people with SCH were 
between the two other groups in terins of total symptom score (13.7%, p<0.05 in 
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comparison to the euthyroid group). This symptom score has high specificity 
(74.7% - 95%) but low sensitivity (2.9% - 28.3%) and low positive predictive 
value suggesting that the absence of a symptom does not rule out 
hypothyroidism. 
Hypothyroid clinical scoring system: Seshadri and colleagues designed a score 
using symptoms of hypothyroidism and compared it to biochemical testing for 
TSH and thyroxine levels (Seshadri, et al 1989). This score had a false positive 
result in 45% of euthyroid individuals and the authors concluded that this score 
should only be used as a screening tool where resources are limited and 
biochemical testing difficult. 
Other symptom scores: Barker et al (Barker and Bishop 1969) and Harrison et 
al (Harrison, et al 1977) designed tools to detect patients with hypothyroidism 
secondary to treatment for thyrotoxicosis based on computer screening and 
postal questionnaire system respectively, based on symptoms. The utility of 
these early measures in the era of cheap and reliable biochemical hon-none 
measurement is redundant. 
Discussion 
A number of instruments have been used to assess symptoms, health status and 
QoL, to aid diagnosis and monitor treatment in hypothyroidism. This review of 
published literature has found that some of the instruments used for these 
purposes have either not been designed scientifically (lack of validation and/or 
psychometric analyses), or that they have been incorrectly used in measuring the 
stated outcome of the study. This does raise questions about the validity of the 
results found and has implications about the soundness of published literature in 
this area, on which we base our clinical practice. 
The relationship between physiologic and clinical measures and patient-reported 
outcomes are modest and quite variable. Wilson and Cleary have proposed a 
model of different measures of health outcome: biological and physiological 
factors, symptoms, functioning, general health perceptions, and overall quality 
of life (Wilson and Cleary 1995). They have proposed that all these different 
measures have a causal relationship between them and that each one is a 
measure of different physiological parameters, extending from the cell to the 
individual and that person's interaction with society as a whole. There is some 
evidence that this concept works in the hypothyToid setting, where the number 
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of hypothyroid symptoms has been directly related to TSH level (Canaris, et al 
1997). Trying to measure all these outcomes using a single instrument is not 
only difficult but also implies a lack of understanding of the concept. For 
example, the outcome scores of a generic instrument depend not only on the 
disease but also on the other health conditions affecting the individuals in the 
population being studied (Woodcock, et al 200 1). Also, generic instruments on 
their own may lack responsiveness and not be as sensitive to change after 
intervention as a disease-specific one, primarily because such instruments cover 
each area superficially (Jaeschke, et al 1992). On the other hand, disease- 
specific measures, although sampling most aspects of health status or QoL 
relevant to a specific illness, are unlikely to deal with effects due to other co- 
existing conditions. Therefore, when measuring patient-reported outcomes, 
namely symptoms, health status and QoL, different instruments should be used 
for each (Guyatt and Jaeschke 1997). 
The order and method (face-to-face, postal, telephonic, etc) of administration is 
important and needs to be taken into consideration (Cook et al 1993). The 
generic instrument should precede the specific one because this minimises bias 
from order effects -generic health scores are more likely to be favourable if 
disease-specific questions are asked first since the disease items have already 
been responded to and therefore excluded in replies to the generic ones 
(Bowling, et al 1999). The source of patient recruitment should also be bome in 
mind when analyzing scoring systems. For example, patients who self-select for 
thyroid testing may have an underlying psychological illness and any 
comparison with healthy controls is likely to be flawed. 
The limitation of this review is that it has only looked at instruments used in 
controlled trials or those that measure symptoms, health status or QoL. It has not 
reviewed visual analogue scores or instruments to measure cognitive 
functioning. 
In conclusion, hypothyroidism is a common yet complex condition with a wide 
spectrum of presentation and symptoms. Assessing symptoms, health status and 
quality of life is essential in managing and monitoring the condition and to aid 
diagnosis. In this review we have set out the various instruments currently 
available as well as some under development and recommend that clinicians and 
researchers take due care and consideration Nvhen selecting appropriate 
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measures. This could go a long way towards being more patient-centred in our 
approach. 
Table 35. 
Qualities of different instruments used in assessing patient-reported 
outcomes in hypothyroidism. 
Instrument No. of items Patient (P) How developed Validated 
or clinician 
(C) 
completed 
Health status 
and well- 
beinp, 
SF -36 36 P Patient interviews Yes 
NHP 45 (in 2 parts) P Patient interviews Yes 
GHQ 60,30,28,20,12 P Patient Yes 
assessment* 
QOL 
CTQ 104 Both Patient responses Yes4 
symptoms 
Billewicz 
index 14 C Patient exam Yes 
Zulewski score 12 C Patient exam Yes 
TSQ 12 P Patient responses No 
Colarado 
Symptom 14 P Patient responses Yes 
* In primary care setting, " Only in SCH. 
SF-36 - Short Form 36, NHP -Nottingham Health Profile, GHQ - General Health 
Questionnaire, CTQ - Chronic Thyroid Questionnaire, TSQ - Thyroid Symptom Questionnaire. 
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METHODS (B) 
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Hypothesis and endpoints 
Hypothesis: Treatment of SCH with L-thyroxine improves CV risk factors and 
patient-reported outcomes. 
The primary endpoints were improvement in endothelial function and total 
cholesterol levels but changes in patient-reported outcomes were amongst the 
secondary endpoints. 
Patient-reported outcomes, (assessed by questionnaire): 
Perceived health status. 
Hypothyroidism-specific quality of life (QoL). 
Hypothyroid symptoms. 
Hypothyroid-specific satisfaction with treatment. 
There were no disease-specific (hypothyroid) instruments available to assess 
QoL, symptom bother scores and satisfaction with treatment. Therefore, 
collaboration with health psychologists with immense experience in 
questionnaire design and validation was initiated. 
The SF-36v2 was utilised for the assessment of perceived health status. 
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Designing the questionnaires 
Introduction 
Although there has been much interest in clinical aspects of hypothyroidism and 
its treatment over the past 20 years, psychosocial aspects have received less 
attention. Sonino and Fava have pointed out the need for multidimensional 
assessments of the effects of treatment in thyroid disorders, including 
psychosocial aspects (Sonino and Fava 1998). However, there is no published 
self-completion measure of QoL in hypothyroidism. A literature search found 
two measures, neither of which fulfils the requirements for a condition-specific 
measure of QOL: the Canadian disease-specific Chronic Thyroid questionnaire, 
comprising questions relating to symptoms of hypothyroidism (Jaeschke, et al 
1996), is for completion by health professionals during interviews with patients; 
the QOL-Thyroid Scale evaluates the impact of thyroid hormone withdrawal on 
aspects of QoL of patients with thyroid cancer undergoing scanning procedures 
(Dow, et al 1997), and is not suitable for the majority of people with 
hypothyroidism. The simple tablet treatment regimen for hypothyroidism is 
unlikely to be a major cause of dissatisfaction to patients compared to, for 
example, injecting growth honnone to treat growth hormone deficiency. 
However, some patients with hypothyroidism may not be satisfied with L- 
thyroxine treatment because they do not feel as well as they did before the onset 
of the thyroid disorder. Many patients complain of persistent symptoms while 
taking L-thyroxine (Kaplan, et al 2003). Patients on L-thyroxine replacement 
can have significant impainnent in psychological well being compared to 
controls of similar age and sex (and who had not had thyroid disease), even 
though their TSH levels are within the normal laboratory reference range 
(Saravanan, et al 2002). Such patients are likely to be dissatisfied with their 
current treatment. There is some evidence of poor adherence to treatment by 
patients, perhaps signifying some dissatisfaction with treatment. Ladenson 
quoted unpublished data from one American clinical laboratory that indicated 
the possibility that patients do not fully adhere to two thirds of thyroxine 
prescriptions dispensed (Ladenson 2002). Toft and Beckett (Toft and Beckett 
2003) reported, "Some patients achieve a sense of well-being only if free T4 is 
slightly eleN, ated and TSH low or undetectable. " There is also research and 
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increasing discussion in the literature about the benefits of combined treatment 
with L-thyroxine and triiodothyronine (Bunevicius, et al 1999) (Sawka, et al 
2003) (Walsh, et al 2003) (Saravanan, et al 2005). A sensitive measure of 
treatment satisfaction is needed for clinical trials of any new treatments or 
treatment combinations in the future. No such measures of treatment satisfaction 
are known to exist at present. 
There are instruments in place for the diagnosis of hypothyroidism on the basis 
of symptoms (Billewicz, et al 1969) (Zulewski, et al 1997) but they are for 
completion by health professionals. Other symptom measures exist, usually 
designed specifically for a clinical trial (Jaeschke, et al 1994) (Canaris, et al 
1997) (Saravanan, et al 2002) (Cooper, et al 1984), but which do not appear to 
have been validated psychometrically, or designed on the basis of interviews 
with patients. Although patients were involved in the identification of important 
symptoms in the development of the Chronic Thyroid Questionnaire, the 
measure itself is completed by 3 clinicians (Jaeschke, et al 1994). Measures of 
symptom frequency or relative change (Canaris, et al 1997) (Saravanan, et al 
2002) (Cooper, et al 1984) are not eliciting how much 'bothered' a patient is by 
a symptom: a symptom might occur frequently, but not trouble the patient 
unduly and vice versa. There is a need for a short, validated self-completion 
measure of the most common hypothyroid symptoms that has been developed 
through interviews with patients. 
This study aimed to design three new condition-specific questionnaires based on 
the views and experiences of people with hypothyroidism, which were: the 
Underactive Thyroid-Dependent Quality of Life Questionnaire (ThyDQoL), the 
Underactive Thyroid Treatment Satisfaction Questionnaire (ThyTSQ) and 
Underactive Thyroid Symptom Checklist (ThySC). 
Materials and Methods 
Patient recruitment criteria 
Patients were recruited at three U. K. centers: Queen Elizabeth Hospital, 
Gateshead, Royal Surrey County Hospital, Guildford, and St. Thomas' Hospital, 
London, Nvith some patients also being identified and recruited at primary care 
clinics local to the Gateshead and London hospitals. Recruitment took place by 
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telephone or in person during clinics. The patients were representative of the age 
range and typical female: male ratio found in hypothyroidism (approximately 
6: 1), and of a wide sociodemographic and ethnic mix, noting that there is higher 
prevalence of thyroid disease in white compared to black people (Hollowell, et 
al 2002). The age range was 18+ years (no upper limit). There was to be a broad 
spectrum of hypothyroidism, ranging from subclinical to overt, and including 
those with postpartum hypothyroidism, or those rendered hypothyroid after 
surgery or radioiodine therapy. The proportion of people with subclinical 
hypothyroidism was limited to a maximum of 10% of the total. The great 
majority of patients would be treated with L-thyroxine. Exclusion criteria were: 
pregnancy, current or previous thyroid cancer, and non-English-speakers. 
Patients with other chronic conditions such as diabetes or heart disease were not 
excluded, nor were patients with central hypothyroidism, even though the latter 
might have particular difficulty differentiating the symptoms of hypothyroidism 
from those of other pituitary-hypothalamic hormone deficiencies. 
Interviews 
Psychologists experienced in questionnaire design conducted semistructured 
interviews with 38 patients. Each interview lasted approximately 75 minutes and 
was tape-recorded. An iterative approach was used to determine item selection 
for the new questionnaires. Twenty-five of the 38 interviews started with open 
questions about the effects of hypothyroidism on QoL, and experiences of 
treatment. These 25 patients were asked: "If you woke up tomorrow to find that 
you no longer had underactive thyroid, and you were producing normal amounts 
of thyroid hon-none, how would that affect your quality of life? " Life domains 
and aspects of treatment mentioned spontaneously by patients and before they 
were presented with draft questionnaires were noted down. Interviewees then 
completed and commented on the draft questionnaires, and possible changes to 
the questionnaires were discussed and new or modified items piloted with 
subsequent patients. To check that questionnaires could be completed easily, 
without the priming effects of previous open questions, 13 of the later interviews 
NA, cre reversed (i. e., the nearly finalized draft questionnaires Nvere presented first 
before any open questions about QoL and treatment satisfaction ývere asked). 
These 13 patients were not asked the above question imagining life without 
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underactive thyroid. Few "spontaneous" mentions were therefore possible in 
reversed interviews, although some patients started to talk freely as soon as the 
interview started, and any spontaneous mentions were noted and included in 
summaries of spontaneous mentions. Interview data were analysed for content. 
The following research ethics committees (REC) gave approval for the 
interview study: Gateshead Local REC, South West Surrey Local REC, and 
Lewisham REC. 
Patient recruitment 
Gateshead recruited 18 patients, and I additional volunteer was interviewed (a 
sibling who accompanied her sister to interview but who did not complete the 
questionnaires); Guildford recruited 9 patients and London 10 patients. All but I 
of the 38 interviewees were being treated with L-thyroxine. Primary care 
practitioners or hospital clinicians diagnosed all participants after a minimum of 
two thyroid function tests at least three months apart. Table 36 provides details 
of patient characteristics, and shows that patients with a broad spectrum of 
hypothyroidism were recruited. 
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Table 36. 
Patient characteristics and centre recruitment details. 
n 
Source of recruitment Hospital clinic 26 
Primary care II 
Self-referral I 
Mean age (range) 51.9 (29-79) 38 
Ratio women: men 30: 8 
Diagnosis of Primary autoimmune 27 
hypothyroidism Primary (secondary to thyroidectomy 9 
or radioiodine) 
Secondary 2 
Treated with L- 37 
thyroxine 
Other conditions Osteoarthritis 6 
Asthma 4 
Type 2 Diabetes Mellitus 3 
Pernicious anaernia 3 
Lupus I 
Rheumatoid arthritis I 
Polycystic ovarian syndrome I 
Ethnicity White Caucasian 35 
African or Afro-Caribbean 3 
ThyDQoL questionnaire 
The first draft of the ThyDQoL for use in early inter-views was informed by a 
review of the literature on hypothyroidism and discussions with clinicians. 
Design of the ThyDQoL was based on the Audit of Diabetes-Dependent Quality 
of Life (ADDQoL) (Bradley, et al 1999), which in turn was influenced by the 
generic interview method known as the SEIQoL (Schedule for the Evaluation of 
Individual Quality of Life (McGee, et al 1991). Adaptations of the ADDQoL for 
people with renal disease [RDQoL (Bradley 1997)], macular disease [MacDQoL 
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(Mitchell and Bradley 2004)], diabetic retinopathy [RetDQoL (Woodcock, et al 
2004)] and growth hon-none deficiency [HDQoL (McMillan, et al 2003)] were 
also considered when designing the TbyDQoL, and relevant items adapted for 
inclusion. All these questionnaires define QoL as "how good or bad you feel 
your life to be, " on the basis that QoL is "what the patient says it is" (Joyce 
1994). Twenty-six of 34 interviewees did not understand the term 
"hypothyroidism. " An additional 5 patients were confused by the distinction 
between hypothyroidism and hyperthyroidism. On the other hand, the term 
"underactive thyroid" was used spontaneously by 21 patients, and understood by 
15 more patients. One patient did not understand the term, and one patient was 
unsure of the difference between underactive and overactive thyroid. Because a 
great majority of patients understood the term underactive thyroid, it was used to 
refer to the hypothyroid condition throughout, after the first few interviews had 
been conducted. 
Overview items: The first section of the ThyDQoL has two items providing an 
overview of the respondent's QoL. Question I (QI-present QoL) asks people to 
rate their present QoL on a 7-point scale from excellent to extremely bad (scored 
+3 to -3). Question 11 (Q11-impact on QoL) asks people to rate what their QoL 
would be if they did not have underactive thyroid, on a 5-point scale from vel-Y 
inuch better to wor.,; e (scored -3 to +1), providing a global measure of perceived 
impact of underactive thyroid on QoL. Responses to the two overview items (QI 
and Q11) showed that present QoL was between good and excellent for the great 
majority (8 1 %), and from bad to extremely bad for only two patients (6%). 
Despite this, 62% perceived the overall impact of hypothyroidism on QoL as 
negative (i. e., that their QoL would be better if they did not have underactive 
thyroid). However, 38% reported that the disorder had no impact on their QoL. 
Life domains: The first draft of the ThyDQoL then had 40 life domain items 
that cover relationships, work and leisure, physical aspects including symptoms, 
cognitive aspects including memory, psychological aspects including 
depression, and managing everyday activities. Many of these items are derived 
from the ADDQoL and versions for other disorders. Domains are introduced by 
a hypothetical statement with five response options, e. g., If I did not have 
underactive thyroid, my Nvorking life would be ... vei: v nutch 
better, nuich 
bctter, a little better, the saine, ivorse (the impact rating: scored from -3 to +1). 
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Respondents then rate how important that domain is to their QoL on a four-point 
Likert scale from vety iniportant to not at all iinpoi-tant (the importance rating: 
scored from 3 to 0). A weighted domain impact score is obtained by multiplying 
the domain's impact rating by the corresponding importance rating. Weighted 
domain scores range from -9 to +3 (maximum negative to maximum positive 
impact of hypothyroidism. on the domain). Similar to the ADDQoL, the 
ThyDQoL is individualised. It takes into account the relevance for the individual 
of each aspect of life covered in the questionnaire, by giving respondents the 
opportunity to indicate whether a particular domain, (e. g., work or sex life), is 
not applicable. In a "free comments" section at the end of the questionnaire, 
patients may describe any other ways in which underactive thyroid, and any 
treatment affect their QoL, allowing for the addition of further domains to the 
questionnaire in the future, as part of its continuing development. 
The instructions on the finalised questionnaire make it clear to patients that they 
should consider their QoL from the point of view of the treated condition, if 
applicable. The 25 patients (those not participating in a reversed interview) who 
were asked how their QoL would be affected if they no longer had underactive 
thyroid, mentioned 18 areas of life specifically at this point. The key areas of 
life affected were: energy, weight, physical appearance, bodily discomfort (e. g., 
cold intolerance, aches and pains), and physical capabilities. 
The selection of 18 domains was arrived at through the iterative interview 
process, taking particular account of the life domains that received spontaneous 
mentions, patients' marked responses, and comments while completing the 
ThyDQoL. Nine of the 18 domains have "not applicable" response options. 
Hypothyroidism was perceived as having a negative impact on applicable 
domains by 3 9% to 81% of patients, and the domains were important to most 
people. The most severely impacted domains were: energy, physical 
capabilities, motivation, physical appearance, and weight. However, for all 18 
domains there were some patients who perceived hypothyroidism as having no 
impact on the domain, particularly for domains social life, future, and getting 
out and about. In the majority of domains there were no reports of any positive 
impact of hypothyroidism, as expected, but there was one woman who reported 
the positive impact of having the condition diagnosed and successfully treated, 
after some years of experiencing tiredness and other symptoms. Another patient 
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reported a positive impact in that she had become more understanding of people 
with health problems or disabilities. Although some domains received few 
spontaneous mentions, (sex life, relationship, future), they were included in the 
final version of the ThyDQoL because they received reports of negative impact 
on QoL when patients were completing the questionnaires, and were usually 
important when applicable. Item means are shown in table 37 for the 18 patients 
in the later interviews (by which stage mostly finer adjustments to items were 
being made but underlying concepts remained the same). This show the greatest 
negative weighted impact of hypothyroidism was perceived to be for bodily 
discomfort (4.6 ± 3.95), energy (4.17 ± 3.09) and motivation (-3.57 ± 3.03). 
Twelve of the final 18 domains on the ThyDQoL were derived from or are 
similar to domains on the ADDQoL (for diabetes). Additional domains not 
found on the ADDQoL were derived from other questionnaires: 2 from the 
HDQoL (for growth hormone deficiency) and 2 from the MacDQoL (for 
macular degeneration). Weight and depression are important further domains 
(not used in previous DQoL measures), because excessive weight gain and 
depression following onset of hypothyroidism were frequently mentioned as 
being particularly distressing. Of the 40 domains in the first draft ThyDQoL, 18 
items were dropped over the course of interviews, for the reason that they were, 
for the majority of patients, not applicable or not important, and/or not 
negatively impacted by hypothyroidism, and/or there were no spontaneous 
mentions of the domain before the questionnaire item was presented. Items 
dropped were: feelings about fertility, physical stamina, bodily pain, local or 
long distance journeys, self-confidence, way people in general react to me, 
financial situation, depend on others, depend on medication, sleep, lose things, 
tolerance of stress, handle my personal affairs, shopping, do things for others, 
living conditions, spiritual/religious life, and people fuss or worry about me. In 
addition four items relating to specific symptoms of hypothyroidism (problems 
with memory, concentration, voice/speech, and appetite) were also dropped 
from the earlier drafts of the ThyDQoL because the majority of patients reported 
they were not applicable. They have been included, together with other more 
common symptoms mentioned by the patients, in a new short, 15-item 
Underactive Thyroid Symptom Checklist, suitable for self-completion. 
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Table 37. 
ThyDQoL Item Means and standard deviations from final eighteen 
interviews. 
Number Abbreviation Mean ± SD N 
Q1 Present QoL 1.29 0.99 17 
Q11 Hypothyroid-dependent QoL -1.11 0.96 18 
1 Spare time -1.39 2.12 18 
2 Working time -2.56 ± 2.6 9 
3 Holidays -2.4 ±3 15 
4 Family life -3 ± 3.43 18 
5 Social life -1.35 ± 2.47 17 
6 Relationship -2.25 ± 2.93 12 
7 Sex life -0.58 ± 1.24 12 
8 Physical capabilities -3.56 ± 3.37 18 
9 Energy -4.17 ± 3.09 18 
10 Speed -3.06 ± 3.65 18 
11 Getting out and about -2.83 ± 3.24 18 
12 Household tasks -2.78 ± 3.04 18 
13 Physical appearance -1.94 ± 2.41 17 
14 Weight -3.43 ± 3.16 14 
15 Bodily discomfort -4.6 ± 3.95 10 
16 Depressed -1.6 ± 1.67 5 
17 Motivation -3.57 ± 3.03 14 
18 Future -1.89 ± 3.09 18 
ThyTSQ questionnaire 
The first draft of the ThyTSQ was prepared after a review of the literature and 
discussions between clinicians and psychologists. Its design was based on the 
widely used Diabetes Treatment Satisfaction Questionnaire [DTSQ (Bradley 
and Lewis 1990)] and related questionnaires for people with renal disease 
[RTSQ (Barendse, et al 2005)], and human immunodeficiency virus [HIVTSQ 
(Woodcock and Bradley 2001)]. Instnictions ask patients to consider their 
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experience of treatment for underactive thyroid over the previous few weeks. 
The first draft of the ThyTSQ comprised 10 questions including items 
concerning satisfaction with current treatment, convenience, and understanding 
of treatment, 6 of which were derived from the DTSQ questionnaire for people 
with diabetes. Patients respond to each item by circling a number on a scale 
from 6 to 0, indicating their degree of satisfaction with that aspect of treatment 
(e. g., from very satiýfied to very dissatiýfied) as in the following example: 
How satisfied are you with the current treatment for your underactive 
thyroid? 
very satisfied 6543210 very dissatisfied 
Half the patients in the first sets of interviews (10/20) spontaneously reported 
negative experiences of treatment around the time of diagnosis. These related to 
delays in diagnosis, and/or in prescribing L-thyroxine treatment, and/or lack of 
information provided about the condition or the treatment. Even though patients' 
experiences of current treatment might be positive, in some cases these past 
negative experiences interfered with completion of questions about current 
treatment, because patients wanted to express their dissatisfaction with earlier 
treatment/mistreatment. A separate section was therefore drawn up, after half 
the interviews had been conducted, with questions covering satisfaction with 
past treatment, the ThyTSQ-Past. It is an extension of the main questionnaire, 
which was renamed the ThyTSQ-Present. Following the iterative process, the 
final version of the ThyTSQ-Present has seven items including questions about 
satisfaction with current treatment, control of symptoms of underactive thyroid, 
convenience, and patient understanding of treatment. Three items were dropped 
from the early draft ThyTSQ-Present concerning side effects, flexibility and 
safety of treatment, as these were not perceived to be relevant issues by the 
patients interviewed. Least satisfaction was found for patients' understanding of 
their condition (mean 4.58) and for how well the treatment was working 
(mean 4.97), but there were high means (5.0) for the other five items on 
satisfaction with present treatment (table 38). The ThyTSQ-Past has four items 
concerning satisfaction with the way doctors dealt with the patient or the thyroid 
condition around the time of diagnosis, and satisfaction with information 
provided about the condition and its treatment. Sixteen patients spontaneously 
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mentioned some dissatisfaction with past treatment before they saw the draft 
ThyTSQ. When draft questions about past treatment were being tested in later 
interviews, 8 of 18 patients expressed some degree of dissatisfaction with 
aspects of early treatment. Least satisfaction with past treatment was reported 
for information provided by doctors about the condition and about the treatment 
(both means less than 4.0). The wide range of responses selected for the 
majority of items in both treatment satisfaction measures is indicative of the 
likely responsiveness of these measures to different treatments. 
Table 38. 
ThyTSQ (present and past) item means from 36 patients. 
Number Abbreviation Mean ± SD N 
ThyTSQ- 
Present 
I Present satisfaction 5.17 ± 1.05 36 
2 How well working 4.97 ± 1.11 36 
3 Convenient 5.08 ± 1.44 36 
4 Understanding of condition 4.58 ± 1.46 36 
5 Encourage others 5.56 ± 1.16 36 
6 Controlling symptoms 5.33 ± 0.78 12 
7 Continue with treatment 5.53 ± 0.84 36 
ThyTSQ- 
Past 
I Past satisfaction 4.20 ± 2.35 10 
2 Infon-nation of condition 3.36 ± 2.06 14 
3 Information of treatment 3.43 ± 2.47 14 
4 Taken seriously 4.85 ± 1.77 13 
The Underactive Thyroid Symptom Checklist (ThySC) 
When designing the ThyDQoL a number of symptoms were initially included in 
the measure, such as tiredness and voice problems. However, during the 
interviews with patients, the majority of these symptoms were found to be 
unsuitable for inclusion as ThyDQoL domains, being too specific in nature to be 
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important for many aspects or life, e. g. voice problems, or because some 
patients were unsure whether they were attributable to hypothyroidism. A total 
of 38 interviews were conducted with patients when designing the ThyDQoL, 
but as these progressed it was decided to develop a separate questionnaire, the 
Underactive Thyroid Symptom Checklist (ThySC), for completion by patients. 
ThySC design was influenced by design of the Diabetes Symptom Checklist 
(Grootenhuis, et al 1994) and the Asthma Symptoms Questionnaire (Steen and 
McColl 1995). Symptoms selected for inclusion were based 6 on the literature, 
consultations with endocrinologists, and were the most frequently mentioned 
symptoms in the interviews. The method used to design the ThySC was the 
same as for the ThyDQoL, and the ThySC was finalised and piloted in semi- 
structured interviews with 10 patients conducted at two centres (London and 
Surrey): 2 men and 8 women, [mean age 49 ± 14.3, range 32 - 67 years]. The 
checklist of 15 symptoms has a 4-point symptom bother scale measuring 
perceived symptom severity, and is introduced: 
"This questionnaire asks you about symptoms that can be associated with 
underactive thyroid and that you may have experienced in recent weeks ". 
Respondents provide a bother rating for applicable symptoms, indicating how 
much the symptom bothers them from not at all, a little, quite a bit, very much 
(scoring 0,1,2 and 3 respectively). Any patient who reports that they do not 
have a symptom is given a symptom bother rating of zero (not at all bothered). 
The terrn 'in recent weeks', whilst not specific, has been found during 
interviews or in questionnaire development work to be interpreted as meaning 
the past three to six weeks. Although it would be possible to specify a time 
period (e. g. the past four weeks), in practice patients are not able to remember so 
precisely when symptoms occur and such specificity may give an illusion of 
precision that does not exist. 
The ThySC was then further tested in a sample of hypothyroid patients (n=1 10) 
in whom the ThyDQoL and ThyTSQ were being validated. Table 39 describes 
the frequency of symptoms as well as mean bother scores. 
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Table 39. 
Frequency and mean bother scores of symptoms of hypothyroidism 
(n=11O). 
Symptom % (n) Mean ± SD Median 
Tiredness 90(99) 2.11 ± 0.77 2 
Weight gain 59(65) 2.22 ± 0.93 3 
Feeling cold 53 (58) 2.12 ± 0.75 2 
Constipation 42(46) 1.74 ± 0.88 1.5 
Hair 44(48) 2.25 ± 0.86 3 
Skin 60(66) 2.00 ± 0.91 2 
Nails 46(51) 1.69 ± 0.84 2 
Appetite 22(24) 1.54 ± 0.98 1 
Hearing 33 (36) 1.75 ± 1.05 1 
Voice 24(26) 1.58 ± 1.14 1 
Speech 25 (27) 1.89 ± 0.89 2 
Memory 54(59) 2.00 ± 0.93 2 
Concentration 56(61) 2.07 ± 0.91 2 
Feeling giddy 46(51) 2.00 ± 0.88 2 
Depression 73 (80) 2.13 ± 0.83 2 
Discussion 
The Thy-DQoL is an individualized patient-centred measure of the impact of 
hypothyroidism on QoL and the ThyTSQ measures satisfaction with treatment 
for this disorder. The ThyDQoL has two overview items to assess current QoL 
and overall impact of hypothyroidism on QoL, and 18 items covering specific 
domains of life that may be impacted by hypothyroidism, domains that were 
important to the great majority of interviewees. The ThyTSQ was divided into 
two separate and independent sections: the 7-item ThyTSQ-Present, which 
measures satisfaction with current treatment for hypothyroidism, and the 4-itern 
ThyTSQ-Past measuring past satisfaction with treatment around the time of 
diagnosis. Over the course of the iterative interview process, many draft items 
were dropped from the early versions of the questionnaires, and new items 
inserted, or different forms of wording used. This has shown the importance of 
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developing condition-specific questionnaires rather than using generic measures, 
or making superficial modifications to questionnaires designed for other 
conditions. 
There is considerable support for the domains selected for inclusion in the 
ThyDQoL. Patients who were asked what effect there would be on their QoL if 
they did not have underactive thyroid spontaneously mentioned all but 2 of the 
final 18 domains. The exceptions were holidays and depression, but these were 
often mentioned in other parts of the interviews. Despite treatment with L- 
thyroxine, hypothyroidism. was found to have a negative impact on QoL, 
particularly for the domains of bodily discomfort, energy, motivation, physical 
capabilities, weight and physical appearance. This confirms the reports of 
continuing symptoms and effects of hypothyroidism on QoL that appear in 
newsletters produced by thyroid patient organisations (e. g., British Thyroid 
Foundation) and also recent discussion in the medical literature (Kaplan, et al 
2003). 
A problem for a measure of QoL in hypothyroidism is that patients may have 
treated comorbidities such as pernicious anaernia or diabetes, which often have 
diffuse symptoms that are indistinguishable from those caused by 
hypothyroidism. The advantage of the ThyDQoL, however, is that each item 
specifically mentions "underactive thyroid, " encouraging the respondent to 
focus on this condition rather than any others that they might have. There is 
evidence that the related condition-specific questionnaire, the ADDQoL for 
diabetes, is more sensitive to the effects of diabetes in those with co morbidities 
than generic measures of health status (Woodcock, et al 200 1), and we would 
expect the ThyDQoL to have similar properties. Furthermore the ThyDQoL is 
not designed to distinguish between people who are, for example, depressed for 
reasons unrelated to their hypothyroidism and those who are depressed owing to 
inadequate L-thyroxine replacement. However, it will distinguish between 
people who believe that their depression is caused by hypothyroidism and those 
that think that they have depression for other reasons (and who will indicate that 
underactive thyroid has had no impact on their feelings of depression). The 
overall total score for the ThyDQoL will provide the average weighted impact 
on QoL, for individual or group comparison with scores of other individuals or 
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groups. The next step was to validate the newly designed questionnaires and to 
assess their psychometric properties. 
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Validation of the questionnaires 
This chapter concerns the evaluation of these questionnaire's psychometric 
properties. 
Participants and Methods 
In this cross-sectional study, the ThyDQoL, the ThyTSQ and ThySC 
questionnaires were completed by hypothyroid patients recruited from the 
diabetes and endocrinology clinic at Queen Elizabeth Hospital, Gateshead, UK 
(fewer than 5% of whom were attending the hospital for their primary 
hypothyroidism) and three local primary care practices in which all patients 
were approached who fitted the inclusion criteria. The age range was 18+ years 
(no upper limit), and all patients had a diagnosis of hypothyroidism based on 
two blood tests taken at least three months apart. People known to have mental 
health problems likely to render them incapable of understanding and 
completing the questionnaires were not included. The Gateshead Local Research 
Ethics Committee gave approval for the research, which was carried out in 
compliance with the Helsinki declaration. 
The mean age of the sample was 55.1 years, and mean duration of 
hypothyroidism was 8.3 years. The ratio of women to men was 9: 2, similar to 
the sex ratio of thyroid disease found in the general US population in a recent 
study (Hollowell, et al 2002). The great majority of patients had autoimmune 
hypothyroidism (N = 98,89%) of which II patients had subclinical 
hypotbyroidism. The great majority (N = 103,94%) were receiving L-thyroxine 
replacement. Measurements of TSH levels were available for 95 patients (86%) 
(median 2.4 mIU/L) but in the case of free thyroxine (FT4) only 49 patients 
(45%) (mean 17.4 pmol/L). 
Questionnaire coinpletion rates 
Healthcare professionals prompted patients recruited and respondents to 
complete any missed items on the questionnaires, or at the three primary care 
clinics (where patients were not prompted to complete missing data). The Flesch 
Reading Ease statistic was calculated to be 54.1 (ThyTS Q-Pre sent) and 57.2 
(ThyTSQ-Past). These are slightly less than the optimal 60-70 (in a possible 
score range of 0 to 100, vvhere a higher score indicates greater reading ease). 
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The Flesch statistic takes into account the average number of syllables per word 
and words such as our recruitment sources might create artifactual correlations 
in the combined sample, if the subgroup mean scores differed consistently 
across items. This was investigated by converting the scores to standardised z- 
scores within each subgroup before combining the sub-sets of scores. Such 
standardisation renders group means identical and thereby removes the 
possibility of correlations caused by subgroup differences (a method adopted 
when developing the ADDQoL). Forced one-factor solutions on the raw scores, 
and then on the z-scores, produced two sets of factor loadings that were then 
compared using correlation and regression analyses. There was no significant 
difference between loadings of standardised and raw scores: the correlation of 
0.998 was close to 1, the constant was 0.0, and the slope of the regression line 
(1.00 1) did not differ significantly from 1, [t (15) = 60.28, p >0.05]. Thus initial 
analyses demonstrated that the four recruitment groups could be treated as one 
sample for reliability and factor analyses (for which larger N is desirable). 
Statistical analyses 
No data from respondents selecting a N/A response option on the ThyDQoL 
would normally be included in factor and reliability analyses. N/A responses are 
treated as missing by the statistical package used (SPSS for Windows, Release 
10.0). Furthermore, if the SPSS default of listwise deletion of missing data is 
used, all cases that have any missing values across all 18 items are lost to 
analysis, so considerable data could be lost. From 3 to 50% of volunteers 
selected N/A on items where the option was available, N/A responses were 
therefore coded as zero for factor and reliability analyses, with pair wise 
deletion of data missing for other reasons, as in the original development of the 
ADDQoL. Normality of distributions was determined through investigation of 
histograms and z (skew) scores (comparing the skewness value with zero using 
the z distribution), where z (skew) scores between ±2.58 are indicative of 
normality . The minimum acceptable 
Cronbach's alpha coefficient of internal 
consistency reliability was taken as 0.8 and acceptable item-total correlations 
were >0.2. Factor structure was explored using Principal Components as an 
extraction method with Varimax rotation, with salient loadings taken as > 0.4. 
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The ThyDQoL 
Descriptive statistics 
Domains reported as most severely (and negatively) impacted by 
hypothyroidism were: motivation (mean weighted impact = -4.84), weight 
4.5 1), and depression (-4.36), (maximum possible range -9 to +3) (table 40). 
The majority of respondents (7 1 %) perceived that hypothyroidism had had a 
negative impact on overall QoL (mean QII: Thyroid dependent QoL was -1.25), 
and Present QoL was rated as between good and neither good nor bad (mean 
0.89). Transformations of any non-normal distributions left three items with 
slightly skewed distributions [z (skew) ranging from 2.8 to 4.0]. 
Table 40. ThyDQoL item descriptive statistics in validation study (n=108). 
Number Abbreviation Mean ± SD N 
Q1 Present QoL 0.89 1.02 108 
Q11 Hypothyroid -dependent QoL -1.25 0.99 108 
1 Spare time -2.49 ± 2.71 107 
2 Working time -3.46 ± 3.3 54 
3 Holidays -2.37 ± 2.63 90 
4 Family life -2.74 ± 2.93 105 
5 Social life -2.00 ± 2.57 106 
6 Relationship -2.91 ± 3.18 88 
7 Sex life -2.69 ± 3.12 75 
8 Physical capabilities -3.23 ± 2.82 105 
9 Energy -4.21 ± 3.11 107 
10 Speed -2.78 ± 2.52 108 
11 Getting out and about -2.60 ± 2.90 108 
12 Household tasks -3.37 ± 2.89 106 
13 Physical appearance -3.24 ± 3.24 108 
14 Weight -4.51 ± 2.97 86 
15 Bodily discomfort -4.29 ± 2.81 89 
16 Depressed -4.36 ± 2.73 76 
17 Motivation -4.84 ± 2.79 95 
18 Future -2.87 ± 2.86 107 
Average Weighted Impact 18 -3.11 ± 2.2 108 
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Reliability andfactor analyses and correlations 
The 18-item ThyDQoL had very high internal consistency reliability 
[Cronbach's alpha =0.949, standardised item alpha = 0.95, N= 97 (N/A 
responses coded as zero)]. All corrected item-total correlations were satisfactory 
(>0.2, range 0.49 to 0.88), the lowest being the item 'depression' which also 
detracted slightly from overall scale alpha (0.95). A forced 1-factor analysis 
showed all 18 items had satisfactory loadings (>0.5) on the single factor 
(accounting for 55.4% of the variance), indicating that all applicable domains 
could be combined into an overall Average Weighted Impact score (AWI- 18), 
reflecting a maximum of 18 weighted domain impact scores. The AWI- 18 mean 
score of -3.11 (2.2) indicated overall negative perceived impact of 
hypothyroidism on QoL. To assess the effects of missing data on ThyDQoL 
reliability, reliability analyses were run sequentially, deleting the strongest item 
each time, (i. e. deleting the item having the lowest 'alpha if item deleted' and 
therefore contributing most to the scale's internal reliability). Calculation of 
ThyDQoL AWI- 18 was reliable at alpha = 0.9 with a maximum of five items 
missing and reliable at alpha = 0.8 with a maximum 10 missing items. It is 
therefore reasonable to calculate AWI- 18 providing at least half of the items (i. e. 
domain-specific items) have been completed. 
The correlation between AWI- 18 and QII: Thyroid-dependent QoL, [r = 0.69, 
p <0.00 1, N= 108], was sufficiently high for QII to replace the full ThyDQoL 
for some purposes. With respect to AWI- 18 and overview items, no significant 
sub-group differences were found in treatment (noting that only 6.5% of patients 
were untreated), nor a significant correlation with TSH levels was noted. 
However, the difference in QII: Thyroid-dependent QoL between those with 
overt and subclinical hypothyroidism approached significance (Bonferroni 
correction required p value 0.05/3 = 0.0 17). 
The ThyTSQ 
Descripth, e statistics 
Non-normality, (negative skew towards high satisfaction with treatment) was 
found in most ThyTSQ items and was dealt with successfully by conducting 
reflect and log trans forination s, leaving two items with a small degree of non- 
normality [z (skew) = 4.2]. ThyTSQ-Present item means indicate that overall 
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patients were satisfied with all aspects of their treatment (table 4 1). Patients 
were most satisfied with convenience of treatment (item 3, mean 5.24), and least 
satisfied with their understanding of their condition (item 4, mean 4.19). Mean 
Present Satisfaction was 32.5 (7.8) (maximum possible range 0- 42). Of the six 
patients (5.9%) who had Present Satisfaction scores of < 21 (expressing 
dissatisfaction with current treatment) five had available TSH measurements: 
mean 1.64, range 0.12 to 3.53, i. e. were being treated so that their TSH levels 
were within the laboratory reference range of 0.4 to 4.0 mlU/L. Patients were 
more satisfied than dissatisfied with all four aspects measured by the ThyTSQ- 
Past, but had least satisfaction with infonnation provided about the condition or 
its treatment at time of diagnosis. Mean Past Satisfaction was 17.5 (6.1) 
(maximum possible range 0- 24). Nineteen patients (18.4%) had Past 
Satisfaction scores < 12 indicating overall dissatisfaction with past treatment. 
Table 41. 
ThyTSQ item means in validation study (n-=l 10) 
Number Abbreviation Mean ± SD N 
ThyTSQ-Present 
I Present satisfaction 4.89 ±1.27 103 
2 How well working 4.22 ± 1.47 102 
3 Convenient 5.24 ± 1.18 103 
4 Understanding of 
condition 
4.19 ± 1.73 103 
5 Encourage others 5.1 1.26 103 
6 Controlling symptoms 4.36 1.27 103 
7 Continue with treatment 4.52 1.43 103 
ThyTSQ-Past 
I Past satisfaction 4.72 1.68 103 
2 Information of condition 3.94 1.8 103 
3 Infon-nation of treatment 4.2 1.72 103 
4 Taken seriously 4.59 1.78 103 
178 
Correlations 
ThyTSQ-Present no. 7: "continue with treatment" correlated negatively with 
BMI (rho = -0.23, p=0.03, N= 92), no. 3: "convenient" correlated with TSH 
levels (rho = -0.22, p=0.4, N= 88) indicating that those with high BMI were 
more dissatisfied to continue their present treatment, and those with high TSH 
levels were more dissatisfied with convenience of treatment. Variables Lpresent 
satisfaction, 2: how well working, 6: controlling symptoms and 7: continue all 
correlated positively with age (rho values range from 0.32 to 0.40, p<0.001, N 
ranging 102 to 103), and ThyTSQ-Past 1: past satisfaction, Iinformation- 
condition also correlated with age (rho = 0.23 and 0.21 respectively, p<0.05) 
indicating improved satisfaction with increasing age. There were no significant 
correlations between the Satisfaction scores and the number of co-morbid 
conditions that patients had or duration of hypothyroidism. 
Sub-group differences in ThyTSQ variables 
The only significant sub-group difference found was a sex difference: women 
had higher satisfaction with the control of their hypothyroid symptoms, median 
5, compared with men, median 4 (U = 528.5, p=0.034) There were no 
significant differences in ThyTSQ-Present or Past Satisfaction scores, between 
respondents whose TSH levels were within the reference range of 0.4 to 4.0 
mIU/L, (N = 46), and those below (N = 12), and above this range (N 29) (p 
0.092), nor between those who had autoimmune hypothyroidism (N 91) and 
those with hypothyroidism caused by treatment (N = 12). 
Reliability andfactor analyses 
The 7-item ThyTSQ-Present had very high internal consistency reliability 
[Cronbach's alpha = 0.907, standardised item alpha = 0.914, (N = 102)]. All 
corrected item-total correlations were satisfactory, the lowest being 0.504 (item 
4: understanding of condition), which was also the only item to increase overall 
scale alpha if deleted (alpha if item deleted was 0.925) and therefore detract 
slightly from the scale reliability while broadening the content. The 4-item 
ThyTSQ-Past had high internal consistency reliability [Cronbach's alpha = 
0.896, standardised item alpha = 0.896, (N = 103)]. All corrected item-total 
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correlations were satisfactory, the lowest being 0.692 (item 1: past satisfaction). 
No item detracted from the ThyTSQ-Past scale alpha. 
An unforced principal components analysis, conducted on the 11 items, 
(transformed to near normality), of the Satisfaction score (range 0 to 42) and all 
four ThyTSQ-Past items could be summed into a separate ThyTSQ-Past 
Satisfaction score (range 0 to 24). A lower score indicates greater dissatisfaction 
with treatment, and a higher score indicates greater satisfaction with treatment. 
We do not recommend summing the Present and Past Satisfaction scores into an 
overall Treatment Satisfaction score for the two sections combined. The 
correlation between the Past and Present Satisfaction scores was rho = 0.649, p< 
0.001; Cronbach's alpha = 0.8 with no more than one item of missing data. 
The ThySC 
Descriptive statistics 
The most common reported symptoms were tiredness (90% of respondents), 
feeling depressed or low, and skin problems. The mean number of symptoms 
reported per patient was 7.4 (3.2), N= 107, with six patients indicating they had 
13 or more symptoms. Almost one third reported being very much bothered by 
symptoms of tiredness, weight gain or depression when applicable. The highest 
mean bother ratings were for hair, weight gain, depressed, and cold. When data 
were examined from the 57 respondents who had either no co-morbidities (N 
42), or whose only co-morbidities were likely to be perceived by patients as 
symptomless (hypertension and hypercholesterolaernia, N= 15), the picture was 
only a little different: the most common reported symptoms were tiredness, 
depression, problems with concentration and skin, weight gain, memory and 
cold (full results not reported). 
Reliabiliýl, andfactor analyses 
Exploratory psychometric analyses were performed on the ThySC scale fon-ned 
by the symptom bother ratings although the checklist, being a number of 
disparate symptoms, was not expected to have high internal consistency 
reliability or any particular factor structure. 
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ThySC internal consistency reliability was unexpectedly high: Cronbach's alpha 
= 0.808, standardised alpha = 0.81, N= 95, with all corrected item-total 
correlations >0.2. Only two items would increase alpha if deleted from the scale 
(5: hair and 9: hearing), and by no more than 0.002 (full results not shown). 
Results of unforced and forced factor analyses were unclear, with insufficient 
evidence of satisfactory subgroups of symptoms that could produce reliable 
subscale scores. Forced one factor analyses showed 12/15 items loaded >0.44 
but constipation, hair and hearing fell short of this (0.35 to 0.28) indicating that 
a total score is not fully justified. This result was not unexpected. 
Correlations and subgroup differences 
Chi-Square tests found no significant differences in symptom frequency of 
thyroxine treated and untreated patients. The only correlations between TSH (a 
tissue marker for severity of hypothyroidism) and ThySC bother ratings to 
approach significance were for constipation [rho = -0.43, p=0.009, N= 36] and 
depression [rho = -0.35, p=0.0035, N= 68] (the required significance after a 
Bonferroni correction is 0.0033). 
Relationships between the ThySC and ThyDQoL questionnaires 
When both ThyDQoL and ThySC questionnaires are administered to patients it 
would be prudent, if analysing relationships between ThyDQoL AWI and 
ThySC symptom bother ratings, to exclude patients' responses to the four 
ThyDQoL symptom domains (energy, weight, bodily discomfort and 
depression) from the calculation of the AWI score, i. e. a maximum of 14 items 
should be included in the AWI-14 score. Analyses showed a very high internal 
consistency reliability of the 14-item ThyDQoL (Cronbach's alpha = 0.944, N 
99), with lowest corrected item-total correlation of 0.57. All loadings on a 
forced I -factor analysis were >0.6. This provided evidence for the reliability and 
validity of calculating overall AWI-14. Mean ThyDQoL AWI-14 for the sample 
was -2.86 (2.22), slightly less negative than -3.11 (2.2) for the full 18-item 
AWI- 18, as expected. When correlating AWI- 14 with ThySC bother ratings, the 
strongest significant negative correlations were found (in decreasing order) with 
tiredness, concentration, depressed, weight gain, cold, speech and skin, 
indicating that increased symptom bother was associated with greater negative 
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impact of hypothyroidism on QoL. The correlations with AWI-14 were very 
similar to those with the full 18-item ThyDQoL AWI- 18, indicating that 
concerns about spuriously high correlations between ThySC and AWI- 18 were 
not supported. Correlations between symptoms and AWI scores were low to 
moderate (range -0.1 to -0.6), an indication that symptoms and QoL are distinct 
and separate patient-reported outcomes. A stepwise multiple regression analysis 
was conducted to evaluate how well the bother ratings for the five symptoms 
with the highest correlations with QI: Present QoL i. e. tiredness, depressed, cold, 
concentration and giddy, predicted Present QoL. Only tiredness was a 
significant predictor of Present QoL: [F(1,98) =31.1, p <0.00 I ]. The sample 
multiple correlation coefficient was 0.49, indicating that 24% of variance in Ql 
could be accounted for by tiredness: the greater the bother rating for tiredness, 
the worse the present QoL. Moderate significant negative correlations were 
found between the number of applicable symptoms and ThyDQoL overview 
items QI: Present QoL (r = -0.42), and Qll: Thyroid dependent QoL (r = -0.43) 
(p <0.001, N= 105) indicating decreased Present QoL, and greater negative 
impact of hypothyroidism on QoL with increasing numbers of symptoms. 
Discussion 
The ThyDQoL is a individualised measure of the perceived impact of 
hypothyroidism on QoL, with high completion rates indicating good 
acceptability to respondents. Internal consistency reliability was excellent and 
factor analyses highly supportive of the combination of all 18 weighted domains 
into a single average score, the ThyDQoL AWI- 18 score, which indicated 
moderately severe perceived negative impact of hypothyroidism on QoL in this 
sample. Useful information can be elicited from the single overview items. On 
average, respondents' Present QoL (QI) was perceived to be between good and 
neither good nor bad and Q11, concerning impact of hypothyroidism on QoL, 
could provide an approximate substitute for the full ThyDQoL for some 
purposes, (e. g. when respondent burden is of particular concern), as the 
correlation between Q11 and overall ThyDQoL AWI- 18 was high (r = 0.69). 
Analysing individual domains can obtain rich information separately. For 
example, it was found that, despite most patients receiving L-thyroxine 
replacement to non-nalise TSH levels, hypothyroidism still had a marked 
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negative impact, particularly on motivation, weight, feelings of depression, 
bodily discomfort and energy, which may well impact on several other domains, 
such as spare time activities or work. 
Over 70% of respondents reported feeling depressed or having bodily 
discomfort in recent weeks. Content validity was supported, as no new 
ThyDQoL domains emerged when analysing the free comments section, and all 
existing domains detected negative impact of hypothyroidism with mean 
weighted domain impact scores of -2 or less. 
The ThyTSQ-Present measures satisfaction with present treatment, and the 
ThyTSQ-Past measures satisfaction with treatment around the time of diagnosis, 
but treatment in the broader sense of the term, to include medical care and 
interactions with healthcare professionals. Use of the ThyTSQ-Past is 
recommended to avoid any negative experiences of past treatment interfering 
with completion of questions about current treatment, though if it were used in a 
clinical trial it might only be completed once, at baseline, (in the present study 
they were used together). Use of the ThyTSQ-Present alone without the 
ThyTSQ-Past would need further psychometric evaluation. The measure is short 
and quick to complete, with minimal respondent burden, and the very high 
completion rates indicating good acceptability to respondents. The factor 
structure was clear. When the 11 items of both sections were combined in one 
unforced factor analysis, two clean factors emerged, with Past and Present items 
loading on separate factors. Unforced analyses perfon-ned on each separate 
section produced one factor each, with very high factor loadings, which lent 
support for summing the individual item scores into Present and Past 
Satisfaction scores. The internal consistency reliability of each section was also 
excellent. The moderate correlation between the total scores of the two parts is 
an indication that they are measuring different but related constructs. 
When the free comments were analysed, they showed that the areas of 
dissatisfaction mentioned were, for the most part, already covered by the items 
of the questionnaire, suggesting that respondents were emphasising or 
explaining dissatisfaction already reflected in existing items. Insufficient 
numbers of patients specified particular issues to justify the addition of new 
items, hence the measure would appear to have good content validity, however, 
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the measure is still at a relatively early stage of development, and new items 
may be added in the future when more data become available. Construct validjt%, 
was not assessed in this exploratory study as no prior hypotheses were 
formulated. The only significant sub-group difference found was that women 
had higher satisfaction than men with the control of their hypothyroid 
symptoms. Satisfaction improved with increasing age for both Past and Present 
scores, perhaps because people expect to have more health problems, as they 
grow older and, with lower expectations of treatment, are more likely to be 
satisfied with treatment. 
Generally high satisfaction rates were found, but a small proportion of patients 
were dissatisfied, giving support to anecdotal reports from clinicians. More 
patients expressed dissatisfaction with their present understanding of the 
condition and with information provided about the condition in the past than any 
other item on the ThyTSQ-Present and Past respectively. Although 
dissatisfaction with L-thyroxine therapy has been defined in relation to 
persistence of symptoms (Walsh 2002), it is clear, not only from interviews 
conducted when developing this questionnaire but also from the analyses 
presented here, that symptoms are not the only aspect causing dissatisfaction. 
This study has found support for having the section on satisfaction with past 
treatment, as scores on Past Satisfaction tended to be lower than those for 
Present Satisfaction with treatment, and some patients clearly welcomed the 
opportunity to report their dissatisfaction as evidenced by the larger number of 
patients using the free comments section of the ThyTSQ-Past. 
This study has shown that more consideration needs to be given to the 
interaction between patient and doctor at the time of diagnosis. More 
consultation time may be required at the point when a patient is first told that 
they have a condition that requires life-long treatment. Patients may be too 
distressed at the time they are first told they have hypothyroidism, to absorb 
much of the inforination they are given, especially as cognitive functioning of 
people with untreated hypothyroidism is reduced in some cases (del Ser 
Quijano, et al 2000). They may welcome information leaflets that they can take 
home and study in their own time. Whilst the daily tablet regimen in itself is not 
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complicated, some patients may not understand why their dosage must be 
increased slowly until equilibrium is reached between hypo and 
hyperthyroidism. Others may be despondent if treatment does not return them 
to their previous state before onset, and not fully adhere to the tablet treatment 
regimen. Thus it is possible that increased adherence to treatment would result 
if patients understood their treatment better. Use of the ThyTSQ questionnaire 
will pinpoint lack of understanding in individual patients, who can then receive 
more help from healthcare professionals. 
Although further studies will be needed in the future to assess test-retest 
reliability, sensitivity to change (ThyTSQ-Present only), and construct validity, 
the questionnaire is ready to be used in clinical trials of treatments for 
hypothyroidism. It can be used also with individual patients, completed 
questionnaires forming the basis for discussion between patients and health care 
professionals. 
The Underactive Thyroid Symptom Checklist measures both symptom 
frequency and the degree to which patients are bothered by symptoms associated 
with hypothyroidism. All 15 symptoms were experienced recently by at least 
some patients and there was a wide spread of frequencies of responses from not 
at all bothered to very much bothered. Internal consistency reliability was 
unexpectedly high, but factor analysis did not support the calculation of a total 
symptom bother score. Analysis of the most frequently reported symptoms 
(tiredness, depression, weight gain, and problems with skin, concentration and 
memory) and bother ratings, confirmed the typical picture of hypothyroidism: 
physiological symptoms connected with slowing of the metabolism and also 
reduced psychological well-being and impaired cognitive functioning. Although 
measures of health status are often and erroneously described as QoL measures, 
in this study symptoms (an aspect of health status) and QoL were distinct and 
separate patient-reported outcomes, as indicated by low to moderate correlations 
between symptom bother ratings and ThyDQoL AWL 
The ThyDQoL includes four symptom items that are also covered on the TbySC 
symptom measure, namely energy, weight, bodily discomfort and depression. It 
is recommend that these four items be excluded from the calculation of 
ThyDQoL AWI when the questionnaire is administered with the ThySC, to 
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avoid duplication and spurious correlations between the two questionnaires. The 
equivalent symptoms on the ThySC (tiredness, depressed, weight gain and cold) 
still had some of the strongest correlations with AWI- 14, suggesting that the 
impact of those symptoms on QoL is reflected in ratings of many domains, and 
symptom- spec i fic domains are not required in the ThyDQoL, although they are 
likely to increase face and content validity where no symptom measure is used. 
If troublesome symptoms can be reduced, QoL of patients may be improved. 
The data suggested that patients were most bothered by hair problems, weight 
gain, depression, feeling cold, and tiredness and that healthcare professionals 
could direct their efforts to alleviating these symptoms if they wish to improve 
the QoL of their patients. Symptoms can be selected for the ThySC to suit the 
purposes of a particular clinical trial. Further symptoms may need to be added if 
required (e. g. side effects of a new drug under evaluation), although the 
rationale of any deletions or additions would need to be justified. 
In conclusion, the ThyDQoL, ThyTSQ and ThySC are new condition-specific 
questionnaires measuring the perceived impact of hypothyroidism on QoL, 
satisfaction with treatment and bother ratings for 15 symptoms respectively, and 
allowing multidimensional assessments of the effects of treatment in 
hypothyroidism. All questionnaires perform well with good acceptability to the 
great majority of respondents, and have excellent internal consistency reliability. 
Domains can be analysed separately if required and an overall score calculated 
for ThyDQoL and ThyTSQ. Additional symptoms may be added to the ThySC 
to suit the requirements of different studies. Sensitivity to change of all 
measures now needs to be evaluated in clinical trials. 
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RESULTS (B) 
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Baseline characteristics of patient-reported outcomes. 
Baseline parameters of patient reported outcomes are outlined in tables 42 - 44. 
Table 42. 
Baseline scores of perceived health status as measured by SF-36v2 (n=100). 
Domains Mean score 
(SD) 
Physic al-Functioning 71.4(26.4) 
Role-Physical 64.6(28.7) 
Bodily Pain 64.6(27.4) 
General Health 59.3(22.2) 
Vitality 39.1 (22.6) 
Social Functioning 69.6(28.0) 
Role-Emotional 70.5(27.7) 
Mental Health 63.8(19.4) 
Physical Component Summary Score 45.9(10.6) 
Mental Component Summary Score 41.9(12.2) 
As can be seen above, the most impacted perceived health status domain 
was vitality. The SF-36 Q scores were then compared with normative 
population scores to assess the degree of impainnent in health status, as seen 
in next chapter. 
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Table 43. 
Baseline QoL scores as measured by ThyDQoL (n=100). 
Domains Mean scores (SD) 
General QoL 0.89(l. 0) 
Thyroid-dependent QoL -1.24(l. 0) 
Spare time -3.0(2.4) 
Work life -3.1(2.7) 
Holidays -2.6(2.6) 
Family life -3.2(3.0) 
Social life -2.4(2.4) 
Close relationship -2.9(2.9) 
Sex life -2.6(2.5) 
Physical capabilities -3.4(2.9) 
Energy levels -4.3(3.1) 
Speed of doing things -2.7(2.4) 
Getting out and about -2.7(2.9) 
Household tasks -3.0(2.9) 
Physical appearance -2.5(2.6) 
Weight -3.5(2.7) 
Bodily discomfort -3.6(2.9) 
Depressed -3.7(2.8) 
Motivation -4.4(2.8) 
Worries about future -3.1 (3.2) 
Average Weighted Impact- 18 -3.0(2.9) 
Overall QoL was perceived to be good by the SCH patients but 
hypothyroidism was thought to have a negative impact on QoL. The two 
domains of motivation and energy were perceived to have been most 
negatively influenced by SCH. The rest of the domains showed varying 
degrees of negative impact of SCH. 
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Table 44. 
Baseline frequency and bother scores of symptoms of hypothyroidism 
(n=100). 
Symptoms Frequency Bother scores (SD) 
Tiredness 93 2.0(0.9) 
Depression 71 1.7(0.9) 
Weight gain 53 2.0(0.8) 
Feeling cold 52 1.8(0.8) 
Hair problems 36 1.9(0.9) 
Skin problems 52 1.8(0.8) 
Nail problems 42 1.4(0.8) 
Constipation 31 1.5 (0.9) 
Voice change 23 1.6(0.8) 
Speech change 24 2.1 (0.8) 
Suppressed Appetite 17 1.0(0.6) 
Hearing problems 29 1.8(0.8) 
Memory impairment 49 2.0(0.8) 
Concentration impairment 54 1.7(0.9) 
Dizziness 47 1.8(0.9) 
Tiredness was reported by a large number of patients and depression by 
many. Bother-scores were similar for tiredness, weight gain, speech and 
memory impairment. 
Amongst these questionnaires, only the SF 36 Q is a generic instrument 
whereas all the others are disease-specific ones. Therefore, only the SF 36 
Q scores can be compared with other populations to gauge the impact of 
SCH on perceived health status. This was therefore done by comparing 
scores of patients aged 18-65 years (n=71) with those of the UK normative 
working age population. 
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Perceived health status in patients with subclinical 
hypothyroidism compared to normative UK 
population. 
The presence of symptoms of hypothyroidism in patients with SCH \vhen 
compared with the general population is controversial due to the non-specific 
nature of many hypothyroid symptoms, which are also common to many other 
conditions, and due to the different types of patient samples studied (Canaris, et 
al 1997) (Canaris, et al 2000) (Nystrom, et al 1988) (Eden, et al 1988) 
(Zulewski, et al 1997) (Cooper, et al 1984). 
The lifetime prevalence of depression in patients with SCH is double that of the 
general population and has been reported to reduce the efficacy of antidepressant 
treatment (Saddock and Saddock 2000); it is associated with anxiety (Sait 
Gonen, et al 2004) and changes in mood and cognitive functioning (Hendrick, et 
al 1998). There is also evidence that exercise capacity may be impaired due to 
significant reduction of exercise-related stroke volume, cardiac index, vital 
capacity and reduced anaerobic thresholds (Kahaly 2000). All these factors may 
affect subjective perception of health status. 
Subjective health status is a key component in the evaluation of any medical 
condition and therapeutic intervention. In patients with SCH, symptoms may 
contribute to perceived impairment of health-related quality of life (Jaeschke, et 
al 1994). Health status can be measured by the widely used generic Short Form- 
36 (SF-36) questionnaire. As there have been some concerns about the wording 
and layout of the original SF-36, the developers have designed a second version 
- the SF-36v2. The normative data for the SF-36v2 in the UK was obtained from 
a postal survey of patients randomly selected from general practitioner records, 
which achieved a response rate of 64.4% (n = 8889). The SF-36v2 was shown to 
have improved reliability and reduced floor and ceiling effects compared with 
the previous version of the SF-36 (Jenkinson, et al 1999). Respondents were also 
asked to report demographic details and any long-term illnesses, and 36.6% 
reported a chronic long-standing illness. Therefore the health status of people 
with SCH using the SF-36v2 was compared to UK non-native population scores. 
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Patients 
Only 71 patients, mean age (SID) 48.7 years (9.67), range 23-64; 15 males, in 
the 18 to 64 year age group were considered for comparison with the UK SF- 
3 6v2 normative data, as normative data are not available for older adults. The 
mean (SID) TSH concentration was 6.6 (2.5) mIU/L, range 4.1-16 and the FT4 
concentration was 13.9 (1-9) pmol/L, range 10.3-19. The frequency of other 
chronic diseases was: hypertension 9.5%, hypercholesterolaernia 1.3% and 
arthritis (osteoarthritis, gout or rheumatoid arthritis) 21.9%. Results of two 
participants found to be on treatment for asthma were not included in the 
analyses. The results of 27 participants aged 65 to 80 years were used for within- 
SCH group comparisons. 
SF-36v2 
Perceived health status was evaluated by the SF-36v2 questionnaire. The 
questionnaire is composed of 36 items, 35 of which are classed into eight scales 
of varying length. For each SF-36v2 dimension, raw item scores are coded, 
summed and transformed on to a scale ranging from 0 (worst possible perceived 
health status) to 100 (best possible health status). The single item on perceived 
changes in health status over the previous 12 months was not considered. The 
degree of divergence from the scores for the normative population of an 
individual patient or specific patient population can be measured using az 
transformation, taking into account the effects of age and gender. For each SF- 
36v2 scale, a z-score was calculated by subtracting the mean scale score of the 
normative population sample (matched forage and sex) from the scale score of 
the study group and dividing this difference by the standard deviation of the 
non-native population sample. This was carried out individually for each 
participant for each scale and the overall group mean was calculated. A z-score 
value of 0 corresponds to the mean value of the non-nal population, a z-score 
value of -1 or -2 corresponds to one or two standard deviations below the 
non-nal population respectively. Z-scoring was preferred to the 0- 100 based 
scoring algorithm to compare with the UK non-native scores because it provides 
a basis for meaningful comparison across scales and for easier interpretation 
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(Ware, et al 2000b) (Garratt et al 1993). Control values were obtained in 
relatively large numbers from random samples of the UK population aged 
between 18 and 64 years (n = 8889), as described above. This procedure has 
previously been used in the UK in the study of health status in patients with 
different diseases such as Parkinson's disease and multiple sclerosis (Riazi, et al 
2003); heart failure and left ventricular systolic dysfunction (Hobbs, et al 2002) 
and low back pain, menorrhagia, suspected peptic ulcer and varicose veins 
(Garratt, et al 1993), and elsewhere in thyroid disease (Bianchi, et al 2004). 
Statistical analyses 
Means (SD) were used to report descriptive data and 95% confidence intervals 
(95% CI) were used to report the difference in the means between the study 
participants and the non-native population. Student's unpaired t-test was used to 
compare the subgroup means. Z-scores were also used to report transformed 
scores as discussed previously. A mean z-score <0.2 was considered clinically 
non-significant, between 0.2 and 0.5 as a small difference, between 0.5 and 0.8 
as a moderate difference and >0.8 as a large difference (Kazis, et al 1989). 
Correlation analysis (Spearman's rho for non-parametric data or Pearson's r for 
parametric data) was used to assess the relationship between each SF-3 6 scale 
measured and biochemical and demographic parameters. Internal consistency 
reliability - that is, the extent to which there is a correlation between items on a 
scale - was assessed by Cronbach's alpha, an inter-item correlation statistic, 
with a value range of 0-1 (Cronbach LJ 195 1). Levels of >0.9 are usually agreed 
to signify excellent internal consistency reliability. AP value of <0.05 was taken 
as statistically significant. SPSS version 11.0 was utilised for computing the 
statistics (SPSS Inc., Chicago, IL, USA). 
Results 
In comparison with a large UK population reference group, scores on all eight 
scales of the SF3 6v2 were significantly reduced (Table 45). The difference was 
attenuated but still significant when people with SCH and other chronic diseases 
(e. g. arthritis, hypertension and hyperchole sterol aem i a) were excluded from the 
analyses (n = 24). Z-scores for all 71 participants studied were significantly 
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lower than the non-native data for all scales of the SF-36 but only the vitality 
(VT) scale showed a large difference, that Is >0.8 (Fig. 17) 
Table 45. 
Differences in absolute SF-36 scores in patients with SCH compared with 
age- and sex-matched normative data. 
SCH patients UK normative Difference in means 
Mean score Mean score (SD); (95% CI) 
(SD); n=71 n=8660 
Physical 76.0(25.0) 88.0(19.7) 11.9 (7.4 - 16.5) 
functioning 
Role physical 68.3 (29.7) 87.2(22.0) 18.9 (13.8 - 23.9) 
Bodily pain 68.6(27.0) 78.8 (23.0) 10.2 (4.9 - 15.5) 
General 60.1 (22.3) 71.1 (20.4) 11.0 (6.3 - 15.7) 
health 
Vitality 37.2 (23.8) 58.0(19.6) 20.9 (16.4 - 25.4) 
Social- 69.5 (27.5) 82.8(23.2) 13.3 (7.9 - 18.6) 
functioning 
Role 72.5 (26.8) 85.8(21.2) 13.3 (8.4 - 18.2) 
emotional 
Mental health 63.4(18.9) 71.9(18.1) 8.6 (4.4 - 12.8) 
SF-36 score range: 0 to 100 (poor to excellent health status). 
Figure 17. SF-36v2 scale scores of patients with SCH (mean with 95% 
confidence interval) compared with age- and sex-matched controls in a UK 
cohort (zero line). Note: a negative z-score indicates lower health status in the 
SCH group compared with normative data. PF, physical functioning; RP, role 
physical; BP, bodily pain; GH, general health; VT, vitality; SF, social 
functioning; RE, role emotional; MH, mental health. 
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The rest of the z-scores showed either moderate (role physical (RP), general 
health (GH), social functioning (SF) and role emotional (RE)) or small (physical 
functioning (PF), bodily pain (BP) and mental health (MH)) differences. When 
analysed separately for men (n = 15) and women (n = 56), the results of the z- 
score analysis showed that women tended to have lower scores for all scales 
compared with men, although not significantly so (figure 18). Men had 
significantly lower z-scores in all scales except PF when compared with men 
from the UK norms whereas women had significantly lower scores on all scales. 
Figure 18. 
Sex differences in z-scores for each SF-36 scale for patients Nvith SCH (it 
71). Solid bars, males; shaded bars, females. PF, physical functioning; RP, role 
physical; BP, bodily pain; GH, general health; VT, vitality; SF, social 
functioning; RE, role emotional; MH, mental health. 
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Health status scores did not differ in people with thyroid autoimmunity, as 
determined by the presence of anti-TPO antibodies (n = 39), although the two 
groups were well matched for age, sex and biochemical thyroid function tests. 
None of the scales of the SF-36v2 correlated with either TSH or FT4 levels. As 
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expected, TSH values correlated significantly with FT4 (r = -0.238, P=0.04). 
The z-scores for the VT scale correlated significantly with age (r = 0.3 5, P= 
0.002). This was statistically significant even if Bonferrom correction requiring 
ap value of 0.006 (0.05/8) was applied. Comparison of absolute scores of older 
people with SCH (aged 65-80 years) (n = 27) with the younger group studied (n 
=7 1) showed that the older group had significantly impaired health status only 
for the PF, RP and BP scales (difference in means (95% Cl): 17.72 (6.4 - 29.04), 
13.93 (1.32 - 26.54) and 14.93 (2.97 - 26.89) respectively). 
Cronbach's alpha coefficient ranged from 0.91 to 0.93 signifying excellent 
internal consistency reliability for all eight SF-36 scales in this sample of 
patients with SCH. 
Discussion 
Perceived health status is more than just the presence or absence of disease or 
symptoms and encompasses social, physical and emotional dimensions. 
Clinicians do not routinely assess patients' perceptions of their health status, but 
it is increasingly being argued that the patient's perspective is as valid as that of 
the clinician in evaluation of a medical condition and its outcomes (Leplege and 
Hunt 1997). The normative data in this study for comparison of scores for all 
scales comprised a random sample from the general population and not a 
disease-free population. Hence it is probable that some of these individuals had 
thyroid disease and therefore the results obtained here may well be an 
underestimation of the true value. This is all the more likely since 36.6% of the 
normative population reported chronic long-standing illness (patients with 
chronic diseases are more likely to respond to a postal health survey than 
disease-free individuals), whereas patients with such conditions, apart from 
hypertension, arthritis and hypercholesterolaernia, were excluded in the present 
study. 
Bianchi and colleagues recently reported that there were no differences in 
perceived health status (as measured by the SF-36 and the Nottingham Health 
Profile instruments) between their Italian patients Nvitb SCH, and age- and sex- 
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matched Italian population norins (Bianchi, et al 2004). The results reported 
here are different from their observations. This may be due to the different 
population and normative data used in the analysis as well as the fact that the 
comparison sample in the present study was younger owing to the lack of 
normative data for people older than 64 years in the UK. 
Limitations of this study are that patients were not identified from a screening 
programme and were recruited from primary care practices. Thus patients with 
presence of symptoms at the higher end of the scale and/or with other co- 
morbidities were more likely to have been studied. However, the results 
obtained still remain significantly different from the normative scores even when 
data were analysed after excluding people with other chronic conditions. It is 
quite possible that some conditions such as hypertension and 
hypercho Ie sterol aemi a are 'silent' and hence affect health status the least 
(Stewart, et al 1989). Also, it would seem that men with SCH tend not to have 
any impain-nent of physical functioning as compared with normative scores for 
men of the same age. There is no direct explanation for this and further research 
is required. Also, older people (>64 years) with SCH have significantly lower 
scores on the physical scales (PF, RP and BP) when compared with younger 
people. This was not an unexpected finding as others have obtained significant 
age gradients in some SF-36 subscales (Brazier, et al 1992), but the lack of 
normative data for comparison with this older group is disappointing, especially 
since SCH is more prevalent in older people. Although it is clear from this study 
that people with SCH have impaired perceived health status, it is yet to be 
clarified whether normalizing serum TSH level would improve it. 
In conclusion, this comparison has shown that perceived health status is 
significantly impaired in people presenting with SCH and this should be 
considered when managing this condition. 
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Effect of L-thyroxine on QoL, symptoms of 
hypothyroidism, perceived health status and satisfaction 
with treatment. 
The baseline data suggested that patients with SCH have an impaired QoL, 
perceived health status as well as a considerable number of symptoms. The 
following tables 46 - 53 document the response to intervention with L-thyroxine 
and compare it to placebo. Satisfaction with treatment was also assessed in all 
patients. 
Perceived health status: 
Table 46. 
Effect of L-thyroxine on perceived health status, as measured by the SF 
36v2 in patients with SCH compared to placebo (n=100). 
L-thyroxine 
Mean (SD) 
Placebo 
Mean (SD) 
Adjusted difference 
(95% CI) t 
p value 
Physical- 
Functioning 
72.9(25.2) 71.3(26.9) 1.9 (-1.7 to 5.5) 0.15 
Role-Physical 69.3 (29.3) 68.6(31.3) 0.6 (-5.8 to 7.0) 0.78 
Bodily Pain 66.4(27.1) 64.8(28.1) 1.7 (-3.2 to 6.6) 0.34 
General Health 61.3 (19.5) 59.7(19.8) 1.5 (-2.5 to 5.4) 0.32 
Vitality 47.1 (22) 43.7(22.7) 3.4 (-2.5 to 9.3) 0.11 
Social Functioning 75.1 (27.4) 74.9(25.3) 0.2 (-6.4 to 6.9) 0.92 
Role-Emotional 74.1 (28) 75.5(25.1) -1.7 (-8.9 to 5.4) 0.50 
Mental Health 67.3(20) 66.2(17.8) 1.0 (-3.9 to 6.0) 0.56 
Physical 
Component 
Summary Score 
46.7(9.9) 45.7(11.2) 0.83 (0 to 1.66) 0.15 
Mental Component 
Summary Score 
44.8(12.1) 44.7(10.4) 0.04 (-1.4 to 1.5) 0.97 
TA QI US ICG ior sup. 1 cc t zijlu pctiou ciickx, ý 
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Table 47. 
Effect of L-thyroxine on perceived health status, as measured by the SF 
36v2 in patients with SCH with discordant TFTs excluded (n=71). 
L-thyroxine 
Mean (SD) 
Placebo 
Mean (SD) 
Adjusted 
difference (95% 
CI) I 
P 
value 
Physical- 
Functioning 
74.6(25.4) 73.1 (25.8) 1.9 (-2.3 to 6.1) 0.23 
Role-Physical 70.4(30.1) 70.5(31.1) -0.3 (-7.6 to 7.0) 0.90 
Bodily Pain 67.6(26.9) 65.5(27.9) 2.1 (-3.6 to 7.8) 0.31 
General Health 61.1 (19.7) 60.5(21) 0.6 (47 to 5.9) 0.75 
Vitality 47.4(23.2) 44(23.1) 3.5 (-3.4 to 10.4) 0.17 
Social Functioning 78(26.5) 77.6(24.6) 0.64 (-6.4 to 7.6) 0.80 
Role-Emotional 75 (28.8) 78.5(23.8) -3.1(-11.8 to 5.6) 0.33 
Mental Health 68.9(19.8) 67.2(18.3) 1.8 (40 to 7.5) 0.39 
Physical 
Component 
Summary Score 
46.2(10.1) 45.5(10.9) 0.8 (-1.0 to 2.5) 0.27 
Mental Component 
Summary Score 
43.9(11.8) 43.8(12.2) 0.2 (-3.4 to 3.9) 0.86 
I AUJUSLCU im SUL)JUCL allu PC[ lou 
SF-36v2 subscales: 0 to 100 (poor to good health status). 
There was no significant difference in either the individual domains of the SF 
36v2 or the summary scores on L-thyroxine as compared to placebo. There was 
a trend towards improvement, but the sign test statistic failed to reach 
significance (p=0.07) in favour of L-thyroxine. One of the explanations could 
be that the study was not powered to detect a significant change in this 
instrument. It is calculated that to reach statistical significance, the number of 
patients randomised would have needed to be much higher. For example, to 
detect a significant improvement in Vitality (the subscale that showed the most 
improvement in the SF-36 v2), we calculate that a much larger sample would 
have been needed (n=3 10). 
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Hypothyroid specific Quality of life: 
Table 48. 
Effect of L-thyroxine on QoL, as measured by the ThyDQoL in all patients 
with SCH compared to placebo (n=100). 
L-thyroxine 
Mean (SD) 
Placebo 
Mean (SD) 
Adjusted difference 
(95% CI) ' 
P 
value 
General QoL 0.95(0.91) 0.88(0.94) 0.1 (-0.3 to 0.5) 0.43 
T-QoL -1.1 (1) -1.2(0.9) 0.2 (0.02 to 0.36) 0.04 
Spare-time -2.6(2.5) -2.9(2.7) 0.3 (-0.1 to 0.7) 0.21 
Work-life -2.7(3) -2.8(2.7) 0.1 (-0.5 to 0.6) 0.82 
Holidays -2.8(2.9) -2.7(2.9) 0 (-0.4 to 0.5) 0.87 
Family-life -3.1 (3.1) -3.1 (2.9) 0 (-0.4 to 0.4) 0.95 
Social-life -2.5(2.7) -2.5(2.6) 0 (-0.4 to 0.4) 0.96 
Close relationship -2.7(2.9) -2.9(3) 0.1 (-0.3 to 0.5) 0.67 
Sex-life -2.3(2.7) -2.7(2.8) 0.3 (0.02 to 0.7) 0.03 
Physical 
capabilities 
-3.1 (2.9) -3.1 (2.8) 0 (44 to 0.4) 0.87 
Energy levels -3.5 (2.8) -3.6(2.8) 0.1 (-0.3 to 0.6) 0.56 
Speed of doing 
things 
-2.4(2.5) -2.3(2.4) -0.1 (-0.5 to 0.3) 0.63 
Getting out and 
about 
-2.2(2.7) -2(2.5) -0.1 (-0.5 to 0.2) 0.44 
Household tasks -2.6(2.8) -2.8(2.7) 0.1 (-0.2 to 0.5) 0.50 
Physical 
appearance 
-2.3(2.9) -2.5(2.8) 0.2 (42 to 0.6) 0.29 
Weight -3.1 (2.8) -3.2(2.6) 0 (-0.5 to 0.5) 0.86 
Bodily discomforl -3.2(2.8) -3.6(2.6) 0.2 (45 to 1) 0.50 
Depressed -4.3(2.8) -4.5(2.7) 0.5 (-0.4 to 1.5) 0.25 
Motivation -3.6(2.7) -3.7(2.7) 0.4 (44 to 0.9) 0.16 
Worries about 
future 
-2.5 (3) -2.8(2.9) 0.2 (42 to 0.7) 0.23 
AWI- 18 -2.7(2.4) -2.8(2.3) 0.1 (-0.3 to 0.5) 0.45 
t-Aqlusted for sub-lect and perioa ellecLs 
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Table 49. 
Effect of L-thyroxine on QoLq as measured by the ThyDQoL in patients 
with SCH with discordant TFTs excluded (n=71). 
L- 
thyroxine 
Mean (SD) 
Placebo 
Mean (SD) 
Adjusted difference 
(95% CI) 
P 
value 
General QoL 1.0(0.9) 1.0(l) 0.1 (-0.0 to 0.2) 0.51 
T-QoL -1 (0.9) -1.2(l) 0.3 (0.08 to 0.52) 0.01 
Spare-time -2.3(2.4) -2.7(2.6) 0.4 (43 to 1.1) 0.12 
Work-life -2(2.5) -2.5 (2.5) 0.5 (43 to 1.3) 0.15 
Holidays -2.1 (2.7) -2.5 (2.8) 0.3 (44 to 1.0) 0.23 
Family-life -2.5(2.8) -2.9(2.8) 0.2 (-0.4 to 0.8) 0.38 
Social-life -2(2.5) -2.4(2.7) 0.4 (-0.3 to 1.1) 0.73 
Close relationship -2.1 (2.8) -2.4(2.8) 0.1 (-0.5 to 0.7) 0.25 
Sex-life -1.9(2.6) -2.4(2.9) 0.3 (0.05 to 0.7) 0.01 
Physical 
capabilities 
-2.8(2.9) -3 (2.8) 0.1 (-0.5 to 0.7) 0.68 
Energy levels -3.1 (2.8) -3.5(2.9) 0.4 (43 to 1.1) 0.21 
Speed of doing 
things 
-2(2.3) -2.1 (2.2) 0.1 (-0.5 to 0.7) 0.66 
Getting out and 
about 
-1.7(2.5) -1.8(2.4) 0 (46 to 0.6) 0.91 
Household tasks -2.1 (2.6) -2.5(2.6) 0.4 (42 to 1.0) 0.11 
Physical 
appearance 
-2.1 (2.9) -2.5 (2.9) 0.4 (42 to 1.0) 0.13 
Weight -2.8(2.7) -3.2(2.8) 0.3 (42 to 0.8) 0.22 
Bodily discomfort -2.6(2.7) -3.4(2.5) 0.4 (44 to 1.2) 0.38 
Depressed -4.2(2.9) -4.7(2.7) 0.9 (43 to 2.1) 0.11 
Motivation -3.1 (2.8) -3.8(2.8) 0.9 (0.1 to 1.7) 0.009 
Worries about 
future 
-2(2.9) -2.6(3) 0.4 (-0.2 to 1.1) 0.07 
AWI- 18 -2.3 (2.3) -2.7(2.3) 0.3 (0.01 to 0.6) 0.01 
f AdJUSted tor subject and periocl etlects. 
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Maximum score range: ThyDQoL individual QoL domains: -9 to +3, TQoL 
(Hypothyroid-dependent QoL) score range: -3 to +1 (maximum negative to 
maximum positive perceived weighted impact of hypothyroidism on QoL). 
AWI- 18 (Average weighted impact of all 18 domains) score range -9 to +3, 
provides a total summative score, the more negative the score, the greater the 
perceived negative impact of hypothyroidism on QoL. 
Hypothyroid-dependent quality of life (QoL), therefore showed a significant 
improvement overall as shown by TQoL. The domain on sex-life also showed a 
significant improvement on L-thyroxine. When individuals with discordant 
TFTs were excluded from analyses, then additionally motivation and AWI- 18 
became significantly improved. 
Symptoms of hypothyroidism: 
The symptoms associated with hypothyroidism as assessed by the ThySC were 
investigated to observe if L-thyroxine improved them. The frequencies of the 
different symptoms are reported in table 50 for all one hundred patients. Table 
51 reports the frequencies of hypothyroid symptoms in patients with discordant 
results excluded. 
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Table 50. 
Effect of L-thyroxine on reported frequency of hypothyroid symptoms 
(n=100). 
Symptoms (%) L-thyroxine Placebo Adjusted difference' P value 
Tiredness 78 89 11 0.005 
Depression 52 62 11 0.08 
Weight gain 37 44 6 0.32 
Feeling cold 29 36 6 0.16 
Hair problems 38 36 -7 0.11 
Skin problems 38 45 7 0.18 
Nail problems 37 36 -1 0.82 
Constipation 25 27 2 0.69 
Voice change 24 21 -3 0.47 
Speech change 23 21 -2 0.56 
Suppressed 
Appetite 
12 16 3 0.32 
Hearing 
problems 
27 24 -4 0.47 
Memory 
impairment 
45 45 0 0.99 
Concentration 
impain-nent 
49 46 -3 0.56 
Dizziness 39 38 -1 0.83 
T Aujusteci ior suDjecL anu pci iou ci icL; Lb. 
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Table 51. 
Effect of L-thyroxine on hypothyroid symptoms in patients with SCH after 
excluding discordant TFTs (n=71). 
Symptoms L- 
thyroxine 
Placebo Adjusted 
differencet 
P value 
Tiredness 75 87 15 0.007 
Depression 48 58 10 0.11 
Weight gain 37 41 3 0.68 
Feeling cold 27 34 6 0.25 
Hair problems 35 32 -5 0.56 
Skin problems 34 45 12 0.04 
Nail problems 37 39 3 0.59 
Constipation 27 27 0 0.99 
Voice change 23 21 -3 0.78 
Speech change 23 23 0 0.99 
Suppressed 
Appetite 
13 14 1 0.76 
Hearing 
problems 
27 23 -4 0.36 
Memory 
impainnent 
41 44 2 0.48 
Concentration 
impairment 
46 45 -1 0.81 
Dizziness 30 31 2 0.79 
I IAUJUSLCU 101 SUUJC(.; L UHU PIZIIUU VIIULAý-. 
This showed that L-thyroxine reduced significantly the number of people 
complaining of tiredness. In addition, when people with discordant results were 
excluded, then the symptom of skin problems also reduced significantly. It is 
estimated that the NNT (number needed to treat for one person to benefit) is 9.1 
for tiredness. 
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For all other symptoms, the sign test did not show any significant improvement 
(p=0.6). The symptoms bother score did not show any significant difference for 
any symptom. 
Treatment satisfaction: 
Satisfaction with treatment with L-thyroxine was assessed by the ThyTSQ and 
compared to placebo. The ThyTSQ-Past was used but not reported since it 
would not be expected to be influenced by current treatment. It did not show 
any change. 
Table 52. 
Effect of L-thyroxine on satisfaction with treatment for SCH (n=100). 
L- Placebo Adjusted difference P 
thyroxine Mean (95%ci), value 
Mean (SD) (SD) 
Satisfaction 4.2(l. 7) 4.2(l. 7) 0.0 (-0.3 to 0.3) 0.98 
Treatment 3.3 (1.8) 3.0(1.7) 0.21 (-0.1 to 0.5) 0.35 
working 
Convenient 5.3(l. 2) 5.3 (1) -0.0 (-0.2 to 0.2) 0.90 
Understanding 4.1 (1.7) 4.2(l. 6) -0.2 (-0.4 to 0.1) 0.40 
of problem 
Encourage 4.5(l. 6) 4.5(l. 8) 0.0 (-0.3 to 0.3) 0.91 
others 
Control 3.2(l. 8) 3.2(l. 7) 0.2 (-0.2 to 0.5) 0.49 
symptoms 
Continue with 3.6(2) 3.5 (1.9) 0.1 (-0.2 to 0.4) 0.68 
treatment and 
dose 
Total score 28.1 (8.7) 27.7(8.9) 0.4 (-1.6 to 2.3) 0.70 
I /-%U. ] US LCU 101 S LIL). IVL LdIIU JA: 1 I UU ýII UL 0. 
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Table 53. 
Effect of L-thyroxine on satisfaction with treatment with discordant TFTs 
excluded (n=71). 
L- 
thyroxine 
Mean (SD) 
Placebo 
Mean (SD) 
Adj usted 
difference 
(95%Cl)' 
P 
value 
Satisfaction 4.3(l. 7) 4,3(1.6) -0.0 (45 to 0.4) 0.91 
Treatment working 3.4(l. 8) 3.1 (1.7) 0.3 (-0.0 to 0.6) 0.18 
Convenient 5.2(l. 2) 5.4(0.9) -0.3 (0.0 to -0.6) 0.19 
Understanding of 
problem 
4.2(1.6) 4.3 (1.5) -0.1 (-0.3 to 0.1) 0.36 
Encourage others 4.5(l. 6) 4.6(1.6) -0.0 (-0.3 to 0.3) 0.69 
Control symptoms 3.3 (1.8) 3.2(1.7) 0.1 (-0.3 to 0.5) 0.42 
Continue with 
treatment and dose 
3.8(2.0) 3.6(l. 9) 0.3 (-0.1 to 0.7) 0.50 
Total score 29.1 (8.7) 28.4(8) 0.6 (-1.5 to 2.7) 0.60 
T Aujusteu lor suoject anu periou ellvýts. 
ThyTSQ: range 0 to 42 (higher scores indicating greater satisfaction with 
present treatment). 
Patients with SCH did not notice any significant difference between L-thyroxine 
and placebo in tenus of satisfaction with treatment. The sign test too did not 
show any significant trends (p=0.68). 
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The effect of thyroid autoantibodies and serum TSH 
levels at baseline on various parameters after treatment 
Forty-nine patients had positive anti-TPO antibodies (titre > 50). The results 
were then compared in all 100 patients with regards to positive versus negative 
antibody status. This showed no significant changes between individuals who 
were anti-TPO positive compared to anti-TPO negative with regards to patient- 
reported outcomes. 
Participants were then compared with regards to their baseline TSH levels. 
Sixty-two individuals had TSH < 6.1 mIU/L (the mean TSH of the group) and 
the remaining 38 had TSH > or = 6.1 mIU/L. There was no difference in any 
aspect of patient-reported outcomes in either group. 
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DISCUSSION (B) 
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Synopsis of study findings 
This randomised controlled study shows that treatment of SCH with L-thyroxine 
provides significant improvement in some patient-reported outcomes. Unique 
disease-specific questionnaires assessing QoL, symptom-bother and satisfaction 
with treatment were designed and validated with good effect. At baseline, 
perceived health status was found to be impaired as compared to a normative 
population. In the prospective crossover trial, assessment of patient-reported 
outcomes utilising these questionnaires as well as the widely used SF-36 showed 
that QoL and the frequency of tiredness significantly improved by treatment 
with L-thyroxine, although there was no significant change in satisfaction with 
treatment or perceived health status. 
Possible mechanisms and explanations of findings 
The effect of L-thyroxine treatment on patient-reported outcomes was mixed. 
The perceived negative impact of hypothyroidism on QoL and on sex-life was 
reduced (as measured by the disease-specific ThyDQoL). However, although all 
subscales of the generic health status measure, the SF-36 v2, (apart from Role- 
emotional), tended towards an improvement with L-thyroxine therapy, none 
reached statistical significance. This is not surprising given that generic 
instruments are less sensitive than disease-specific ones in assessing response to 
treatment, but could also be due to the fact that the study was not designed to 
detect a significant difference in patient-reported outcomes. For example, to 
detect a significant improvement in Vitality (the subscale that showed the most 
improvement in the SF-36 v2), it is calculated that a much larger sample would 
have been needed (n=3 10). However, health status of patients with SCH (as 
assessed by a disease-specific instrument) was not improved by L-thyroxine in 
the study by Jaeschke and colleagues (Jaeschke, et al 1996), but the 
disadvantage of that study was that treated patients' mean TSH was not optimal 
(4.6 mIU/L). The effect of L-thyroxine on reducing perceived negative impact 
of hypothyroidism on sex-life is interesting and warrants further research into 
the underlying mechanism. This may be due to the effect of thyroid hormones 
on psychological aspects (e. g. reducing tiredness) as well as on other hormones 
(e. g. reducing prolactin levels). L-thyroxine has been shown to improve 
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impaired sexual function and performance in men with hypothyroidism (Carani, 
et al 2005). The present study indicates that fewer patients reported tiredness 
following L-thyroxine therapy although patients' scores for symptom severity 
did not improve. The increased prevalence of tiredness in SCH could be due to a 
direct result of thyroid hormones on skeletal muscle (Argov, et al 1988). It could 
also be due to a more central effect on mood (Sait Gonen, et al 2004). The 
reason for the lack of improvement in any symptom bother scores is unclear and 
may be due to patients having adapted to their symptoms. 
Comparison with relevant findings from other published studies 
This is the first RCT to have assessed QoL and treatment satisfaction In patients 
with SCH. This study has shown that overall QoL improves with L-thyroxine 
treatment in SCH but also that the domains that improve significantly are sex- 
life and motivation. In comparison, other studies have assessed health status 
(Jaeschke, et al 1996), symptoms and mood (Cooper, et al 1984) (Nystrom, et al 
1988) (Meier, et al 200 1) (Kong, et al 2002) (Jorde, et al 2006). Symptoms of 
tiredness improved significantly in the present study. Other RCTs have shown 
inconsistent results. Other studies have used tools to assess symptoms that report 
a total mean score. This makes it difficult to analyse, which individual 
symptoms improve, if any. For example, the Basel thyroid study, conducted by 
Meier and colleagues, found a significant reduction in symptoms only in the 
subgroup of patients with TSH levels above 12 mIU/L (Meier, et al 2001). It is 
difficult to find out which of the symptoms measured (by Billewicz and 
Zulewski questionnaires) actually improved. The reason for these inconsistent 
results may be that some hypothyroid symptoms improve with L-thyroxine 
treatment in patients with SCH whereas others do not. The other reason for the 
significant result in the present study (where most patient's TSH levels were 
below 10 mIU/L) could be the relatively large number of patients studied that 
has detected a significant improvement in symptoms which other smaller studies 
failed to identify. 
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Limitations of the study 
The limitations of the present study are that patients were not identified from a 
population sample, the length of treatment was only twelve weeks, and the dose 
of L-thyroxine was a fixed 100 mcg per patient. Twelve weeks may be 
insufficient time for some benefits (such as perceptible reduction in some 
symptoms and psychological factors) to become apparent to patients. 
Summary 
Treatment with L-thyroxine reduces perceived negative impact of 
hypothyroidism on QoL and improves tiredness. There is improvement in sex- 
life and motivation, the mechanism of which needs to be elucidated. 
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ThYDQoL 
This questionnaire asks about your quality of life and how it has been affected by 
underactive thyroid 
Your quality of life is how good or bad you feel your life to be. 
There are no right or wrong answers 
Section A 
The questions on this page are overview questions 
Please tick the box that best indicates your response. 
The first question asks about your general quality of life 
1) In general, my present quality of life isý 
R F-I 11 
. 1, 
F-I EJ F-I EJ 
excellent very good good neither bad very bad extremely 
good nor bad 
bad 
The next question asks about the impact of your underactive thyroid and any 
thyroid treatment on, your qUality of life in recent weeks 
11) If I did not have underactive thyroid, my quality of life would be: 
EI EI 1: 1 11 EI 
very much MUCh a little the same worse 
better better better 
This copy is for information only - for use, please contact Professor Bradley 
I hyDOý, ý Ili cif G: ýifv IS! aTcy 22 7 Cý Sta-cziic UK Et'ýý IýI, i 'ýv 22 7 03i I log, ý I ý, ' 7 
Psycnolo)y Rosexcn. Dep: of Psyctwcýy, Rcvý Uot-ve's tý. o' Lc, 'Con. EýI-nm Surfcy 1 ', 1%, '20 CEX UK 
230 
Section B 
The following questions are about how underactive thyroid has affected different aspects of 
your life in recent weeks If you are currently being treated for underactive thyroid please 
consider the effects of the treated condition 
Part (a)ý Tick one box to show how underactive thyroid and any treatment affect this aspect 
of your life 
Part (b) Tick one box to show how important this aspect of life is to your quality of life 
I (a) If I did LI! 21 have underactive thyroid, I would enjoy the things I do in my spare time: 
F] El MM El 
very much more much more a little more the same less 
(b) The things I do in my spare time are: 
M El El El 
very important important soime'vvhat important not at all important 
-J 
2 Are you currently working? Yes DN0[: ] 
If no, do you want to work? Yes Ej No F1 
If yes to either ClUestion. complete (a) and (b) 
If no to both questions, go straight to Question 3 
(a) It I did not have underactive thyroid, my working life Would be: 
MM EJ EJ EJ 
vefy much better much better a little better the same worse 
(b) For me, working life is: 
M El EJ 
very important important sonievvhat important not at all iniportaril 
3 Do you ever want to go on holiday? 
Yes 0 If yes, complete (a) and (b) 
No E] If no, go straight to Question 4. 
(a) If I did not have underactive thyroid, my holidays would be: 
EJ El EJ El EJ 
very much better much better a little better tfie same worse 
(b) For rne, holidays are: 
EJ 
very important important sonieývhat impor-tant riot at all important 
This copy is for information only - for LISe, please contact Professor Bradley 
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4 Do you have family / relatives? 
Yes F-1 If yes cornplete (a) and (b). 
No E] If no, go straight to Question 5 
(a) If I did not have underactive thyroid. my family life Would be: 
0 r-] EJ El F-1 
very mUch better much better a little better the sanie worse 
(b) My family life is: 
R 11 El 
very important important somewhat iniportant not at all important 
5 (a) If I did t7ot have underactive thyroid, my social life would be: 
F-1 F-1 r-] F1 EJ 
very much better mUch better a little better the same worse 
(b) My social life is: 
El F] El 
very important important somewhat important not at all important 
6 Are you married or in a close personal relationship? Yes E] NoE] 
If no, would you like to have a close personal relationship? Yes F-1 NoE] 
If yes to either question complete (a) and (b). 
If no to both questions, go straight to Question 7. 
(a) If I did LLQJ have underactive thyroid, my closest personal relationship would be: 
F1 1: 1 El F] EJ 
very much better much better, a little better the same worse 
(b) For me, ha ving a close personal relationship is; 
F-1 F-1 El D 
very important important somewhat important not at all important 
This copy is for information only - for use, please contact Professor Bradley 
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7 Do you have a sex life? Yes Ej No Ej 
If no, would you like to have one? Yes Fý No 
If yes to either qUestion. complete (a) and (b) 
If no to both questions, go straight to Question 8. 
(a) If I did not have underactive thyroid, my sex life would be: 
1-1 F] Fý Fý F1 
very much better much better a little better the same worse 
(b) For ine, a sex life is: 
El El El 
very important important somewhat jr-riportant not at all important 
8 (a) If I did not have underactive thyroid, physically I could do. 
El El El El EJ 
very much more much more a little rnore the same less 
(b) For me, how much I can do physically is;,.. 
El 
very important important somewhat important not at all important 
9 (a) If I did not have unde I ractive thyroid, my energy levels would be: 
EJ 11 r-] 0 El 
very much higher much higher a little higher the sarne lower 
(b) My energy levels are: 
11 D El 
very 'important important sornewhat important not at all m-)portant 
10 (a) If I did not have underactive thyroid, the speed I could do things would be: 
171 ED F-1 R EJ 
very much faster much faster a little faster the same slower 
(b) The speed I can do things is: 
00 EJ Fý 
very important important sornewhat important riot at all impomant 
This copy is for information only - for use, please contact Professor Bradley 
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(a) If I did not have underactive thyroid, getting out and about (e. g. shopping, short trips) 
Would be: 
El El 
very much easier much easier a little easier the same more difficult 
(b) For me, getting out and about is: 
1: 1 El El 
very important important somewhat important not at all in 
12 (a) If I did not have underactive thyroid, I could handle my household tasks: 
El El F-1 Fý El 
very much better r-nuch better a little better the same worse 
(b) Handling household tasks is: 
EJ Fý El EJ 
very important important somev%., hat importarit riot at all important 
13 (a) If I did not have underactive thyroid, iny physical appearance WOUld be: 
El mm EJ El 
very much better rriuch better a little better the coame worse 
(b) My physical appearance is: 
m El EJ 
very important importatit sornewhat important not at all important 
14 Do you consider yourself to be underweight? Yes NoE] 
Do you consider yourself to be overweight? YesEj NoE] 
If yes to either qUestion. complete (a) arid (b)ý 
If no to both questions, go straight to Question 15 
(a) If I did not have underactive thyroid, my weight would be: 
M EJ M M M 
very much better much better a little better the same ý, vorse 
(b) For me, my weight is: 
MM 1_1 M 
very important irriportatit sornewhat important not atall importaiit 
This copy is for Worrintion oily - for use, pkase contact Professor Bradley 
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15 Have you had any bodily discomfort (e. g. aches, feeling cold, constipation) in recent 
weeks? 
Yes f-1 If yes. complete (a) and (b) 
No E] If no, go straight to Question 16, 
(a) If I did not have underactive thyroid, my experience of bodily discomfort would be: 
E-1 E-1 M r7 F] 
very nlUch less MLIch less a little less the same greate,, 
(b) For me, not having bodily discomfort is: 
D F7 F1 E-1 
very important important somewhat important riot at all important 
16 Have YOU felt depressed or low in recent weeks?, 
Yes E] If yes. complete (a) and (b), 
No 0 If no, go straight to Question, 17, 
(a) If I did not have underactive thyroid, I would feel depressed or low: 
El El EJ El 
very much less much less a little less the same more 
(b) For ine, not feeling depressed or low is: 
El El F 
veiy important ,. important sornewhat important not at all important 
17 Do you, eVer lack motivation (e. g. feel You can't be bothered to do things)? 
yes-, If yes, complete (a) and (b). 
N6 Fý If no, go straight to Question 18. 
(a) If I did not have underactive thyroid, my motivation to do things would be: 
El 0 Fý El El 
very MUch greater much greater a little gfeater the same less 
(b) My motivation to do things is. 
EJ El El 
very important miportant somewhat importaM not at all Important 
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18 (a) If I did =1 have underactive thyroid, my feelings about the future (e. g. worries, hopes) 
would be: 
EJ F1 El 
very much better mUch better a little better the same worse 
(b) My feelings about the future are: 
M El El 11 
very important important somewhat important not at a] important 
Are there any other ways in which underactive thyroid and any treatment affect your quality 
of life, that have not been covered by the qUestionnaire? 
Yes No 
Thank you for comploting this questionnaire. 
This copy is for information only - for use, please contact Professor Bradley 
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The Hypothyroidism Treatment Satisfaction Questionnaire: 
ThyTSQ- Present 
The following questions are concerned with the treatment for your underactive thyroid 
(including blood monitoring and any medication) and your experience over the past 
few weeks. Please answer each question by circling a number on each of the scales. 
1 How satisfied are you with the current treatment for your underactive thyroid? 
very satisfied 6543210 very dissatisfied 
2 How well do you feel the treatment is working? 
very well 6543210. very badly 
3. How convenient have you found your treatment to, be recently g remembering to 
take the medication, getting prescriptions)? 
very convenient 6543210 very inconvenient 
4 How satisfied are you with Your Linde 
very satisfied 
5, Would you encour 
Yes. I would 
definitely 
encouraae th 
No, I WOUld 0 
definitely not 
enCOLlrage them 
6. How weV do you feel that the treatment is controlling symptoms of underactive thyroid'? 
very well 6543210 very badly 
I, 
7, How satisfied would you be to continUe with Your present treatment and dose? 
very satisfied 6543210 very dissatisfied 
Please make sure that you have circled one number on each of the scales above. 
very well 6543210 very badly 
How satisfied would you be to continue with Your present treatment and dose? 
very satisfied 6543210 very dissatisfied 
This copy is for information only - for use, please contact Professor Bradley 
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0 very dissatisfied 
with underactive thyroid to have your kind of treatment2 
underactive thyroid? 
Are there any other features of your recent treatment for underactive thyroid. causing either 
satisfaction or dissatisfaction, that have not been covered by the questionnaire? 
Yes 
n 
No El 
This copy is for information only - for use, please contact Professor Bradley 
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The Hypothyroidism Treatment Satisfaction Questionnaire: 
ThyTSQ- Past 
The following questions are concerned with your early experiences both before 
and after you were told you had underactive thyroid. 
Please answer each question by circlin-q a number on each of the scales. 
1 How satisfied were you with the way doctors dealt with your underactive 'hyrold 
around the tinie it was first diagnosed? 
very satisfied 6543210 very dissatisfied 
2 How satisfied were you with the Inforniation provided by doctors about 
underactive thyroid? 
very satisfied 6543210 very dissatisfied 
3 How satisfied were you with the inforniation provided by doctors about the 
treatment for underactive thyroid? 
very satisfied 6543210 very dissatisfied 
4, How satisfied were You that doctors took you and YoUr underactive thyroid seriously? 
very satisfied 6543210 very dissatisfied 
Please make sure that you have circled one number on each of the scales above. 
Are there any other features of your early experiences of treati-nent for Underactive thyroid, 
causing either satisfaction or dissatisfaction, that have not been covered by the questionnaire? 
Yes 
[: ] 
No 
Fý 
Thank you for completing this questionnaire. 
This copy is for information only - for use, please contact Professor Bradley 
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Hypothyroid Symptom Checklist 
This questionnaire asks you about symptoms that can be associated with underact'Ve thyroid and that you may have experienced in recent weeks. 
For each question - if you answeryes to part (a) please complete part (b) of that 
question 
- if you answer no to part (a), go straight to the next question. 
Please tick the box that best indicates your response. 
I (a) Have you felt tired in recent weeks? Yes Ej No 
(b) If yes, how much does feeling El El El El 
tired bother you? not at all a little quite a bit very much 
2(a) Have you gained weight in recent weeks? Yes E] No Ej 
(b) If yes, how much does your El EJ EJ El 
weight gain bother you? not at all a little quite a bit very much 
3(a) Have you felt colder than other people in recent weeks? Yes Ej No E] 
(b) If yes, how much does feeling cold EJ El EJ EJ 
bother you? not at all a little quite a bit very much 
4(a) Have you had constipation in recent weeks? Yes Ej No E] 
(b) Ifyes, how much does EJ 
constipation bother you? not at all 
El 
a little 
El 
quite a bit 
El 
very much 
5(a) Have you had hair problems in recent weeks 
loss, coarseness)? 
(e. g. hair Yes Fý No E] 
(b) If yes, how much do hair problems El 
bother you? not at all 
El 
a little 
El 
quite a bit 
El 
very much 
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6(a) Have you had skin problems in recent weeks 
dryness, coarseness)? 
(e. g. Yes E] o El 
(b) If yes, how much do skin El 
problems bother you? not at all 
El 
a little 
El 
quite a bit 
EJ 
very much 
7(a) Have you had nail problems in recent weeks 
brittleness, flaking)? 
(e. g. Yes Ej No El 
(b) If yes, how much do nail problems El 
bother you? not at all 
El 
a little 
EJ 
quite a bit 
El 
very much 
8(a) Have you had loss of appetite in recent weeks? Yes E] No E] 
(b) If yes, how much does loss of El 
appetite bother you? not at all 
EJ 
a little 
El 
quite a bit 
El 
very much 
9(a) Have you had hearing problems in recent weeks? Yes E] No E] 
(b) If yes, how much do hearing EJ 
problems bother you? not at all 
EJ 
a little 
E] 
quite a bit 
EJ 
very much 
I O(a) Have you had voice problems in recent weeks 
(e. g. hoarseness, huskiness)? 
Yes E] No Ej 
(b) if Yes, how much do voice EJ 
problems bother you? not at all 
El 
a little 
El 
quite a bit 
EJ 
very much 
II (a) Have you had speech problems in recent weeks 
slowness, inaccuracy)? 
(e. g. Yes Ej No E] 
(b) If yes, how much do speech 1: 1 
problems bother you? not at all 
EJ 
a little 
El 
quite a bit 
EJ 
very much 
12(a) Have you had memory problems in recent weeks? Yes E] 0 
(b) Ifyes, hoNvmuchdomemory El 
problems bother you'? not at all 
EJ 
a little 
El 
quite a bit 
El 
\-cry much 
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13(a) Have you had problems with your concentration in recent 
weeks? 
Yes El o EJ 
(b) If Yes, how much do concentration EJ 
problems bother you? not at all 
El 
a little 
El 
quite a bit verv mLich 
14(a) Have you felt giddy or dizzy in recent weeks) Yes E] o EJ 
(b) If yes, how much does giddiness or 
11 
dizziness bother you? not at all 
El 
a little 
EJ 
quite a bit 
EJ 
very iiiLicli 
15 (a) Have you felt depressed or low in recent weeks? Yes El No E] 
(b) If yes, how much do feelings of El 
depression bother you? not at all 
EJ 
a little 
El 
quite a bit 
EJ 
N'cry niucli 
Thank you for completing this questionnaire. 
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